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Summary 
Haematopoietic stem cells (HSCs) are multipotent stem cells that sustain long-life 
haematopoiesis. External signals delivered from the bone marrow (BM) niche are 
crucial for HSC homeostasis, alongside a cell intrinsic transcriptional program driven 
by transcription factors (TFs). Translocations, epigenetic and genetic mutations 
altering TF activity, subvert HSC homeostasis leading to the development of pre-
leukaemic stem cells (pre-LSCs) and LSCs that drive the development and 
maintenance of acute myeloid leukaemia (AML).  Gata2, a zinc finger TF expressed 
in the haematopoietic system, is essential for the generation and survival of HSCs in 
development, however the requirement for Gata2 in adult HSCs is less clear. 
Perturbation of GATA2 function by loss of function mutations of the GATA2 gene, 
gives rise to immunodeficiency syndromes with a high risk of transformation to 
myelodysplastic syndrome and AML. Conversely, overexpression of GATA2 is 
observed in approximately 40% of AML patients and has been linked with poor 
prognosis. However, the precise biological impact of GATA2 expression on AML cell 
fate, including LSCs, has yet to be interrogated.  
In this thesis, Gata2 is established as a critical, dose dependent regulator of HSC and 
AML cell fate. Conditional, acute deletion of Gata2 in vivo leads to a rapid loss of HSCs 
in a cell autonomous fashion, suggesting a survival defect in GATA2 deficient HSCs 
and defining a crucial requirement for Gata2 in HSC maintenance. Employing a step-
wise mouse model of AML it was found that acute deletion of Gata2 delays the in vivo 
development and maintenance of LSCs driven by Meis1a/Hoxa9 oncogene 
expression, but was dispensable for Mll-af9-mediated AML. In addition, RNAi or small 
molecule inhibition of GATA2 via K-7174 triggers apoptosis of human AML cells and 
murine pre-LSC cell lines. K-7174 also targets the leukaemia initiating population in 
pre-LSC cell lines and enhances the killing activity of standard chemotherapeutics. 
Therefore, GATA2 blockade or targeting of GATA2 related pathways may open new 
therapeutic options for AML. The work described here establishes the basis for future 
work aiming to interrogate the mechanisms mediated by Gata2 in HSCs and LSCs in 
AML, and to examine the therapeutic potential for GATA2 mediated pharmacological 
inhibition in AML.  
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1.1. Normal haematopoiesis  
 
1.1.1. Current view of the haematopoietic system  
 
Haematopoiesis is a dynamic process that guarantees the supply of all blood cell types 
throughout the lifetime of an individual (Orkin and Zon 2008; Jagannathan-Bogdan et 
al. 2013; Ogawa 1994; Kent and Eaves 2016) In adults, haematopoiesis takes place 
predominantly in the bone marrow (BM), although it also occurs in extramedullary sites 
– the spleen and liver - in some situations such as severe infection, pregnancy and 
dramatic blood loss (Orkin and Zon 2008). Haematopoiesis is initiated in the embryo 
in three distinct waves; two primitive waves and the definitive wave (Dzierzak and 
Medvinsky 1995). In the mouse embryo, the first wave takes place in the yolk sac (YS) 
at embryonic day 7 (E7) and produces primitive erythroid, megakaryocytes, and 
macrophages (Dzierzak and Medvinsky 1995). The second wave appears at E8.5 in 
the YS and gives rise to bipotential erythroid-myeloid progenitors (EMP) (Dzierzak and 
Medvinsky 1995). The definitive wave occurs in the aorta-gonad-mesonephros (AGM) 
at E10.5 (Dzierzak and Medvinsky 1995; Ciau-Uitz et al. 2014; Costa et al. 2012; 
Yoder 2004) by means of the endothelial-to-haematopoietic transition (EHT) process, 
in which specialised endothelial cells – named hemogenic endothelial cells (HEC) – 
are capable of giving rise to haematopoietic stem cells (HSCs) (Dzierzak and 
Medvinsky 1995; Ciau-Uitz et al. 2014; Costa et al. 2012; Yoder 2004). Multipotent 
HSCs are detected in the foetal liver (FL) by E14, and finally migrate to the BM shortly-
before birth (Orkin and Zon 2008).  
 
In adults, HSCs sit atop of the haematopoietic hierarchy in the BM, are able to self-
renew, and give rise to multipotent and lineage-restricted progenitors that 
progressively lose proliferative potential and differentiate into the mature blood cell 
types (Orkin and Zon 2008). Pioneering studies between 1961 and 1969 from Till and 
McCullough, demonstrated the potential existence of HSC with many properties; the 
ability to engraft an irradiated recipient (McCulloch and Till 1960), self-renewal - 
demonstrated by the ability of transplanted HSCs to reconstitute an irradiated host 
after serial transplantation (BECKER et al. 1963), formation of myeloid colonies (CFU-
S) in the spleen after BM transplantation (Siminovitch et al. 1963), multilineage blood-
forming capacity (Wu et al. 1968), and physical purification (Worton et al. 1969). Since 
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the 1980s, the development and advancement of fluorescence activated cell sorting 
(FACS) technology and the parallel development of fluorescence-labelled antibodies 
recognising cell-surface markers has facilitated the identification of prospectively 
isolated classes of HSC and progenitor subsets (Herzenberg et al. 2006; Quirke 1992; 
De Rosa et al. 2001). The use of transplantation assays in mice has been a very useful 
tool to assess the short term (8-12 weeks) and long term (16 weeks) engraftment and 
reconstitution ability, of specific subsets of FACS isolated HSC and progenitor cells, 
whilst also measuring the self-renewal ability of stem cells to give rise to itself and 
reconstitute the blood system of secondary recipients (Purton and Scadden 2007; 
Ema et al. 2007). Therefore, FACS and transplantation assays, together with the ability 
to engineer deletion of specific genes in mouse models, have defined our knowledge 
of highly purified HSCs and progenitor cell subsets. Based on these experiments, a 
classical hierarchical model of mouse and human haematopoiesis has been 
formulated as detailed in Figure 1.1. Briefly, HSCs (Lin-Sca1+c-kit+CD150+CD48-) give 
rise to transient multipotent progenitor (MPP) (Lin-Sca1+c-kit+CD150-CD48-), 
haematopoietic progenitors (HPC)-1 (Lin-Sca1+c-kit+CD150-CD48+), and HPC-2 (Lin-
Sca1+c-kit+CD150+CD48+), that will further commit into myeloid restricted common 
myeloid progenitor (CMP) (Lin-Sca1-c-kit+CD16/32-CD34+) producing lineage-
restricted progenitors, megakaryocyte-erythrocyte progenitor (MEP) (Lin-Sca1-c-
kit+CD16/32-CD34-) and granulocyte-macrophage progenitor (GMP) (Lin-Sca1-c-
kit+CD16/32+CD34-) which will inturn go through precursor stages and terminal 
differentiation of megakaryocytes, erythroid and myeloid cells (Ogawa 1993; Kitajima 
et al. 2006; Ema et al. 2014; Doulatov et al. 2012; Rieger and Schroeder 2012)ma. 
Alternatively, lymphoid-primed multipotent progenitor (LMPP) (Lin-Sca1-c-
kit+Flt3+CD34+) arise from MPP and give rise to common lymphoid progenitor (CLP) 
(Lin-Sca1lowc-kitlowCD127+) that will generate T and B precursor cells that will 
terminally differentiate into mature T and B lymphocytes (Miranda-Saavedra and 
Göttgens 2008; Brown and Ceredig 2009; Jagannathan-Bogdan et al. 2013; Kondo et 
al. 1997).  
 
In humans, the identification and study of purified HSCs has been limited by access 
to appropriate in vitro and in vivo models to test human cells (Doulatov et al. 2012; 
Kent and Eaves 2016; Majeti et al. 2007; Ng and Alexander 2017; Cuellar-Rodriguez 
et al. 2012; Notta et al. 2011; Laurenti and Dick 2012). The development of more 
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specialised in vitro cultures with an array of cytokines, allowed for the development of 
long term culture-initiating cell (LTC-IC) (Ramsfjell et al. 1999; Sutherland et al. 1993). 
However, the most substantial development is that of immunodeficient mice which can 
accept transplantation and engraftment of human BM cells without rejection due to 
xenogeneic boundaries (C. Y. Park et al. 2008). Since then, improved immunodeficient 
mice have been engineered, NOD/SCID/IL-2Rγnull (NSG), which have become the 
most routinely used in human studies (Brehm et al. 2012; Beyer and Muench 2017), 
although new engineered mice expressing human cytokines or harbouring human 
stromal cells (currently in development) will provide further insights for future human 
haematopoiesis research (Goyama et al. 2015; Tsukada et al. 2017; Saito et al. 2016).  
Through LTC-IC assays and transplantation experiments, human HSCs were first 
identified within the CD34+ CD38- compartment (Larochelle et al. 1996; Bhatia et al. 
1997), which has been further refined to a CD34+ CD38- CD90+CD45RA–CD49f+ 
population (Wisniewski et al. 2011; Notta et al. 2011).  
 
 
 
 
 
HSC
MPP
HPC-1
HPC-2
CMP
LMPP/MLP
CLP
GMPMEP
MyelopoiesisErythropoiesisMegakaryopoiesis
Lymphopoiesis
LSK	CD150+ CD48-
LSK	CD150- CD48-
LSK	CD150+ CD48+
LSK	CD150- CD48+
LIN- CD34+ CD38- CD45RA- CD90+ CD49f+
LIN- CD34+ CD38- CD45RA- CD90- CD49f	-
LIN- CD34+ CD38- CD45RA+
Mouse
Human
Lin-Sca1lowc-kit+Flt3+CD34+
LIN- CD34+ CD38+ CD10+	CD127+
Lin-Sca1lowc-kitlowCD127+
LIN- CD34+ CD38+ CD45RA-CD135+
Lin-Sca1-c-kit+ CD34+ CD16/32-
LIN- CD34+ CD38+ CD45RA-CD135-
Lin-Sca1-c-kit+ CD34- CD16/32-
LIN- CD34+ CD38+ CD45RA+CD135+
Lin-Sca1-c-kit+ CD34+ CD16/32+GMP
Figure 1.1. Haematopoietic hierarchy. HSCs reside at the top of the haematopoietic hierarchy where they sustain lifetime
haematopoiesis. HSCs give rise to multipotent progenitor cells that progressively proliferative potential while differentiating into the main
blood cell types. Mouse (blue) and human (purple)CDmarkers that define each population are indicated.
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The traditional linear view of the haematopoietic hierarchy has recently been 
challenged both in the mouse and human systems. In humans, a study from John 
Dick’s laboratory has redefined the human haematopoietic hierarchy eliminating the 
classical CMP oligopotent progenitor (Notta et al. 2016). Instead, in adult BM, HSC 
give rise to transient MPP or MLP that directly produce unipotent progenitors that 
differentiate into erythrocytes, granulocytes, monocytes and lymphocytes. 
Interestingly, their data indicate that lymphocytes emanate from a common progenitor 
for monocytes, but not granulocytes. In this model, it is posited that MEP arises directly 
from HSCs, in agreement with murine studies that show that megakaryocytes localise 
closely to HSCs and secrete critical factors such as Pf4 and Tgf-b that regulate HSC 
quiescence (Olson et al. 2013; Bruns et al. 2014; Yoshihara et al. 2007). In the mouse, 
a similar dynamic model of haematopoiesis has been proposed by Passegué’s group, 
where LT-HSC and SH-HSC (or MPP1) simultaneously produce two myeloid-biased 
MPP2 and MPP3 populations, and a lymphoid-biased MPP4 under steady-state 
conditions (Pietras et al. 2015). These data highlight the plasticity of HSCs, which in 
the first weeks after transplantation produces all the MPP subsets (MPP2-4) focused 
on myeloid cell production, while thereafter the MPP4 subset is able to restore their 
homeostatic function and give rise to the pool of lymphoid cells in an irradiated host 
(Pietras et al. 2015). 
 
We are now entering a new era of single-cell studies that have shed light on the 
heterogeneity of HSCs at the clonal level and their contribution to haematopoiesis 
under steady-state conditions. In vivo barcoding of HSCs in mice showed that 
thousands of lineage-restricted and multipotent progenitors clones, but not HSCs, 
sustain steady-state haematopoiesis (Sun et al. 2014), which was also supported by 
another group that reported only a small fraction of HSCs contribute to native 
haematopoiesis in mice (Busch et al. 2015). However, a growing number of 
publications have disputed these findings (Verovskaya et al. 2014; Yu et al. 2016; 
Biasco et al. 2015; Sawai et al. 2016; Ito and Frenette 2016; Jaenisch et al. 2010; 
Jagannathan-Bogdan et al. 2013; van der Meer et al. 2010). For instance, a recent 
study employed a multi-fluorescent transgenic mouse that allows for in vivo tracking 
and molecular profiling of individual HSC clones (Yu et al. 2016). In agreement with 
contemporary findings in mouse and human, but contrary to the work from Sun et al., 
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this study highlights that native haematopoiesis is sustained predominantly by a few 
HSCs clones. Discrepancies between these studies are due to the lower sensitivity of 
the fluorescence-based methods and the inability to measure clone size in the barcode 
study from Sun et al. Thus, it remains unclear whether HSC or progenitor cells, their 
combination, or cell-type and context, give rise to haematopoietic cells during steady-
state conditions. The theory behind the study of steady-state haematopoiesis is based 
by the fact that HSCs are highly activated during transplantation, and therefore may 
not reflect endogenous haematopoiesis. Nevertheless, it is important to note that the 
steady-state studies were performed under pathogen-free conditions, whilst 
haematopoiesis in humans develop under more physiologically challenging conditions 
(i.e. pathogens, environmental stress, severe infections or blood loss), that may 
actually be more reflective of mouse transplantation assays.  
 
1.1.2. Adult haematopoietic stem cells (HSCs) 
 
HSCs possess critical features to sustain the haematopoietic system. They are able 
to self-renew, which is the faculty to produce other HSCs by either asymmetric or 
symmetric division; they are multipotent, which is the ability to produce all blood cell 
lineages; they undergo apoptosis to protect themselves from genotoxic stress and to 
regulate the number of HSCs; and they are largely quiescent, to prevent HSC 
exhaustion and accumulation of mutations (Kent and Eaves 2016). Understanding cell 
fate decisions underlying HSC biology has been aided by development of genetic tools 
such as tissue-specific conditional mouse models, in which a specific part of a gene is 
flanked by LoxP sites (floxed region) that can be recognised by Cre recombinase and, 
via homologous recombinase, generate deletion of the floxed region (Sauer 1998). 
Recently, CRISPR/Cas9 technology has also permitted the study and function of 
genes and noncoding regions in the haematopoietic system. Table 1.1 summarises 
the haematopoietic Cre-Lox mice used to study HSC cell fate.  
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1.1.2.1. HSC self-renewal and quiescence  
  
Self-renewal is a crucial characteristic of stem cells, and is required to maintain the 
rare number of HSCs throughout life. In adult HSCs, approximately 90-95% of HSCs 
remain quiescence (Passegué and Wagers 2006) in steady-state haematopoiesis and 
in times of physiological demand enter the cell-cycle in order to self-renew or 
differentiate.  
 
The cell-cycle is promoted by cyclin-dependent kinases (Cdk4/6) that phosphorylate 
and inactivate Retinoblastoma (Rb) in late G1 in order to enter into S phase (Laurenti 
et al. 2015; Viatour et al. 2008). The main Cdk inhibitors are p21, p27 and p57, known 
as Cip/Kip family that preferentially target Cdk2 (Cheng et al. 2000; Matsumoto et al. 
2011; Yuan et al. 2004), and Ink4/arf (p16/p19), Ink4b (p15), and Ink4c (p18) that 
repress Cdk4/6 (Yuan et al. 2004). Before entering into cell division, Rb is in a 
hypophosphorylated state and is capable to bind and repress the function of E2f 
transcription factors (Weinberg 1995). In late G1, Cdk4/6 phosphorylate Rb and thus 
releasing its association with E2f which then are able to activate the cell-cycle 
machinery (Weinberg 1995). To circumvent the embryonic lethality of Rb null mice, 
the role of Rb in HSCs was studied employing the Mx1-Cre system. To avoid effects 
from Rb deletion in the BM microenvironment, BM from untreated Rbfl/fl;Mx1-cre mice 
were transplanted into wild-type recipients prior to pIpC induction, thus gene deletion 
occurs solely in HSCs (Walkley et al. 2006). Despite a mild but stable anaemia, no 
short or long-term effects in multilineage or self-renewal abilities of HSCs were 
observed in Rb deficient HSCs (Walkley et al. 2006). To assess whether Rb could 
regulate HSCs in an extrinsic-manner through interactions with BM niche cells, 
Rbfl/fl;Mx1-cre mice treated with pIpC developed myeloproliferative syndrome (MPN) 
Mouse Strain Inducible Specificity Germline Deletion? Mating strategy Issues
Mx1-Cre pIpC (IFN) inducible HSCs
BM microenvironment 
Extramedullary tissues
No +/- X -/-
no preference
Leaky promoter – basal levels of IFN
IFN activates HSCs – it is resolved by day 30 after 
pIpC
Vav-Cre No HSCs
ECs 
ovaries
Yes +/- male X 
-/- female
None
Vav-iCre No HSCs
ECs (some strains)
testes
Yes +/- female X
-/- male
None
Tie2-Cre No HSCs 
ECs
Yes +/- male X
-/-female
None
Table 1.1. Haematopoietic Cre-Lox mouse models to study HSCs
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and has lower levels of HSCs in the BM due to increase differentiation and mobilization 
to extramedullary sites (Walkley et al. 2007). However, Rbfl/fl;Mx1-cre mice 
transplanted with wild-type BM and treated with pIpC are unable to induce MPN. 
Transplant of BM cells from Rbfl/fl;LyzM-cre, which constitutively delete Rb in myeloid 
cells, into Rbfl/fl;Mx1-cre mice develop MPN after pIpC deletion indicating that a 
reciprocal communication between niche and BM myeloid cells is required for Rb-
mediated MPN (Walkley et al. 2007). p21 controls HSC quiescence and self-renewal. 
Mice deficient in p21 have less HSC in a quiescent state (G0), and are unable to 
reconstitute an irradiated host and sustain long-term haematopoiesis in serial 
transplantation assays (Cheng et al. 2000) indicating a self-renewal defect. Both the 
Transforming growth factor-β (Tgf-b) (Ijichi et al. 2004) and the Notch (Catelain et al. 
2014) pathway have shown to activate p21 expression and hence growth arrest of 
HSCs. However, other studies employing different mouse background indicate that 
p21-mediated HSC cell cycle regulation is not required in steady-state, but only during 
stress conditions (i.e. transplantation, myeloablative treatment) (van Os et al. 2007). 
Deletion of p27 has minimal effect on HSCs but rather seems to impact progenitor cell 
function (Cheng et al. 2000). Redundancies between the Cip/Kip members were 
described in p57-/- mice with decreased quiescent cells and self-renewal defects in 
vitro CFC assays and in vivo transplants (Matsumoto et al. 2011). Codeletion of p21 
and p27 exacerbated the phenotype observed in p57 KO mice, whereas the 
phenotype could be rescued by overexpressing p27 (Matsumoto et al. 2011). TGF-
b/Smad signalling pathways also regulate HSC quiescence. Signalling through the 
Smad proteins leads to activation of cell cycle inhibitors such as p15, p21, p27, p57 
and other regulators that promote exit from the cell cycle (G0 state) (Ijichi et al. 2004; 
Larsson et al. 2003; Watabe and Miyazono 2009). Special interest has been raised in 
quiescence-induction mediated by TGF-b-Smad-p57 in both mouse and human HSC 
fractions (Scandura et al. 2004). Interestingly, Smad4 activates Gata2 that in turn 
binds and activates p57 expression to induce proliferation arrest and dormancy of 
murine HSCs (Billing et al. 2016). Plenty of evidence supports a quiescent role of TGF-
b, however opposite and additional functions of the TGF-b pathway have been 
described. These include immune system regulation,  and haematopoietic aging, 
which is understood to be a reflection of the diversity on the ligands, receptors, and 
canonical and non-canonical intracellular pathways that regulate HSC and progenitor 
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cells in a dose and context dependent (Meulmeester and Ten Dijke 2011; Fang et al. 
2012; Larsson and Karlsson 2005).  
 
Deletion of p16/p19 has no consequences in HSC functionality (Stepanova and 
Sorrentino 2005), in agreement with its low expression in young adult HSCs, as a 
result of Bmi1-mediated repression (Park et al. 2003). However, p16 is a critical 
regulator of senescence and its expression rises in aged HSCs alongside a decrease 
in the self-renewal abilities (Attema et al. 2009). Indeed, conditional deletion of p16 
leads to enhanced repopulating capacity and apoptosis resistance in aged HSCs 
(Attema et al. 2009). Conversely, p18 modulates cell-cycle entry in young HSCs as 
shown by the increase in self-renewal capacity of p18-/- HSCs (Yuan et al. 2004). Both 
p18 and p21 regulate cell-cycle entry, but unlike p21 KO HSCs, p18 KO HSCs are not 
exhausted after serial transplantation (Yuan et al. 2004). Bmi1 is a polycomb complex 
protein of TFs that regulate HSC self-renewal (Park et al. 2003). BM, but not foetal 
liver (FL) cells of Bmi1-/- showed fewer numbers of HSCs that are functionally 
compromised in serial transplantation BMT, indicating a self-renewal defect (Park et 
al. 2003). Gene expression analysis showed that Bmi1 regulates HSC self-renewal by 
repressing p16, and to some extent HSC survival by repressing p19 (Park et al. 2003). 
Enforced expression of p16 or p19 reduces the proliferative capacity of HSCs (Park et 
al. 2003). Similarly to Bmi1, BM analysis of Gfi1-/- mice showed reduced frequency of 
HSCs with higher proportion of cycling HSCs that performed poorly in serial BMT 
assays (Zeng et al. 2004), suggesting that Gfi1 deletion leads to HSC exhaustion. In 
contrast, conditional deletion of C-myc using the Mx1-cre system leads to enhanced 
self-renewal and differentiation block of HSCs (Wilson et al. 2004). Mechanistic 
studies indicate that C-myc repress N-cadherin transcription thus releasing HSCs from 
the HSC niche in the BM to start the differentiation program (Wilson et al. 2004). 
Proliferation and expansion of murine and human HSCs in vitro and in vivo is 
accomplished by Hoxb4/HOXB4 overexpression (Antonchuk et al. 2002; Beslu et al. 
2004; Krosl et al. 2003), and in human CB HSCs, the expansion phenotype is, at least 
in part, mediated by C-KIT, GATA2 and GFIB (Fujiwara et al. 2012).  
 
The tumour suppressor p53, also known as the “guardian of the genome”, is a key 
regulator of HSC quiescence and self-renewal. In homeostasis, p53 is bound and 
ubiquitinated by the E3-ubiquitin ligase MDM2 (Pant et al. 2012). P53 activation can 
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be triggered by endogenous or exogenous stress signals leading to the 
phosphorylation of amino acids disrupting the binding of MDM2 and the consequent 
formation of a p53 tetramer which then triggers cell-cycle arrest or senescence to fix 
the damage produced in the DNA, or if the damage cannot be repaired, p53 activates 
the expression of pro-apoptotic members of the Bcl2 family to induce apoptosis and 
avoid the transmission of mutations to progenitor cells (Pant et al. 2012). P53 is able 
to induce cell-cycle arrests through p21 activation to stop the progression in the G1 
phase (Pant et al. 2012). Alternatively, p53 disrupts the G2 phase complex cyclin 
B1/cdc2 complex (Pant et al. 2012). P53-/- mice showed a 2-to-3-fold expansion in the 
number of LSK cells (Chen et al. 2006). When bone marrow cells were transplanted, 
recipients injected with p53 null BM cells had increased repopulation activity compared 
to control mice (Tekippe et al. 2003), however when HSC where transplanted, p53 null 
HSCs showed a repopulation defect (Chen et al. 2006), similar to that observed with 
p21 null HSCs (Akala et al. 2008). 
 
The phosphatidylinositol 3-kinase (Pi3k) pathway also regulates the quiescence of 
HSCs. Specifically, inhibition of Pi3k/Akt/mTor signalling by the phosphatase Pten, the 
main negative regulator of this pathway, is essential to preserve the HSC pool (Zhang 
et al. 2006). Indeed, Pten-/- mice have hyperactivated Pi3k/Akt/mTor signalling, driving 
HSC proliferation within 5 days and the loss of self-renewal and HSC exhaustion in 
transplantation assays (Zhang et al. 2006). The exacerbated proliferation is facilitated 
by Akt-mediated inhibition of FoxO, leading to p21 and p27 inhibition, and therefore 
entry into the cell-cycle (Zhang et al. 2006). Longer term monitoring of Pten-/- mice 
leads to a myeloproliferative neoplasm (MPN) phenotype that can progress to acute 
leukaemia (Yilmaz et al. 2006).  
 
The Wnt/b-catenin pathway has been associated with self-renewal of HSC, although 
contradictory results have been reported. Briefly, the lack of Wnt ligands leads to the 
creation of a destruction complex formed by Axin, Apc, Gsk3b and b-catenin in which 
b-catenin is phosphorylated and ubiquitinated for degradation by the proteasome. 
Upon Wnt ligand-receptor binding, Gsk3b phosphorylation by Dvl dissembles the 
destruction complex allowing b-catenin to accumulate in the cytoplasm and 
translocate into the nucleus where it activates/represses gene expression together 
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with Tcf and other co-activators/repressors (Clevers and Nusse 2012). Co-culture of 
human CD34+ BM cells with WNT2B, WNT5A or WNT10B ligands can expand HSPCs 
while preserving the HSC phenotype (Murdoch et al. 2003). Introduction in murine 
HSCs of a constitutive active form of b-catenin can expand HSCs and efficiently 
reconstitute an irradiated mouse, whereas overexpression of the repressor Axin stops 
HSC proliferation (Baba et al. 2006). However, an engineered mouse model 
expressing stable b-catenin, expanded HSCs which then performed poorly in 
transplantation assays, indicating a functional HSC defect (Kirstetter et al. 2006). Loss 
of function experiments using Cre-Lox deletion of b-catenin in mice are also 
controversial. Deletion using the haematopoietic-specific Vav-Cre line leads to self-
renewal defects in serial transplantation experiments, while deletion with the 
conditional Mx1-Cre promoter showed no defects in self-renewal of HSCs (Zhao et al. 
2007; Jeannet et al. 2008). These differences are thought to be due compensatory 
effects from environmental or extramedullary deletion of b-catenin in the Mx1-cre 
model, or by dependency of b-catenin in foetal HSCs that cannot be compensated in 
adult HSCs in the Vav-Cre model.  
 
1.1.2.2. HSC survival  
 
The fine balance in the number of the HSC pool is regulated by apoptosis. HSCs under 
genotoxic or stress conditions undergo apoptosis to avoid accumulation of mutations 
that lead to aplastic, dysplastic and neoplastic haematopoiesis. Elucidating the 
molecular drivers that confer HSC survival is critical to tackling BM failure syndromes, 
MDS and AML where apoptosis is dysregulated (Lowe and Lin 2000; Alenzi et al. 
2009).  
 
To date, a select group of TFs are known to act as critical regulators of adult HSC 
survival, these include Etv6, Cited2, and Nkap (Hock et al. 2004; Kranc et al. 2009; 
Opferman 2005). To conditionally delete a specific gene in an acute-fashion manner 
in HSCs, studies have employed the Mx1-Cre mouse model, where Cre expression is 
under the regulation of the IFNa pathway that is experimentally activated by the 
administration of a double-stranded RNA named poly(I);poly(C) (pIpC) (Kühn et al. 
1995). Deletion of these TFs in adult mice leads to a cell-autonomous loss of HSPCs 
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and BM failure (Hock et al. 2004; Kranc et al. 2009; Opferman 2005). Nkap is a 
repressor of Notch signalling (Pajerowski et al. 2009), and interestingly another 
negative regulator of Notch at the protein level, Notchless, induces HSPCs loss after 
condition deletion with the Mx1-Cre promoter (Le Bouteiller et al. 2013). Curiously 
these results are reminiscent of the phenotype observed after acute deletion of Mcl1 
(Opferman 2005), an anti-apoptotic member of the Bcl-2 family (Michels et al. 2005), 
in HSCs using the same Cre-lox system. Excluding Etv6 and Mcl1, where the 
mechanism was not investigated , these critical regulators protect HSC from apoptosis 
cell dead, at least in part, mediated by the p16/p19/p53 axis (Le Bouteiller et al. 
2013)(Kranc et al. 2009; Pajerowski et al. 2010).  
 
1.1.2.3. HSC differentiation  
 
In response to external and internal stimuli, approximately 100 billion blood cells are 
formed every day to replenish the turnover of blood cells in the haematopoietic system 
(Reya et al. 2001). Hence, strict regulation of the molecular machinery that 
orchestrates the differentiation program of HSCs is vital to fight infections and avoid 
cytopenia, autoimmune diseases or the onset of malignancies. Lineage-specific 
ligand-receptor pairing transmits signals through signalling pathways that activate 
and/or repress TFs that drive the molecular and consequently phenotypic 
differentiation of HSPCs into mature haematopoietic cells (Sarrazin and Sieweke 
2011).  
 
Differentiation towards lymphoid lineage is driven by Flt3-ligand signalling in MPPs, 
that induces differentiation to the CLP, and together with Pu.1, CLPs start expressing 
IL7r that is bound by IL7, produced in the BM niche. At this point, activation of the 
Notch signalling pathway induces Gata3 expression to produce CD3+ T cells that travel 
to the thymus to complete the differentiation process (Masopust and Schenkel 2013). 
In contrast, B cell differentiation is supported by TFs, E2a and Early B cell factor (Ebf) 
(Sigvardsson et al. 2002; Dias et al. 2005). This process is similar in humans, where 
FLT3L-CD135 interaction in MPPs activates GATA2 expression that gives rise to 
MLPs, a common precursor to lymphoid cells and monocytes and DCs (Laurenti et al. 
2013).  
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Erythrocyte production is regulated by the Epo-EpoR interaction in MEP progenitors 
(Kuhrt and Wojchowski 2015), which internalise the signal mediating the Jak/Stat 
pathway to upregulate erythroid specific genes such as Gata1 (Wierenga et al. 2010) 
and activate the expression of erythroid markers such as CD71 and TER119 as they 
go through the different S1-S5 precursor stages until they release their nuclei to 
progress from reticulocyte to mature erythrocyte (Koulnis et al. 2011). The 
Gata1/Gata2 switch plays an important role in the development of red blood cells (see 
1.3. Gata2). Upon Tpo stimulation, megakaryocyte progenitors expressing the Tpo 
receptor, Mpl, differentiate to megakaryocytes which release platelets, a portion of the 
megakaryocyte cytoplasm (Ng et al. 2012; Deutsch and Tomer 2006).  
 
In addition to its role in the regulation of HSPCs, the Scf/c-kit/Pi3k pathway also 
regulates mast cell differentiation (Chen et al. 2005). In this context, Gata2 also 
appears as an essential regulator of mast cells, as it binds and activates the 
transcription of the C-kit promoter and reinforces mast cell differentiation (Ohmori et 
al. 2015; Maeda et al. 2010).  
 
Myeloid differentiation commences with cytokines such as GM-CSF, G-CSF, M-CSF, 
IL-6 and IL-3 (Mossadegh-Keller et al. 2013; Sarrazin and Sieweke 2011; Umetani et 
al. 2000). This activates Pu.1 expression that interacts with other TFs such as Gata1 
to induce myeloid commitment to the CMP progenitor (Nerlov and Graf 1998; Nerlov 
et al. 2000). Gata1 expression is reduced from the CMP to GMP transition (Huang et 
al. 2009), which is driven by Cebpa (Wang et al. 2006) and Runx1 (Ng et al. 2013). 
Activation of Irf8 drives monocyte or DC differentiation (Sichien et al. 2016) while Gfi1 
and Lef1 predominantly give rise to granulocytes (van der Meer et al. 2010; Doulatov 
et al. 2012).  
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1.1.3. Bone marrow niche 
 
The idea that the BM microenvironment or niche influences haematopoiesis was first 
hypothesised in 1978 by Schofield (Schofield 1978). However, it was not until early 
2000s that it was possible to identify and study the cells that form the BM niche. 
Nevertheless, in the last 5 years the understanding about the niche cell types and 
niche factors that regulate HSCs has increased massively due the advances in 
imaging and the development of niche specific mouse models.  
 
The BM niche comprises heterogeneous cell populations, including endothelial cells, 
perisinusoidal cells, periarteriolar cells, adipocytes, osteoblasts, megakaryocytes, 
monocytes, macrophages, nerve fibres and associated Schwann cells, and 
mesenchymal stem cells (MSC, also known as skeletal stem cells (SSC)) (Figure 1.2). 
The advent of new genetic tools to dissect the BM niche has provided different and 
overlapping nomenclature for niche cells types. Table 1.2 summarise the genetic 
mouse models, cell-type specificity and overlapping niche cells that have been 
employed so far.  
 
BM mesenchymal stem cells (BM-MSCs) are a rare type of multipotent progenitor that 
reside in the BM niche and have the capacity to give rise to adipocytes, chondrocytes 
and osteoblasts in vitro and in vivo (Park et al. 2012). To date, there is still a need for 
more defined markers of MSCs to better purify these BM stromal cells with 
multilineage capacity. For instance, Nes-GFP+ and Lepr+ cells are highly enriched in 
MSCs ability in vitro, based on CFU-F formation and multilineage differentiation (Xie 
et al. 2015; Bo O Zhou et al. 2014). Table 1.2 shows the main markers used to identify 
MSC in the mouse system.   
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Figure 1.2. Bone marrow niche. HSCs reside close to the perivascular niches. The perisinusoidal
niche is formed by fenestrated sinusoids, sinusoidal ECs, and perisinusoidal stromal cells (Lepr+,
CXCL12-abundant recitular CAR cells, NestinGFPdim). The periarteriolar niche includes a central
arteriole, arteriolar ECs, and periarteriolar stromal cells (NG2+, NestinGFPhigh). Other components of the
BM niche include megakaryocytes, macrophages, nerve fibres and associated non-myelinating
Schwann cells,MSC/SSC, and osteoblasts.
CLP
Megakaryocyte
Osteoblast
HSC
sinusoid
Sinusoidal EC
Bone
Macrophage
Arteriolar EC
Arteriole
Periosinusoidal
stromal cells
Non-myelinating 
Schwann cell
Periarteriolar
stromal cells
Nerve
MSC / SSC
Arteriole
Mouse Strain Inducible Specificity Germline Deletion? Mating strategy Issues
VE-Cadherin-CreERT2 Tamoxifen-inducible
Adult: ECs
Embryo: ECs and HSCs no
+/- X -/-
no preference
Adult induction does 
not target all ECs
Prx1-Cre No MSCs and perivascular cells N.D +/- male X -/- female None
Nestin-Cre No 
MSCs and perivascular cells 
(GFPhi periarteriolar, GFPdim
perisinusoidal)
Other organs (depends on strain)
Yes +/- X -/-no preference
Different strains 
available have 
different cell-
specificity 
LepR-Cre No MSCs and perisinusoidal cellsBrain cells No 
+/- X -/-
no preference None
Osx1-GFP::Cre
Doxycycline
mediate 
inhibition
Osteoprogenitors No +/- male X -/- female
growth retardation 
and malocclusion 
occur in mice carrying 
Cre
Mouse Col2.3-Cre No Mature osteoblasts No +/- X -/-no preference None 
Adipoq-Cre Tamoxifen-inducible Adipocytes No
+/- X -/-
no preference None
NG2-CreERT2 Tamoxifen-inducible
Perioarteriolar cells in adults
Broader range of BM MSCs in 
embryo and 3-weeks old
No +/- X -/-no preference
Different cell 
specificity young and 
adult mice
Table 1.2. Haematopoietic Cre-Lox mouse models to study the BM niche
N.D. – Not determined
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Despite first evidence suggesting that HSCs are close to the inner interface of bone, 
the endosteum or osteoblastic niche, (Lévesque et al. 2010; Arai and Suda 2007), the 
current view of the BM niche no longer supports this theory. Rather, only a subset of 
lymphoid progenitors seems to be in close association with the osteoblastic niche in 
the endosteum (Ding and Morrison 2013). HSCs locate in the perivascular niche, that 
comprise endothelial and stromal cells in contact with sinusoids – perisinusoidal - or 
arterioles – periarteriolar, that also includes nerve fibres and non-myelinating 
Schwann cells (Chen et al. 2016). It appears that most of HSCs (80%) reside near the 
perisinusoidal niche, 10% in transitional zones between arterioles and sinusoids, and 
10% in the periarteriolar niche, located in the centre of the BM niche and run parallel 
to the bone, while sinusoids are found perpendicularly orientated and distributed 
across the BM niche (Kunisaki et al. 2013; Acar et al. 2015). The different location of 
HSCs in different niches might underscore different HSCs subsets with distinct self-
renewal and differentiation faculties within the BM. The perisinusoidal niche is the most 
hypoxic region (Nombela-Arrieta et al. 2013), and while the main mediators of hypoxia 
signalling, Hif1a and Hif2a are dispensable for HSC maintenance and self-renewal in 
a cell-autonomous manner (Vukovic et al. 2016; Guitart et al. 2013), previous studies 
that deleted Hif1a in HSCs and the BM niche (i.e. using the Mx1-Cre promoter) found 
some HSCs defects, indicating that hypoxia signalling regulates HSC function 
indirectly by modulating BM niche cell activity (Takubo et al. 2010). Perisinusoidal 
HSCs are in close proximity to blood constituents that passage fenestrated sinusoids 
(Itkin et al. 2016). Radical oxygen species (ROS), a byproduct of metabolism, 
negatively impact HSC quiescence and self-renewal while positively regulating 
homing and migration of HSPCs after transplantation (C. Chen et al. 2008; Porto et al. 
2015; Shao et al. 2011). In fact, a third of perisinusoidal HSCs (CD150+CD48-) stain 
for ROS, while no periarteriolar HSCs stain negative for ROS (Itkin et al. 2016). 
However, it can be argued that also a third of HSCs stain positively for CD41 (Oguro 
et al. 2013), which marks megakaryocyte progenitors that associate with sinusoids 
(Tavassoli and Aoki 1989), suggesting that the difference seen in ROS levels in HSCs 
might be actually due CD41 “contamination”.  
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1.1.3.1. BM niche factors are essential for HSC maintenance 
 
HSCs sense the external signals from extracellular growth factors, nutrients, and 
stress that regulate HSC self-renewal, maintenance and differentiation (Suda et al. 
2005). HSCs express known receptors such as Kit, Cxcr4 and Mpl that regulate HSC 
fate decisions, however the cell-specific origin of Scf and Cxcl12 has only recently 
been interrogated. Knock-in reporter mice expressing Scf fluorescence proteins 
showed that Scf is not expressed in haematopoietic cells or osteoblasts, but is mainly 
expressed in perisinusoidal cells, and at very low levels in endothelial cells, and some 
arterioles (Ding et al. 2012). In agreement with this, deletion of Scf in haematopoietic 
cells (using Vav1-Cre), osteoblasts (using Col2.3-Cre), and periarteriolar cells (using 
Nes-Cre, Nes-CreER, Ng2-CreER) does not affect HSCs in young adult mice 
confirming that Scf does not have autocrine effects in HSCs (Ding et al. 2012). 
Deletion with Ng2-Cre depletes HSCs due a broad expression of Ng2+ in niche cells 
during foetal stages (Ding et al. 2012; Bo O. Zhou et al. 2014). Conversely, deletion 
of Scf in endothelial cells (Tie2-Cre) and perisinusoidal cells (Lepr-Cre) leads to HSC 
depletion in steady-state conditions (Ding et al. 2012). Co-deletion of Scf in endothelial 
and perisinusoidal cells results in loss of quiescence and serially transplantable 
defects (Ding et al. 2012), indicating maintenance of adult HSCs by Scf produced from 
perisinusoidal and endothelial cells. 
 
Using the same approach, it was found that Cxcl12 is highly expressed in 
perisinusoidal cells, at lower levels in endothelial cells, and is even further attenuated 
in osteoblasts (Ding and Morrison 2013; Greenbaum et al. 2013; Asada et al. 2017). 
Deletion of Cxcl12 in megakaryocytes (by Pf4-Cre), haematopoietic cells (by Vav-
iCre), and periarteriolar cells (by Nes-Cre, Nes-CreER, Ng2-CreER) does not affect 
adult HSCs (Ding and Morrison 2013). In contrast, deletion of Cxcl12 in endothelial 
cells (Tie2-Cre) leads to HSC depletion whilst deletion in perisinusoidal cells (Lepr-
Cre) leads to HSC mobilization (Ding and Morrison 2013), indicating that different 
sources of Cxcl12 play different functions in HSC regulation. Interestingly, Cxcl12 
deletion in osteoblasts (Col2.3-Cre) depletes lymphoid progenitors from the BM, 
confirming the close proximity of lymphoid progenitors to the osteoblastic niche 
(Visnjic et al. 2004; Zhu et al. 2007). However, a more recent study reinforced that 
NG2+ cells also secrete Cxcl12 and contribute to HSC maintenance in the BM niche 
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(Asada et al. 2017). Discrepancies observed between the studies conducted by the 
Morrison (Ding and Morrison 2013) and Frenette (Asada et al. 2017) labs could be 
explained by the overlapping activity of Cre transgenic mice used, and the differential 
GFP or Cre expression observed within the targeted populations, indicating that these 
Cre mice marks a heterogeneous cell population. This notwithstanding, the current 
dogma supports a model where HSCs fate decisions are modulated by the factors 
provided by endothelial and perivascular niche cells.    
 
Adipocytes represent approximately a 5% of the total Lepr+ cells, and have been linked 
with fatty marrow displacement in aplastic anaemia and other haematological 
disorders and are known to negatively impact HSC function (Brodsky and Jones 
2005). In fact, engraftment of BM cells after irradiation is enhanced in genetically 
engineered mice that are unable to produce adipocytes suggesting, they are negative 
regulators of HSCs in this context (Naveiras et al. 2009). Interestingly, a recent report 
has highlighted a positive HSC supporting role for adipocytes in the BM niche. 
Conditional deletion of Scf in adipocytes (with adipoq-CreER) had no impact in HSC 
under steady-conditions (Zhou et al. 2017). Under regenerative conditions (i.e. 
irradiation or 5-FU treatment), sinusoids are lost and instead adipocytes proliferate 
and become more predominant in the BM (Zhou et al. 2017). Deletion of Scf in 
adipocytes (adipoq-CreER) under these circumstances, delayed haematopoietic 
regeneration and reduced survival of irradiated and 5-FU treated recipients (Zhou et 
al. 2017). Deletion of Scf in endothelial cells after irradiation did not impact HSC 
numbers (Zhou et al. 2017), indicating that adipocytes are the main source of Scf for 
HSCs after haematopoietic injury.  
 
Therefore, the BM niche is highly heterogeneous and contains distinct subpopulations 
that are able to regulate HSCs at different stages of development. There is still 
controversy regarding the contribution of each niche cell type to haematopoiesis, 
however it seems that HSCs are dependent on specific niche cells in steady-state, BM 
regeneration and stress, highlighting the malleability of the haematopoietic to different 
physiologic stressors. Future work is required to further specify niche cell types and to 
discern whether specific subsets of HSC and/or progenitor cells are dependent on 
specific niche cells within the BM.  
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1.1.3.2. HSC differentiation – cell autonomous or niche dependent?    
 
The stem cell theory from McCulloch (Till and McCulloch 1961) supports that HSC 
have an intrinsic program that governs its cell-fate decisions, while Schofield’s niche 
theory (Schofield 1978) postulates that signals from the BM microenvironment direct 
HSC fate. Since then, researchers have provided supportive evidence for each theory, 
reaching a consensus with a combined theory, whereby the crosstalk between HSCs 
and the BM niche mediated by secreted factors (i.e. cytokines, growth factors, 
chemokines), regulate HSC fate decisions. However, the study from Yu et al., (Yu et 
al. 2016) employing a multifluorescent reporter mice that allow the clonal tracking of 
HSCs during differentiation, has raised some questions concerning the impact of the 
BM niche in lineage commitment.  
 
The study from Yu et al. (Yu et al. 2016), supports previous data indicating that HSCs 
are biased towards the production of particular blood lineages, even at the clonal level 
(Hoppe et al. 2016; Dykstra et al. 2007). Different colour-code HSCs clones had 
different myeloid/lymphoid potential; in addition, HSC clones with lymphoid potential 
were less proliferative while myeloid-skewed clones were more proliferative, and this 
was phenocopied after transplantation of specific HSC clones into irradiated mice (Yu 
et al. 2016). Interestingly, this predetermined lineage-bias is not discernible at the 
transcriptional level, but it is marked by its epigenome, DNA methylation and chromatin 
accessibility, suggesting that, at the clonal level, epigenetics regulates how a HSC will 
behave in steady-state and stress conditions. This predetermined lineage-biased HSC 
model raises some questions regarding the plasticity of HSCs and its differentiation 
potential in response to BM niche signals. It was originally theorised that HSC are 
poised by expressing very low levels of TFs that drive differentiation to several 
lineages and that under external stimuli produced an imbalance of this TFs into the 
desired blood cell type (Laslo et al. 2006). This new evidence suggests that it exists 
differential TF expression at the single-cell level in progenitor cells, therefore indicating 
that HSCs are hardwired at the clonal level in a cell-autonomous manner to determine 
their differentiation fate (Baryawno et al. 2017). Nevertheless, these findings do not 
discard the idea that the niche is crucial for HSC activity; for example, it has not been 
ruled out experimentally that the niche could modify the epigenetic status of HSCs. 
With the growing evidence that subsets of HSCs can be found in association with 
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specific BM niches, it is clearly possible that specific niche cells can, at the very least, 
support the predetermined differentiation fate of each HSC clone. 
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1.2. Acute myeloid leukaemia   
 
Acute myeloid leukaemia (AML) is a heterogeneous blood cancer characterised by 
the rapid growth of abnormal white blood cells (termed blasts) and a block in normal 
blood cell differentiation (Hanahan and Weinberg 2011) that presents with variable 
morphology, genetic and epigenetic alterations to influence the prognosis and 
therapeutic response to standard chemotherapeutics and novel therapies (De 
Kouchkovsky and Abdul-Hay 2016; Shafer and Grant 2016). AML is the most common 
type of leukaemia in adults (Hanahan and Weinberg 2011). The prevalence of AML in 
adults is of 3.8 per 100,000 individuals, increasing to 17.9 cases per 100,000 in adults 
older than 65 years old (De Kouchkovsky and Abdul-Hay 2016; Boissel et al. 2005), 
with the median age of adult AML being 67 years old. Morbidity in AML is not directly 
related to the malignancy of the leukaemia cells per se, but instead due the lack of 
functionally mature immune and red blood cells produced; thereby causing 
haemorrhaging and infections leading to mortality (Lowenberg et al. 1999). 
 
Diagnosis of AML has traditionally followed the French–American–British (FAB) 
classification, based on the morphology and cytochemistry alongside the presence of 
more than 30% blasts in the BM (Papaemmanuil et al. 2016) (Table 1.3). Later, the 
World Health Organization (WHO) incorporated the cytogenetic groups and set out 
the frequency of AML blasts in the BM to higher than 20% (Arber et al. 2016)(Table 
1.4). These classifications help to stratify AML patients into good, intermediate, or poor 
prognosis groups that ultimately inform treatment strategy. However, the most relevant 
factor dictating treatment and survival is patient age. The 5-year survival rate is 60% 
in patients aged 15 to 24, almost 40% between 25 and 64, and nearly 5% in patients 
65 and above (Büchner et al. 2005). This is because older (or unfit) patients are 
susceptible to comorbidity related to intensive treatments and often present with 
adverse cytogenetic risk group, frequently derived from MDS or therapy-related AML 
(Büchner et al. 2005).  
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AML can develop as a primary disease, de novo, or can arise secondarily, from 
previous haematological disorders such as cytopenias (Fanconi’s anaemia, congenital 
mono or neutropenia), immunodeficiency syndromes  and myelodysplastic syndromes 
(MDS) –termed secondary AML (De Kouchkovsky and Abdul-Hay 2016; Boissel et al. 
2005). Secondary AML also encompasses therapy-related AML, whereby patients 
from other cancers, (typically colon or breast cancer, or types of leukaemia) as a result 
of treatment with high-dose chemotherapy, gain mutations associated with a complex 
karyotype and adverse prognosis and overall survival (De Kouchkovsky and Abdul-
Hay 2016; Boissel et al. 2005).  
 
FAB subgroup Type of leukaemia PrognosisFrequency in AML Morphology 
M0 Acute myeloblastic leukaemiawithout maturation 
Poor
less than5% 
Immature myeloblasts, lacks definite myeloid 
differentiation by conventional morphology or 
cytochemical analyses 
M1 Acute myeloblastic leukaemiawith minimal maturation 
Intermediate
20% 
Immature myeloblasts predominate, <10% 
promyelocytes, myelocytes or monocytes 
M2 Acute myeloblastic leukaemiawith maturation 
Good
30% 
Immature myeloblasts predominate, but more 
maturation than in M1 
M3 and M3v (variant) Acute promyelocyticleukaemia
Very good
10% 
Promyelocytes predominate, marked 
granulation in more than 30% cells, granules 
not visible by light microscopy in M3v 
M4 and M4EO Acute myelomonocyticleukaemia
Intermediate
25% 
Mixture of abnormal monocytic cells (>20%) 
and myeloblasts/promyelocytes (>20%), 30% 
eosinophils in M4EO 
M5a and M5b Acute monocytic leukaemia Intermediate10% 
Monocytic cells predominate (>80%) in M5a, 
>80% nonerythoid cells are immature 
monoblasts, >20% are mature monocytes in 
M5b 
M6 Acute erythroleukaemia PoorLess than 5% 
Myeloblasts and erythroblasts predominate, 
abnormal multinucleated erythroblasts 
containing PAS-positive blocks 
M7 Acute megakaryoblasticleukaemia
Poor
Less than 5% 
Megakaryocytic cells as shown by platelet 
peroxidase activity on electron microscopy or 
by tests with platelet-specific antibodies, often 
myelofibrosis and increased BM reticulin
Others Undifferentiated acute leukaemia, hypocellular AML Unkown
Table 1.3. French-American-British (FAB) AML classification
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Gain of function mutations of signalling pathway receptors (FLT3, KIT, FGFR, 
NOTCH) or its mediators (RAS, MAP,) leading to constitutive activation are frequently 
observed in AML (Martelli et al. 2013; Link 2012). FLT3 activating mutations as a result 
of internal tandem duplication (FLT3-ITD) or tyrosine kinase domain (FLT3-TKD) that 
confer ligand-independent activation, are very frequent in AML and correlate with 
adverse prognosis (Meshinchi et al. 2006). Specific FLT3 inhibitors compete with ATP 
binding in the intracellular domain and have been used in AML clinical trials (Weisberg 
et al. 2010). Although the first generation of inhibitors had limited success, a second 
AML Classification AML Subtypes 
AML with recurrent genetic abnormalities 
t (8; 21) (q22; q22); RUNX1-RUNX1T1 
Inv (16) (p13; 1q22) or t(16; 16) (p13.1; q22); CBFB-MYH11 
APL with t (15; 17) (q22; q12); PML-RARA 
AML with t (9; 11) (p22; q23); MLLT3-MLL 
AML with t (6; 9) (p23; q34); DEK-NUP214 
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM 
AML (megakaryoblastic) with t (1; 22) (p13; q13); RBM15-MKL1 
Provisional entity: AML with BCR-ABL1
Provisional entity: AML with mutated NPM1 
Provisional entity: AML with mutated CEBPA 
Provisional entity: AML with mutated RUNX1 
AML with myelodysplasia-related changes 
Therapy-related myeloid neoplasms 
AML - not otherwise specified (NOS) 
AML with minimal differentiation 
AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monoblastic/monocytic leukaemia 
Pure erythroid leukaemia
Acute megakaryoblastic leukaemia
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
Myeloid sarcoma 
Myeloid proliferations related to Down’s syndrome 
Transient abnormal myelopoiesis (TAM)
Myeloid leukaemia associated with Down syndrome 
Blastic plasmacytoid dendritic cell neoplasm 
8. Acute leukaemia of ambiguous lineage 
Acute undifferentiated leukaemia 
Mixed phenotype acute leukaemia with t (9; 22) (q34; q11.2); BCR-ABL 
Mixed phenotype acute leukaemia with t (v; 11q23); KMT2A rearranged 
Mixed phenotype acute leukaemia, B/myeloid, NOS 
Mixed phenotype acute leukaemia, T/myeloid, NOS 
Provisional entity: Natural killer (NK)–cell lymphoblastic leukaemia/lymphoma 
Table 1.4. World Health Organisation (WHO) WHO classification of myeloid neoplasms and
acute leukaemia
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generation of FLT3 inhibitors such AC220 show promising results in clinical trials 
(Zarrinkar et al. 2009; Small 2006). Resistance to FLT3 inhibitors are mediated by 
acquired mutations that reactivate FLT3 downstream signalling pathways, including 
PI3K/AKT/MTOR, RAS/MAPK, and JAK/STAT5 also in FLT3-ITD cases (Weisberg et 
al. 2010; Kindler et al. 2010). Despite that, no mutations have been identified in 
members of the PI3K/AKT/MTOR pathway in AML, aberrant activation mediated by 
tyrosine kinase receptor (TKR) or crosstalk between signalling pathways, has been 
described to be responsible for therapy resistance in many cases (Bertacchini et al. 
2015; Porta et al. 2014; Yap et al. 2008). Specific inhibitors of this pathway showed 
modest efficacy in AML clinical trials, although dual and multiple targeting of different 
components of the pathway in combination with chemotherapy show promising results 
(Bertacchini et al. 2015; S. Park et al. 2008; Vachhani et al. 2014; Sandhöfer et al. 
2015). The JAK/STAT pathway is frequently activated by upstream mutations in TKR 
(Furqan et al. 2013; Li 2008), and the main mediator in AML is STAT5, which is able 
to activate the expression of genes driving proliferation and apoptosis resistance 
(Harrison 2012). Activating mutations in RAS are found in approximate 30% of AML 
patients and it has been reported that chemotherapy often activates this pathway 
(Schlenk et al. 2008; Kadia et al. 2012), therefore contributing to drug resistance. 
Recently, mutations in epigenetic regulators (TET2, IDH1/2, DNMT3A) have also been 
implicated in the pathogenesis of AML (discussed in Section 1.2.1 and 1.2.2) (Melnick 
2010).  
 
This thesis will focus on the mutations, (epi)genetic dysregulation, and chromosomal 
inversions or translocations involving TFs leads to aberrant miss-expression of their 
transcriptional targets, which favours leukaemia development. The most common and 
studied TFs in AML include MLL, PML, EVI1, PU.1, GATA1/2, RUNX1, CEBPa, and 
HOX genes. For instance, hereditary AML is caused by mutations in TFs essential for 
haematopoiesis such as RUNX1, CEPBa and GATA2 (Owen et al. 2008). RUNX1 
mutations predispose to familial platelet disorder (FPD), an autosomal dominant 
disease characterised by thrombocytopenia and lower platelet count, with high risk for 
progression of MDS and AML (Harada and Harada 2009). Sporadic mutations in the 
RUNX1 gene have also been described in de novo AML, and in both hereditary and 
sporadic these mutations are linked to adverse outcome (Osato 2004; Schnittger et 
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al. 2011; Gaidzik et al. 2011). Unlike other hereditary AML predisposing genes, 
CEPBa germline mutations cause AML without previous haematological conditions, 
and are normally associated with FAB subtypes of undifferentiated phenotype (Smith 
et al. 2004), in agreement with the role of CEPBa in myeloid differentiation (Wang et 
al. 2006). Patients can present with mono or biallelic CEPBa mutations, and generally 
are included in the good prognosis AML group (Tawana et al. 2015; van Waalwijk van 
Doorn-Khosrovani et al. 2003).  
 
Specific chromosomal translocations can also lead to AML, as exemplified by acute 
promyelocytic leukaemia (APL), FAB M3 AML subtype, characterised by the 
differentiation block at the promeylocytic stage (Ryningen et al. 2008). Initially, APL 
had a grave prognostic (Wang and Chen 2008), however the discovery that APL 
originates with the chromosomal translocation t(15;17)(q22;q21)/PML-RARA present 
in all APL cells, prompted researchers to test the ability of all trans retinoic acid (ATRA) 
to interact, dissociate and provoke the degradation of PML-RARA, thereby inducing 
the terminal differentiation of APL cells into granulocytes (Wang and Chen 2008). 
Currently, differentiation therapy employing ATRA and arsenic trioxide (ATO) is a 
successful therapy able to achieve cure rates up to 80% in APL patients (Cull and 
Altman 2014). Attempts to reproduce this induction of differentiation in other AML FAB 
subtypes have not been successful (Johnson and Redner 2015). For instance, 
addition of ATRA to induction therapies of non-APL AML has failed (Delva et al. 1993). 
This is due to a lack of expression or RAR signalling in non-APL AML, where it has 
been found that many oncogenes in non-APL AML bind and repress RAR (Delva et 
al. 1993). Thus, novel approaches are required to circumvent the lack of expression 
of RAR in non-APL AML in order to release the block in differentiation of AML blasts 
cells. Other chromosomal translocations like t(8;21)(q22;q22)/RUNX1-RUNX1T1 or 
inv(16)(p13q22)/t(16;16)(p13;q22)/CBFB-MYH11 are also included in the good 
prognosis group, and can be treated with relatively high success using intensive 
regimens of chemotherapy (Corbacioglu et al. 2010). In striking contrast, 
translocations implicating EVI1 (3q translocation or inversion), monosomy of 
chromosome 5 or 7, and MLL fusion proteins have generally poor prognosis (Lugthart 
et al. 2008; Krivtsov and Armstrong 2007). 
 
 26 
One of the alterations typically associated with the FAB-M4 or M5 subtypes of human 
AML is the translocation t(9;11)(p22;q23) producing the fusion protein MLL-AF9 
(MLLT3) (Alonso et al. 2008). Mixed lineage leukaemia (MLL) has over 60 different 
fusion partners in AML, although as implied by the name, the MLL gene could be 
rearranged in both AML and acute lymphoid leukaemia (ALL), or present with mixed 
myeloid/lymphoid leukaemia (Super et al. 1997; Krivtsov and Armstrong 2007). The 
wild-type MLL gene encodes a SET domain containing H3K4 histone 
methyltransferase activity that interacts with many other proteins to regulate the 
epigenetic status of the cell (Bernt et al. 2011; Krivtsov and Armstrong 2007). Indeed, 
retroviral insertion of MLL-AF9 in murine HSPCs initiates the leukaemogenic program 
in vitro and is able to induce AML in vivo (Krivtsov et al. 2006; Somervaille and Cleary 
2006). One of the direct targets and main drivers of MLL-AF9 leukaemia is the HOX 
family of TFs, especially HOXA9 (Faber et al. 2009). Overexpression of HOXA9 is 
found in human and mouse MLL-AF9 AMLs, and deletion of HOXA9 abrogates AML 
development (Faber et al. 2009). In addition, co-expression of Meis1a, a HOX 
transcriptional cofactor with Hoxa9 in HSPCs confers aberrant self-renewal and 
promotes leukaemia formation (Kroon et al. 1998). HOXA9 and MEIS1A are not only 
overexpressed in MLL-AF9 AML, but also in 40% of adult AML patients and are linked 
with adverse outcome (Lawrence et al. 1993).  
Gene dosage is a critical factor for AML development, exemplified by PU.1, an Ezb 
transformation-specific sequence (Ets) TF indispensable for myelomonocytic 
differentiation during normal haematopoiesis (Scott et al. 1994; McKercher et al. 
1996). Mutations or down-regulation of PU.1 have been reported to play a central role 
in AML (Bonadies et al. 2010). One of the regulatory mechanisms of PU.1 expression 
is mediated by an upstream regulatory element (URE) (Mak et al. 2011; Li et al. 2001). 
Whereas Pu.1 knockout (KO) mice die at birth (Scott et al. 1994), the KO of URE 
induces a decrease of the PU.1 gene expression by 80%, leading to AML and B-CLL- 
(B-CLL) like disease (Rosenbauer et al. 2004).  
Understanding the molecular basis of TFs in malignant haematopoiesis is essential to 
develop new and targeted therapies for specific AML molecularly defined subtypes. 
Such TF perturbations specifically occurring in HSCs or progenitor cells, lead to the 
emergence of rare leukaemia stem cells (LSCs), which sustain and nurture the bulk of 
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leukaemia cells in AML. Evidence for the existence of LSCs in AML has been an area 
of intense investigation over the last 20 years.  
 
1.2.1. Acute myeloid leukaemia stem cells  
 
LSCs, like their normal HSC counterparts, comprise a small fraction of the total 
leukaemic population, and there is evidence of a hierarchical cellular organization of 
human AML consistent with the cancer stem cell (CSC) model (Figure 1.3) (Dick 
2005). In AML, the first conclusive evidence of LSCs was published in 1997 (Bonnet 
and Dick 1997). Bonnet and Dick fractionated the AML cells from patients using cell 
surface markers and tested the leukaemia initiating capacity (LIC) of each subset of 
AML cells in vivo in transplantation assays (Bonnet and Dick 1997). They obtained the 
highest LIC in a small CD34+CD38- population, which also contains HSCs in healthy 
patients, whilst detecting a lower LIC activity in the CD34+CD38+ subset, containing 
progenitor cells (Bonnet and Dick 1997). During the past 2 decades, distinct surface 
markers have been identified to define LSCs. In the majority of AML patients, 75%, 
are CD34+, defined by more than 10% of CD34 positive cells, while the remaining 25% 
have less than 10% of CD34 positive cells, named CD34- AML, where the highest LSC 
activity resides in the CD34- fraction (Thomas and Majeti 2017). Therefore, it appears 
that different populations with LSC activity are found in both the CD34 positive or 
negative fraction, within the same patient. This in turn led to a study analysing the 
immunophenotype of 100 CD34+ samples, and together with xenotransplantation 
assays, confirmed the coexistence of two distinct LSC subsets in 80% of the samples; 
a fraction resembling lymphoid-primed multipotent progenitors (LMPP-like LSCs) 
defined by Lin-CD34+CD38-CD90-CD45RA+, and a GMP-like LSC subset, Lin-
CD34+CD38+CD123+CD45RA+ (Goardon et al. 2011). The LMPP-like population was 
able to give rise to the GMP-like subset, though this was not a reciprocal event 
(Goardon et al. 2011). In 15% of CD34+ AML, LSCs are believed to reside in a 
dominant MPP-like population (CD34+CD38-CD90-CD45RA-). The highest LSC 
capacity resides in the CD34+CD38- (MPP-like and LMPP-like fractions), and these 
LSCs are molecularly distinct from the GMP-like LSCs (Goardon et al. 2011). Other 
surface markers have been investigated in order to identify LSCs, such CD123, CD44, 
CD47, TIM3, CD99 (Bonardi et al. 2013; Han et al. 2015; Schubert et al. 2011; Jan et 
al. 2011), reflecting both the heterogeneity of the disease itself and LSC populations. 
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Thus, further research is required to define consistent markers of LSCs, to understand 
the underlying biology, in order to track residual disease and stratify patient treatment 
during therapy.   
 
 
 
Efforts in recapitulating human AML biology using transgenic or retroviral mouse 
models, have led to the development and characterisation of mouse models that 
harbour specific chromosomal translocation or mutations. One of the most studied 
translocations in these mouse models is MLL-AF9. Using a retroviral system that 
overexpresses the human MLL-AF9 transgene, two studies led by Krivtsov et al., and 
Somervaille and Cleary, transformed and initiated leukaemogenesis from GMP or 
HSPCs, and were able to induce and propagate AML upon transplantation in irradiated 
mice (Krivtsov et al. 2006; Somervaille and Cleary 2006). They found a leukaemia 
hierarchy, in which LSCs are as frequent as 25-30%, are positive for the mature 
myeloid-markers Mac1 and Gr1, but also express the stem cell marker C-kit 
(Somervaille and Cleary 2006). Krivtsov et al. defined these LSCs as GMP-like since 
they immunophenotypically resembled murine GMP (Lin-Sca-1-c-
Kit+CD34lowCD16/32+) (Krivtsov et al. 2006). Interestingly, GMP-like LSCs resemble 
the gene expression profile of their wild-type counterparts, and the reactivation of a 
Figure 1.3. Stochastic versus cancer stem cell (CSC) model. According to the stochastic model, any cancer cell within a tumour is able to initiate a tumour. In contrast, the CSC model
postulates the existence of biologically distinct classes of cells with different features. Only a subset of cells, CSCs, can initiate tumour growth; CSCs possess self-renewal and produce non
tumour initiating cells that make up the bulk of the tumour.
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HSC self-renewal signature, including Hox genes and Evi1 (Krivtsov et al. 2006; 
Krivtsov et al. 2013). Another epigenetic modifier, Tet2, that is frequently mutated in 
AML (Young et al. 2016), give rise to AML when Tet2-/- mice are crossed with Flt3ITD 
mice. In these animals, the LSC population resides in the MPP-like population (LSK 
CD48+CD150-), while GMP are not able to induce or propagate the disease in this 
model (Shih et al. 2015). Therefore, heterogeneity in AML LSCs is not only observed 
in patients, but also in AML mouse models, which offer a tractable model to develop 
specific inhibitors of LSCs. Indeed, several epigenetic inhibitors, such as BET 
inhibitors, that are currently used in AML, were first tested using mouse LSC models 
that target the bromodomain and extra terminal (BET) family of proteins (BRD2, BRD3, 
BRD4 and BRDT), which bind to histones and are crucial for the chromatin remodelling 
of MLL oncogenic translocations (Fong et al. 2015; Shafer and Grant 2016). Another 
component of the MLL epigenetic complex is the methyltransferase Dotl1, whose 
deletion abrogates MLL-AF9 AML, has led to the development of small molecule 
inhibitors of Dotl1 (Spurr et al. 2016), currently in clinical trials of AML (Nguyen et al. 
2011; Daigle et al. 2013; Daigle et al. 2011). Isocitrate dehydrogenase 1 or 2 (IDH1/2), 
commonly known as Krebs cycle enzyme (Grassian et al. 2014), is also able to 
regulate the epigenetic status by histone modification (Figueroa et al. 2010). Mutations 
on both IDH1 and IDH2 have been found in around 10% of AML patients (Patel et al. 
2011), provoking a differentiation block and DNA and histone hypermethylation, at 
least in part, by disrupting Tet2 activity (Figueroa et al. 2010) and accumulation of the 
oncometabolite 2-hydroxygulatarate (Lin et al. 2015). IDH inhibitors are currently 
showing promising results in AML clinical trials in patients with IDH1 or 2 mutations 
(Levis 2013; Fujii et al. 2016; Shafer and Grant 2016).  
 
In agreement with the CSCs model, LSCs are thought to drive leukaemogenesis by 
nurturing the bulk of blasts cells, and are responsible for AML relapse in response to 
standard chemotherapy (Dick 2005). These properties are endowed in LSCs due to 
the acquisition of an aberrant self-renewal capacity, apoptosis resistance, while also 
being able to maintain a quiescent and hypoxic state (Dick 2005).  
 
Several TFs such as HOXA9 confer self-renewal of LSCs (Kroon et al. 1998). Bmi1 
confers self-renewal of LSCs in MLL-AF9 as Bmi1 deficient LSCs are unable to 
propagate AML into secondary recipients, and these self-renewal effects are mediated 
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in part by Hoxa9 (Smith et al. 2011). The Wnt/β-catenin and hedgehog signalling 
pathway have also been found to be responsible for LSC self-renewal (Wang et al. 
2010; Heidel et al. 2011). miRNA-126 has been recently identified to be highly 
expressed in AML patient and to act as critical regulator of LSCs quiescence 
(Lechman et al. 2016). miRNA-126 overexpression in LSCs induces quiescence and 
thus promotes chemotherapy resistance by negatively impacting the PI3K/AKT/MTOR 
pathway (Lechman et al. 2016), a known regulator of LSC self-renewal (Sykes et al. 
2011).  
 
Quiescence is characterised by a low-level metabolic rate (Laporte et al. 2011; Signer 
et al. 2014), hence understanding what fuels LSCs could be used therapeutically to 
awaken quiescent LSCs that are resistant to apoptosis. Like in HSCs, there is 
controversy about the hypoxia requirements in LSCs. Dominique Bonnet’s group 
found that HIF2 is expressed in AML, and HIF2α knockdown using short hairpin RNA 
(shRNA) resulted in impaired AML growth in vitro and in vivo, highlighting the potential 
use of HIF inhibitors in AML (Rouault-Pierre et al. 2013). HIF2α deficient AML cells 
produce ROS that provoke endoplasmic reticulum (ER) stress, which in turn leads to 
apoptosis by activation of the unfolded protein response (UPR) pathway (Rouault-
Pierre et al. 2013). However, in contrast to the use of shRNA knockdown in cells 
cultured in normoxia (Rouault-Pierre et al. 2013), recent findings using 
haematopoiesis-specific gene knockout mouse models, demonstrate that deletion of 
Hif2α accelerated LSC development in Meis1a/Hoxa9 mouse models and in a Mll-af9 
transgenic mouse models (Vukovic et al. 2015). Interestingly, co-deletion of both Hif1α 
and Hif2α synergise to accelerate the development of AML (Vukovic et al. 2015), 
suggesting that Hif1α and Hif2α are tumour suppressors in AML driven by Mll-af9 and 
Meis1a/Hoxa9 oncogenes, consistent with a previous report showing that Hif1α acts 
as a tumour suppressor in Meis1a/Hoxa9 and Mll-enl mouse models (Velasco-
Hernandez et al. 2014). In addition, it was demonstrated that neither pharmacological 
inhibition or CRISPR/Cas9 deletion of HIF2α affected growth of AML cell lines 
harbouring MLL-AF9 translocation (Vukovic et al. 2015), highlighting the need for 
stratification and assessment of HIF targeting in individuals AML molecular subtypes. 
A role for Hif2α as a tumour suppressor has also gained support from other cancer 
types, such as glioblastoma (Acker et al. 2005).  
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Despite the exhaustive research in understanding LSC biology in AML, and with the 
exception of APL, a meaningful improvement in the survival of AML patients over the 
last 40 years has not been forthcoming (De Kouchkovsky and Abdul-Hay 2016). 
Advances in understanding epigenetic regulation of LSCs and in LSC-BM niche 
interactions have afforded the development of new and specific inhibitors of LSCs with 
clinical potential. Yet, it seems unlikely to find a drug that targets all types of AML 
LSCs, but rather to design specific inhibitors that abrogate the main drivers underlying 
LSC resistance in each cytogenetic and molecular subtype.  
 
1.2.2. AML Pre-LSCs and cell of origin  
 
In mice, several studies aimed to decipher the cell of origin in AML, and the impact of 
gene deletion depending of the cell of origin. MLL-AF9 is able to initiate clonal 
leukaemic colony growth from HSCs, CMP and GMP with similar cloning efficiency in 
vitro, yet in vivo AML development is faster in AML that originates from HSCs 
compared to GMP (Krivtsov et al. 2013). This was underpinned by expression of HSC 
specific genes that confer self-renewal, such as Evi1, which are expressed in L-GMP 
derived from HSCs but not from L-GMP derived from GMP (Krivtsov et al. 2013). This 
signature is capable of stratifying MLL-AF9 AML patients; as a result, L-GMP-HSC 
signature is linked with poor prognosis and shorter overall survival (Krivtsov et al. 
2013). Krivtsov et al., also demonstrated that the L-GMP-HSC signature conferred 
chemotherapy resistance (Krivtsov et al. 2013)(Figure 1.4). Another study employed 
a Mll-af9 knock-in mouse model, in which the MLL-AF9 translocation is under the 
control of the endogenous Mll promoter, develop aggressive AML within 5-6 months 
after birth and closely recapitulate multiple features of human leukaemia (Corral et al. 
1996). This research outlined that HSC, but not CMP or GMP, from preleukaemic Mll-
af9KI mice were able to recapitulate AML in an irradiated host (W. Chen et al. 2008). 
They compared the Mll-af9KI mice with the same retroviral MLL-AF9 model used by 
Armstrong’s lab, and found that the dose of MLL-AF9 in GMPs was much higher in 
the retroviral model compared to the knock-in mice, suggesting that MLL-AF9 can 
reprogram and activate the HSC signature in GMP only at supraphysiological dose 
levels (W. Chen et al. 2008). Finally, since the latency of AML development after 
transplantation was similar to the latency required in the starting Mll-af9KI cohort, the 
authors concluded that HSCs in this model harbour the cell of origin (pre-LSCs), but 
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not LSCs, or that they were not LSCs at the time-frame used for their experiments (8-
week old mice) (W. Chen et al. 2008). Interestingly, when Vukovic et al. (Vukovic et 
al. 2015) transplanted LSK cells from leukaemic Mll-af9KI mice, the recipients also 
developed AML with long latency (30 weeks), however, when they re-transplanted LK 
cells, containing GMP and CMP, into recipients, the latency of AML development was 
shorter (20 weeks), suggesting that LSCs in this model might reside in the progenitor 
compartment (Vukovic et al. 2015). Of relevance, the function of specific genes in 
these models is dispensable or required depending on the cell of origin. For instance, 
genetic deletion of b-catenin showed that LSK but not CMP from Meis1a/Hoxa9 
require b-catenin for LSC development, whereas GMP but not LSK nor CMP require 
b-catenin for LSC development driven by Mll-enl oncogene (Siriboonpiputtana et al. 
2017; Wang et al. 2010; Yeung et al. 2010).   
 
 
 
 
 
Figure 1.4. Cell of origin in AML. The cell of origin in AML could be a HSC or a downstream myeloid progenitor. Mutations or
translocations in HSC or myeloid progenitors (black dotted lines) leads to the generation of Pre-LSC. Pre-LSCs that acquire secondary
mutations become LSCs leading to AML development.
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The dogma of LSC biology and cell of origin in AML changed when attempting to 
identify residual HSCs from LSCs in patients. With the combination of the cell surface 
markers TIM3 and CD99, researchers were able to sort HSCs from LSCs, and 
surprisingly found that most of the patients harboured founder mutations in normal 
HSCs, but not secondary mutations present in LSCs, and these HSCs were termed 
pre-LSCs (Jan et al. 2011; Shlush et al. 2014). Molecular analysis of these pre-LSCs 
showed that they mainly harbour mutations in epigenetic modifiers (TET2, DNMT3A, 
and IDH1/2) but not or few proliferative mutations (Sykes et al. 2015), suggesting that 
the pre-leukaemic status is guaranteed by aberrant epigenetic regulation, while 
acquisition of proliferative mutations may drive the evolution from pre-LSCs to LSCs. 
Xenograft and mouse model studies of these epigenetic modifiers showed that loss of 
TET2 or DNMT3A and gain of function of IDH1/2 leads to enhanced self-renewal 
activity of HSCs (Sykes et al. 2015; Shlush et al. 2014). HSC pre-LSCs from patients 
are able to give rise to multilineage haematopoiesis in NSG mice, whilst also retaining 
the same mutation. Single-cell analysis of pre-LSCs at diagnosis and follow-up 
analysis post treatment at remission and relapse, showed that the frequency of pre-
LSCs at relapse is an indicator of prognosis (Shlush et al. 2017). This suggests that 
pre-LSCs and not exclusively LSCs, are responsible for relapse. Clonal analysis of 
LSCs in AML patients confirmed that in some patients, the LSC clones had different 
secondary mutations at relapse when compared to at first diagnosis, whereas the 
founder mutation was present at all stages (Sykes et al. 2015). Importantly, Pre-LSC 
from patients exhibit chemotherapy resistance; given that LSCs are formed from pre-
LSCs, they thus provide an additional cellular reservoir that may cause relapse and 
leukaemia progression after initial treatment.  
 
Clonal, pre-leukaemic haematopoiesis therefore occurs when HSCs present with 
initiating mutations, especially in epigenetic modifiers, that are a characteristic prelude 
to AML. Efforts are now focusing on elucidating the prognostic value of these 
mutations, and whether preventive treatment would benefit these individuals (Sperling 
et al. 2016; Steensma et al. 2015). Therefore, the identification of pre-LSCs has 
allowed the prospect for preventive treatment; however, the lack of distinct cell-surface 
markers to detect pre-LSCs remains problematic, as they remain indistinguishable 
from normal HSCs.  
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1.2.3. Malignant niche in the initiation and pathogenesis of AML 
 
Harmony between HSCs and the signals that they receive from their surrounding BM 
microenvironment or extramedullary tissues preserves life-long production of blood 
cells. Disruption of these interactions can lead to malignant haematopoiesis, since it 
is thought that malignant cells (i.e. pre-LSCs, LSCs, MDS-CSCs) require a specialised 
niche that support their growth and expansion, whilst are unfavourable for normal 
HSCs, aiding the expulsion or depletion of residual normal haematopoiesis during 
malignant transformation and progression. Whether primed malignant cells secrete 
factors and modify the niche to create a malignant environment, or mutated niche cells 
favour transformation of malignant cells from normal HSCs, are current theories that 
have been proposed.   
 
Fibrosis, neuropathy, and pro-inflammatory cytokines are common features present in 
the BM of leukaemic mice and patients (Scott et al. 2007; Tabe and Konopleva 2015; 
Hanoun et al. 2014). The osteoblastic niche has gained special relevance in 
haematological malignancies. Preferential osteoblastic differentiation of MSCs has 
been shown using mouse models of MPN (Schepers et al. 2013), CML (Bowers et al. 
2015), and AML (Wei et al. 2008). In contrast with normal HSCs, in these settings, 
LSCs preferentially locate near the endosteum (Lane et al. 2011; Zhou et al. 2016), 
are able to recruit Nestin+ cells that undergo osteoblastic differentiation (Hanoun et al. 
2014; Arai and Suda 2007) and release pro-inflammatory cytokines and growth factors 
such as IL-6, G-CSF, GM-CSF, IL-1b that support LSC growth (Ishikawa et al. 2007). 
Human primary AML cells lodged within the osteoblastic-niche in NSG mice and hard 
to engraft primary MDS cells are able to induce MDS-like disease in NSG mice when 
they are co-transplanted with patient derived MSCs (Ishikawa et al. 2007). This 
highlights that mouse and human LSCs are highly niche-dependent, and especially 
osteoblastic-dependent. The Wnt pathway plays an important role in the osteoblastic 
niche in disease initiation. Constitutive expression of stable β-catenin in osteoblasts in 
mice leads to upregulation of Jagged1 and consequent activation of Notch signalling 
pathways in HSPCs, leading to AML development (Kode et al. 2014). In addition, 38% 
of MDS/AML patients show nuclear accumulation of β-catenin in osteoblastic cells in 
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conjunction with upregulation of Notch effectors Hes1, Hes5 and Hey1 in CD34+ AML 
cells (Kode et al. 2014).  
 
The sympathetic nervous system (SNS) is also an important regulator of the BM niche. 
In mouse models of MPN driven by the Jak2 V617F mutation in HSCs, remodelling of 
the BM niche with osteoblastic lineage skewing and loss of nerve fibres accelerates 
MPN development (Arranz et al. 2014), features also seen in patients (Mascarenhas 
et al. 2012). Treatment with b3 agonists reduced disease progression by indirectly 
promoting the formation of Nestin+ MSCs that in turn affected MPN cells (Arranz et al. 
2014). In murine models of AML driven by the Mll-af9 oncoprotein, osteoblastic 
remodelling is also observed in the BM niche, and disruption of b2 adrenergic 
signalling in malignant stromal cells favours AML development (Hanoun et al. 2014). 
Therefore, adrenergic agonists used in the clinic, especially those who target b2/3 
adrenergic receptors, should be considered in clinical trials for haematology 
malignancies. Development of MPN disease seems to be extrinsically initiated by the 
BM niche. A well-known cell-cycle regulator, Retinoblastoma (Rb), is dispensable for 
HSC maintenance in a cell-autonomous manner (Walkley and Orkin 2006), however 
niche-dependent deletion of Rb induces overproliferation and extramedullary 
haematopoiesis of HSCs, key features of a MPN phenotype (Walkley et al. 2007). 
Activating mutations of Ptpn11, that encodes Shp2 phosphatase, a positive regulator 
of the Ras pathway, leads to a MPN in mice (Dong et al. 2016). Cell-autonomous 
activation of Ptpn11 with Vav-Cre produce MPN, but with a weaker phenotype than 
when activated also in the BM niche with Mx1-Cre (Dong et al. 2016). Activation of 
Ptpn11 in differentiated osteoblasts or endothelial cells did not induce MPN, though 
activation in MSCs, perivascular cells and osteoprogenitors leads to HSC 
hyperactivation and secretion of CCL3 with progression to MPN-like disease. In 
addition, pharmacological targeting of CCL3 reversed the development of MPN 
initiated by the BM niche (Dong et al. 2016).  
 
The interactions between the niche and leukaemic cells have other implications for 
therapy and relapse after treatment. Malignant haematopoietic and niche cells can 
build together an environment that protects leukaemic cells, providing sanctuary from 
standard chemotherapy (Jacamo et al. 2014; Duan et al. 2014; Pallasch et al. 2014). 
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For example, mouse and human ALL cells were found surrounded by osteoblasts, and 
Nestin+ with characteristics resembling that of α-smooth muscle cells, thus generating 
a physical and protective niche that attenuates the level of chemotherapeutics that 
reaches leukaemic cells (Duan et al. 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 37 
1.3. GATA family of transcription factors  
 
Transcription factors (TFs) are proteins that are able to sense signals provided from 
signalling pathways, integrate the signal and give an appropriate response in form of 
activation or repression of specific genes. The characteristic feature of a TF is the 
ability to bind the DNA at the promoter or enhancer regions. As a general rule, TFs 
co-operate with other TFs and form multiprotein complexes with co-
activator/repressors that will define the target specificity and refine the type of 
transcriptional regulation (Vaquerizas et al. 2009).  
 
GATA binding proteins are a family of zinc finger (ZF) transcription factors (TFs) that 
bind to “(A/T)GATA(A/G)” sequences in the promoter region of the DNA, to activate or 
repress the transcriptional activity of a target gene (Merika and Orkin 1993; Ko and 
Engel 1993). GATA belong to the subfamily Cys2Cys2 ZF-TFs, in which a zinc ion 
stabilizes the ZF fold structure by interacting with the four cysteines (Merika and Orkin 
1993; Ko and Engel 1993). GATA TFs have two zinc-finger domains that allow binding 
to DNA. Each zinc-finger domain has four cysteine residues that chelate zinc in order 
bind to the DNA or to interact with other TFs (Merika and Orkin 1993; Ko and Engel 
1993). Each zinc-finger domain has different functions, whereby the zinc-finger 
domain 1 or the N-terminal increases the DNA-protein or protein-protein interactions, 
and the zinc-finger domain 2 or C-terminal has ability to bind DNA (Merika and Orkin 
1993; Ko and Engel 1993) (Figure 1.5).  
 
 
Figure 1.5. GATA binding proteins family of Zinc Finger TFs. AA and functional ZF
domain of GATA factors. Four cysteines interacts with a zinc ion which provide structural
stability and is required for proper DNA-protein or protein-protein bindings. Specific AA
represented here belong toGATA3.
Zinc finger 1 Zinc finger 2
Cysteines (C) 
Zn2+ Zinc ion
GATA binding proteins; Zinc-finger Cys4
Adapted and modified from Ho, I-Cheng et al. 2009
N-terminal C-terminal
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There are 6 members in the GATA family (GATA1-6) (Merika and Orkin 1993; Ko and 
Engel 1993). They are each temporally expressed and within specific tissues (Patient 
and McGhee 2002; Lowry and Atchley 2000; Charron and Nemer 1999), although due 
to the strong homology between them, in some biological processes, their expression 
overlaps as they co-regulate each other (Merika and Orkin 1993; Ko and Engel 1993). 
They play major roles in the development and adult maintenance of the 
haematopoietic and cardiovascular system, and breast and prostate tissues (Patient 
and McGhee 2002; Lowry and Atchley 2000; Charron and Nemer 1999). GATA family 
protein activity has also been found in the nervous system, lung, pancreas, gut, 
endothelium, and fat tissue (Patient and McGhee 2002; Lowry and Atchley 2000; 
Charron and Nemer 1999). In broad terms, GATA1-3 is primarily found in the 
haematopoietic system, whereas GATA4-6 is expressed in the heart, liver, lung, 
gonad and gut (Figure 1.6).   
 
 
 
The first GATA member to be identified, GATA1, was described in 1988 in chickens 
(Evans et al. 1988). It plays an essential role in haematopoiesis, specifically in primitive 
and definitive erythropoiesis (Pevny et al. 1991). In fact, Gata1 activates globin gene 
expression, essential for red blood cell function (Miccio et al. 2011). Stuart Orkin’s 
laboratory found that Gata1 KO embryonic stem (ES) cells failed to contribute to 
N
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primitive haematopoiesis in chimera experiments (Pevny et al. 1991). Gata1 is also 
expressed in mast cells and megakaryocytes, but not in HSPCs (Pevny et al. 1991). 
Specifically, higher expression of GATA1 is found in MDS patients (Hopfer et al. 2012), 
while GATA1 mutations are associated with anaemia/thrombocytopenia, and with 
transient myeloproliferative disorder (TMD) and acute megakaryoblastic leukaemia 
(AMKL) in Downs syndrome patients (Ahmed et al. 2004). 	
 
GATA3 and GATA2 were identified in the chicken (Lilleväli et al. 2007), where in the 
first instance, Gata3 expression was detected in T cells (Ho et al. 2009). In line with 
this observation, Gata3 plays a role in T cell development by activating the T cell 
receptor (TCR) (Ho et al. 2009) whilst gene knockout studies found that Gata3 also 
contributes to the formation of T cells in the thymus (Hamburg et al. 2009). In addition 
to its role in T cells, and given its high expression in LT-HSC, a role for Gata3 has 
been postulated in murine LT-HSC. Indeed, in gene knockout studies it has been 
described that Gata3 is required for regulating the cell-cycle entry of LT-HSC (Frelin 
et al. 2013), a finding that has largely been corroborated by other groups (Ku et al. 
2012).  
 
GATA2 was first described in human endothelial cells, where it was required for the 
expression of preproendothelin-1 (Dorfman et al. 1992). In contrast to Gata1, Gata2 
was found to be essential for multiple haematopoietic lineages, and not just restricted 
to the erythroid lineage (Tsai et al. 1994). Gata2 expression is more widespread 
outside of the haematopoietic system; in the brain, kidney, endothelial cells, placenta, 
pituitary gland, prostate, adipocytes and lungs (Sheng and Stern 1999; Dorfman et al. 
1992; Ma et al. 1997; Charles et al. 2006; Xiao et al. 2016; Tsai et al. 2005). In addition, 
dysregulation of Gata2 levels (mutation or altered expression) have been implicated 
in haematological malignancies, and more recently in solid cancers.  
 
1.3.1. GATA2 gene  
 
The murine Gata2 gene is located on chromosome 6 spanning 8.5 kb, while the human 
GATA2 gene, of approximate 14 kb, is located on chromosome 3 (Grass et al. 2006). 
In both systems, the Gata2 gene encodes five exons, and two or three (human) mRNA 
transcripts give rise to different splicing isoforms (Gao et al. 2015). The longest, 
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termed Gata2-IS (I-specific, distal first exon), is preferentially expressed in 
haematopoietic and neuronal cells, while the shorter isoform, named Gata2-IG (I-
general, proximal first exon), is expressed in all the other tissue types (Minegishi et al. 
1998). The distal IS exon contains an untranslated region and therefore both isoforms 
produce the same 480 amino acid protein (Minegishi et al. 1998). To date, the function 
of the IS exon is unclear. For instance, a knock-in mouse driving GFP expression in 
the Gata2 IS promoter, thus abolishing IS promoter activity, displays normal numbers 
of HSPCs (Minegishi et al. 1998; Minegishi et al. 2003), suggesting that the Gata2-IG 
isoform can compensate for the lack of IS promoter activity (Figure 1.7).  
 
 
Figure 1.7. GATA2 isoform and protein regulation. (A) Human GATA2 gene
structure showing IS, IG and a 3rd transcript that not yet been defined. (B)
GATA2 protein structure showing post-translational modifications (PTM)
including ubiquitination, acetylation, sumoylation, and phosphorylation. Protein-
protein interactions with FOG1, PU.1, HDAC, CMYB, are also illustrated (Zn
finger domain participating in the interactions is highlighted). (C) GATA2 cis
regulatory elements named according to their relative position to IS promoter: -
77 kb, -3.9 kb, -2.8, -1.8, +9.5.
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Five different conserved Gata2 cis-acting sites have been described to regulate Gata2 
expression in a temporal and cell-dependent fashion. The regions, named according 
to their relative position to the IS promoter, are the -77 kb, -3.9 kb, -2.8 kb,-1.8 kb and 
+9.5 kb (Katsumura and Bresnick 2017). Interestingly, Gata2 is able to bind to these 
binding sites and activate its own transcription (Katsumura and Bresnick 2017), whilst 
at the same time, other activators or repressors can displace and modulate Gata2 
expression through these cis-regulatory elements (Snow et al. 2010). Genetic deletion 
of each of these sites has shown that in HSPCs, Gata2 binds to the -2.8 kb site to 
maintain high Gata2 levels (Johnson et al. 2012; Gao et al. 2013), while during 
erythroid differentiation Gata1 displaces Gata2 from the -1.8 kb site in order to repress 
Gata2 expression, a requirement for the terminal differentiation of erythroblasts 
(Suzuki et al. 2013). No functional role in haematopoiesis has been attributed to the -
3.9 kb site so far (Katsumura and Bresnick 2017). More recently, it was described that 
the +9.5 kb site localised in the fourth intron, acts as an enhancer in the endothelium 
and HSCs during HSC generation, and in fact, deletion of this site abolishes the 
emergence of HSCs in mice (Gao et al. 2016). The -77 kb site is not required for HSC 
generation, but instead is required for Gata2 transcription in myeloid progenitors, and 
in particular in MEPs (Mehta et al. 2017), since -77 kb knock-out mice produce lower 
number of BFU-E and are unable to induce Gata1 expression (Mehta et al. 2017). 
Finally, compound heterozygote (CH) mice revealed that Gata2 requires both +9.5 kb 
and -77 kb enhancer activity in the same allele to sustain Gata2 expression in myeloid 
progenitors (Mehta et al. 2017). Collectively, understanding the activators or 
repressors of Gata2 in specific cis-regulatory elements has offered insights into the 
important regulatory mechanisms in HSC maintenance and generation and in 
malignancies where Gata2 expression is dysregulated.  
 
1.3.2. Gata2 function during HSCs development 
 
Germline deficient Gata2-/- mice die with anaemia at embryonic day 10.5 (E10.5) 
indicating that Gata2 is required for primitive haematopoiesis (Tsai et al. 1994). 
Chimera experiments showed that Gata2-/- ES cells were unable to contribute to the 
formation of myeloid and lymphoid cells at the FL stage and in 1-to-3-month-old mice, 
suggesting that Gata2 is a pivotal regulator of HSCs in the haematopoietic system 
(Tsai et al. 1994). Further experiments using Gata2-/- ES cells, showed that Gata2 is 
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not required for the terminal differentiation of erythroid and myeloid lineages, yet it is 
required for the proliferation and survival of early haematopoietic progenitor and the 
formation of mast cells (Tsai and Orkin 1997). Finally, the phenotype observed in the 
ES cell haematopoietic differentiation culture was reversed in Gata2-/-;p53-/- mice, 
suggesting that Gata2 and p53 interact during early HSPC formation (Tsai and Orkin 
1997). Analysis of Gata2+/- has demonstrated that Gata2 plays functionally distinct 
roles in the generation of HSCs in the embryo, displaying quantitative defects in HSCs 
in yolk sac (YS), aorta-gonad mesonephron (AGM) and foetal liver (FL), but not in BM, 
and qualitative defects in HSCs in all haematopoietic generating sites throughout 
ontogenesis (Ling et al. 2004).  
 
 
 
To study the absolute requirement for Gata2 in developing HSCs in the FL, a 
tamoxifen-inducible Cre mouse was employed to circumvent the lethal phenotype 
observed at E10.5 in Gata2-/- embryos (Lim et al. 2012). A decrease in the numbers 
and functionality of Gata2-/- FL HSCs was observed (Lim et al. 2012). Mirroring this 
study, in other genetic models, Gata2 has been deleted in haemogenic endothelium 
cells before the generation of HSCs using the Vec-Cre system, and after HSC 
formation using the Vav-Cre system (de Pater et al. 2013)(Table 1.5). Reduced 
numbers and qualitative defects of HSCs in transplantation and CFU assays were 
Mouse	model Deletion	and	specificity Survival Haematopoietic	phenotypes	in knockout	mice	lacking	Gata2	
Haematopoietic	phenotypes	in	recipient	
mice	transplanted	with	HSC/BM	cells
fromGata2	KO	mice
Germline	Gata2 KO	
Germline	Gata2	HET
Germline	ESC E10.5
Alive
Anaemia
Reduce	number	of	HSCs	in	AGM	and	FL
Regeneration	defect	of	BM	HSCs		after	5-FU	
treatment
Reduced	number	and	functionality	of	HSCs	and	
GMPs	in	adult	BM
Increased	BM	HSC	quiescence	and	apoptosis	
Multilineage defects	in	chimera	
experiments	 (HPC	defect)
Self-renewal	 defect	of	FL	and	BM	HSCs
Vec-Cre Germline	E7.5-E8.5
Endothelial	 cells	(ECs)	and	
HSCs	before	HSC generation
E14 FL	anaemia
Reduced	CFU-C
N.D.
Vav-Cre E10.5-11.5
After	HSC	generation
Also	detected	in	ECs
Past E16	 E11	AGM	and	FL	CFU-C numbers	decreased
Decreased	HSC	– reduced	CFU-C	capacity
Increased	apoptosis	of	FL	HSCs
E14	FL	HSC	lack	of	long-term	
reconstitution	
LysM-Cre Myeloid	cells Alive No	changes	in	mature	blood cells N.D.
Tie2-Cre Germline E6.5	
ECs and	HSCs
Embryonic lethal Heterozygous	mice	survive until	adulthood	with	
decreased	myeloid	and	dendritic	cells.	
N.D.	
Tamoxifen-Cre Conditional	upon	tamoxifen
injection
10-14 days	after	tamoxifen
induction
Multilineage defect Multilineage defect
Table 1.5.Gata2 haematopoietic phenotype observed in mouse models
N.D. – Not determined
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observed after deletion of Gata2 with either the Vec or Vav system (de Pater et al. 
2013). These results were accompanied by an increase of apoptotic HSCs, indicating 
that Gata2 is essential for the generation and survival of HSCs in the mouse embryo, 
in a cell autonomous manner (de Pater et al. 2013). In agreement with this, using a 
Gata2 Venus reporter mouse, it was shown that almost all HSPCs express Gata2, 
although rare Gata2-independent HPC population with higher expression of Gata3 
and Gata4 were observed, indicating some redundancy of Gata family members in the 
development of the haematopoietic system (Kaimakis et al. 2016). 
 
1.3.3. Gata2 transcriptional network during HSC development  
 
Although many studies have found interactions and downstream/upstream regulators 
of Gata2 in HSC generation, endothelial-haematopoietic transition (EHT) is a highly 
elaborate process that involves the co-operation and formation of complex TF 
networks. This is exemplified by the study from Pimanda et al. who employed genome 
wide analysis to study the combinatorial interactions for ten TFs involved in HSC 
generation (Scl/Tal1, Lyl1, Lmo2, Gata2, Runx1, Meis1, Pu.1, Erg, Fli1 and Gfi1b) 
(Beck et al. 2013). A network comprising seven TFs named “heptad” of TFs, including 
Scl/Tal1, Lyl1, Lmo2, Gata2, Runx1, Erg, and Fli1, was found to regulate the 
emergence of HSPCs in a combinatorial manner (Diffner et al. 2013). With the 
exception of Lmo2 (McCormack et al. 2010) the remaining TFs have DNA binding 
activity, and the different combinations of this heptad regulate the transcriptional 
activity of target genes by binding to regulatory elements of the promoter regions 
(Diffner et al. 2013).  
 
The first evidence of Notch1 and Gata2 regulation in haematopoiesis was found in 
relation to myeloid and erythroid differentiation using murine cell lines. Overexpression 
of Notch1 in F5-5 or 32D cell lines inhibited erythroid and granulocytic differentiation, 
respectively (Kumano et al. 2001). In this setting, Gata2 was upregulated, and 
repression of Gata2 with dominant-negative Gata3 or Pu.1 overexpression was able 
to rescue the differentiation block phenotype (Kumano et al. 2001). Rbpjk null mice 
have been used to study the ontogeny of HSC in the mouse embryo; Rbjpk is a co-
activator that together with the intracellular domain of Notch activates the transcription 
of Notch-target genes (Robert-Moreno 2005). Rbpjk-/- mice died at E10 with a defect 
 44 
of progenitor output in CFC assays (Robert-Moreno 2005). Gene expression analysis 
of the AGM region showed decrease expression of Runx1, Gata2 and Scl in Rbpjk-/- 
mice (Robert-Moreno 2005). In addition, Gata2 expression in wild-type AGM cells, 
correspond to high Notch1-expressing cells. Moreover, Co-IP assays in AGM cells 
demonstrated that Notch1 binds to the Gata2 promoter, but that interaction was 
ablated in Rbpjk-/- mice, concluding that Gata2 activation by Notch1 is one of the key 
events in haematopoietic determination in the mouse embryo (Robert-Moreno 2005). 
In support of this, it has been reported that Gata2b expression in the zebrafish 
hemogenic endothelium is Notch-dependent (Butko et al. 2015).  
 
Evi1 is a zinc-finger TF that regulates HSC in the embryo and in the adult, and is 
associated with poor prognosis in AML (Sato et al. 2008; Goyama et al. 2008; Lugthart 
et al. 2008). Evi1 KO mice die at E10.5 with developmental defects in several tissues, 
indicating that Evi1 is a key regulator during development (Sato et al. 2008). In fact, 
Evi1-/- embryos displayed a phenotype reminiscent of that observed in Gata2-/- 
embryos, including reduced FL HSC numbers and activity (Sato et al. 2008). Gata2 
expression was decreased in Evi1-/- embryos, and re-expression of Gata2 rescued the 
proliferation defects of Evi1-/- HSCs in vitro (Sato et al. 2008). Finally, it was 
demonstrated that Evi1 binds and activates the transcription of Gata2 (Yuasa et al. 
2005).  
 
Etv2 (Ets variant gene 2) is a TF that regulates mesoderm specification into 
haematopoietic and endothelial lineages (Kataoka et al. 2011). Etv2 expression is 
present at E7.5 in the YS, and Etv2-/- embryos are nonviable after E9.5 (Koyano-
Nakagawa et al. 2012). An Etv2-EYFP transgenic mice confirmed that Etv2 is 
expressed both in haematopoietic and endothelial cells (Liu et al. 2015). It has been 
postulated that Etv2 activates the expression of several TF important for primitive and 
definitive haematopoiesis including Scl, Lmo2 and Fli1 (Liu et al. 2015). In addition, 
co-operation between Etv2 and Gata2 has also been described (Shi et al. 2014). Co-
expression of Etv2 and Gata2 was present in the blood islands of the YS at E7.5, and 
in endothelial and haematopoietic cells at E8.5 (Shi et al. 2014). Interaction between 
Gata2 and Etv2 proteins was corroborated with Co-IP and GST pulldown assays, and 
observed that their interaction increased the transactivation activity of Gata2 and Etv2 
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on the Lmo2 promoter (Shi et al. 2014), providing genetic evidence of a critical multi-
protein complex that governs primitive and definitive haematopoiesis.  
Runx1 is a TF essential for HSC generation (Chen et al. 2009), with its deregulation 
being implicated in MDS and AML pathogenesis (Harada and Harada 2009; 
Watanabe-Okochi et al. 2008). In fact, Runx1-/- embryos die from a complete absence 
of FL HSC (Chen et al. 2009). Runx1 is essential for the HSC formation from the 
haemogenic endothelium as demonstrated by the Vec-cre system, while Runx1-/-;Vav-
iCre mice survive to adulthood without HSC defects (Chen et al. 2009). This indicates 
that Runx1 is dispensable for HSC function once they are formed in the embryo. In 
the same study where it was found that Notch signalling is required to activate Gata2b 
in the hemogenic endothelium, the authors also reported that consequently Gata2b 
activated the transcription of Runx1, indicating that Gata2 is an upstream activator of 
Runx1 in the hemogenic endothelium (Butko et al. 2015). To further corroborate the 
interaction of Gata2 and Runx1, independent synergistic effects were found when 
crossing Runx1+/- and Gata2+/- heterozygous mice (Wilson et al. 2010). Both 
heterozygous mice displayed defects during HSC development, but survive to 
adulthood, as reported previously, however Runx1+/-;Gata2+/- heterozygous mice were 
not viable and FL cells had reduced CFC capacity (Wilson et al. 2010), implicating a 
genetic interaction of Runx1 and Gata2 during the EHT process and, ergo, HSC 
formation.  
 
Scl/tal1 is a bHLH TF first identified as part of the t(14;21)(q11.2;q22) chromosomal 
translocation in T-ALL patients (Visvader et al. 1998). Similarly to Gata2-/- mice, Scl-/- 
embryos die at embryonic day E9.5-10.5 due to anaemia (Porcher et al. 1996), 
indicating that Scl is a key TF during primitive haematopoiesis. Interestingly, despite 
the continued Scl expression in the haemogenic endothelium, FL and adult HSCs, 
conditional deletion of Scl with Tie2-Cre, which is expressed in the ECs and HSCs 
once they are formed, had no impact on HSC formation or maintenance (Schlaeger et 
al. 2005). This suggested that Scl is required for specification of the mesoderm into 
specialised haemogenic endothelium (HE), though is dispensable for HSC generation. 
Another study found that Scl is required for the appearance of Vec+ EC cells marking 
the HE, confirming an early role for Scl in HE specification (Mead et al. 1998). 
Göttgens et al., reported that a protein complex formed by Gata2, Fli1 and Elf1 are 
required for activation of Scl in vivo (Pimanda et al. 2007). Additional studies showed 
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that enforced expression of Gata2 in differentiating EBs induces Scl expression, and 
in addition they found regulatory elements in the Scl promoter occupied by Gata2 
(Lugus et al. 2007). Taken together, it is likely that Gata2 is expressed before the 
appearance of the HE through Notch1 and/or BMP4 signalling, and in conjunction with 
Fli1 activates Scl expression to specification of HE.  
 
Lmo2 (LIM domain only 2) was first discovered in T-ALL (Draheim et al. 2011). In a 
similar vein to the Gata2-/- phenotype, Lmo2-/- embryos lack primitive erythropoiesis 
in the YS and die at E10.5 (Warren et al. 1994). Lmo2-/- ES cells were able to produce 
macrophage colonies, but failed to generate erythroid colonies in vitro (Warren et al. 
1994). Lmo2-/- ES chimera experiments showed that Lmo2 is also essential for 
definitive haematopoiesis and adult HSCs (Yamada et al. 1998). Lmo2 is able to 
interact with Gata factors in different cell contexts; with Gata1 for erythroid 
development (Wang et al. 2007), Gata2 in HPC development and adult HSCs (Coma 
et al. 2013) and Gata3 in T cells and T-ALL (Manaia et al. 2000).  
 
1.3.4. Gata2 function in adult murine HSC  
 
As germline Gata2-/- mice failed to survive to adulthood, in order to study the role of 
Gata2 in adult HSCs, Rodrigues et al., studied the haematopoietic system of Gata2+/- 
mice and found a decrease in the total numbers of HSCs in the BM, together with 
qualitative defects of HSCs in transplantation assays (Rodrigues et al. 2005). Finally, 
they reported an increase of HSC quiescence and apoptosis, coupled with a 
downregulation of the protein levels of the anti-apoptotic gene Bcl-xL in Gata2+/- mice 
(Rodrigues et al. 2005). These data support the idea that gene dosage in the context 
of Gata2 levels must be tightly regulated for proper HSC functionality. A 5-fold 
decrease of BM HSC numbers in Gata2+/- has been confirmed in another study (Guo 
et al. 2013) that used single-cell analysis. Interestingly, the five most differentially 
expressed genes in Gata2high HSC compared to Gata2int HSC, were Cd150, Cd41, 
Gata1, Nmyc and Gata2 itself, suggesting potential downstream target genes of Gata2 
in adult HSCs (Guo et al. 2013).  More recently, Gata2 was conditionally deleted in 
adult mice using a tamoxifen-Cre system, and upon Gata2 deletion multilineage 
differentiation failure was observed in the BM, spleen and thymus of Tx;Gata2-/- mice. 
To overcome the caveats derived from Gata2 deletion in extramedullary sites using a 
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systemic (non-tissue specific) Cre model, they also performed cell-autonomous 
transplantation assays to confirm the multilineage defects from Tx;Gata2-/- BM cells 
and found a depletion of c-kit expression in Tx;Gata2-/- BM cells, indicating HSPCs 
loss after Gata2 conditional deletion (H. S. Li et al. 2016).  
  
1.3.5. GATA2 transcriptional network in adult murine HSC 
 
In addition to a role in HSC formation and FL HSC, the upstream regulator of Gata2, 
Evi1, is also a critical regulator of adult HSC. Evi1 deletion in adult HSC using the 
Mx1-Cre system or lentiviral Cre, results in HSC reduction in vitro and in vivo without 
affecting differentiated cells (Goyama et al. 2008). In addition, haploinsufficient Evi1 
mice display reduced HSC numbers, and reduced recovery after 5-FU treatment 
(Bard-Chapeau et al. 2014). Gata2 was downregulated in lentiviral Cre deleted Evi1-/- 
LSK cells (Goyama et al. 2008). Though Gata2 was not assessed, the phenotype 
observed in Evi-1 haploinsufficient mice is reminiscent of that observed by Rodrigues 
et al., 2005 and Ling et al., 2004 in Gata2 haploinsufficient mice. 
 
Cited2 is a regulator of the hypoxia signalling pathway and is able to bind and inhibit 
Hif1 (Shin et al. 2008). Cited2 deletion in adult HSCs, employing the Mx1-cre system 
gave rise to a rapid loss of HSPCs in a cell-autonomous manner (Kranc et al. 2009). 
Gene expression and rescue experiments demonstrated that the Cited2-mediated 
HSC survival phenotype was mediated via Ink4a/Arf and p53 (Kranc et al. 2009). 
Luciferase and ChIP assays have shown that Cited2 could act as a positive regulator 
of Gata2 (Saito et al. 2015). Indeed, Cited2-/- FL HSCs have reduced number and 
functionality, and Cited2-/- FL LK cells have 4-fold reduction in Gata2 expression (Chen 
et al. 2007).  
 
Tel/Etv6 is one of the first TFs found to be essential for adult HSC. Conditional deletion 
of Etv6 with the Mx1-Cre promoter gave rise to a rapid loss of HSC and BM failure in 
a cell autonomous manner (Hock et al. 2004). Specific deletion of mature 
haematopoietic cells using specific lineage-Cre mice resulted in no changes in the 
frequency of myeloid, lymphoid and erythroid cells, indicating that Etv6 is a critical 
regulator for HSPC maintenance, rather than a regulator of mature haematopoietic 
cell differentiation (Hock et al. 2004). Collaboration between Etv6 and Gata2 was 
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described in the induction of the hemogenic program from mouse fibroblasts (Pereira 
et al. 2013). Using a combination of four TF, including Gata2, Etv6, Gfib and cFos, the 
authors were able to transform mouse fibroblasts into cell expressing endothelial and 
haematopoietic gene programs and a population of LT-HSC marked by CD150+CD48-
cKit+, suggesting the presence of definitive haematopoiesis (Pereira et al. 2013). 
Taken together, these results highlight the potential to generate functional adult HSC 
through a simple cocktail of four TFs. 
 
1.3.6. Gata2 function in myeloid progenitor cells. 
 
While Gata2 is expressed at relatively low levels in myeloid progenitors compared with 
HSCs (see Chapter 3), Rodrigues et al. have shown that Gata2+/- GMPs perform 
poorly in CFC in vitro assays and in in vivo transplantation experiments (Rodrigues et 
al. 2008). They found that Gata2+/- GMPs have lower levels of the Notch target Hes1, 
and that Gata2 directly binds to the Hes1 promoter (Rodrigues et al. 2008). Finally, 
Hes1 overexpression in Gata2+/- GMPs rescued the functional defects, indicating the 
Gata2-Hes1 axis as a regulator of GMP function (Rodrigues et al. 2008). These data 
also highlight the idea that even at low levels of expression, Gata2 has an impact in 
haematopoietic progenitor cell function. Furthermore, this reinforces the idea of a 
cross-talk between Gata2 and Notch1 related pathways, in this case in myeloid 
progenitor regulation.   
 
1.3.7. Exploring Gata2 function using overexpression studies 
 
Gata2 overexpression studies have contributed to the understanding of Gata2 biology, 
and, in concert with analysis of Gata2+/- alluded to above, have specifically highlighted 
that Gata2 levels need to be tightly regulated under physiological conditions. 
Overexpression of Gata2 inhibits erythroid differentiation in primary erythroblasts or 
transformed erythroid cell lines (Ikonomi et al. 2000). In BM cells or leukaemia cell 
lines, enforced expression of Gata2/GATA2 induced megakaryocytic while inhibiting 
erythroid differentiation (Ikonomi et al. 2000)(Huang et al. 2009). Enforced expression 
of Gata2/GATA2 with retroviral, tamoxifen, or doxycycline-based systems, reduced 
proliferation, blocked differentiation, and induced quiescence in mouse and human 
BM HSPCs (Kitajima et al. 2002; Persons et al. 1999; Tipping et al. 2009; Heyworth 
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et al. 1999). Murine or human HSPCs expressing Gata2/GATA2 performed poorly in 
CFC and long-term culture initiating cell (LTC-IC) functional assays, and were unable 
to contribute to haematopoiesis in vivo, although they did not undergo apoptosis 
(Persons et al. 1999; Tipping et al. 2009). Known cell cycle regulators of HSPCs, p21, 
p27, along with Cdk4, and Cdk6 were modulated after Gata2/GATA2 overexpression 
in HSPCs (Persons et al. 1999; Tipping et al. 2009). In agreement with the tight 
regulation of Gata2 levels under normal conditions, it has been described that low-
level Gata2 overexpression can immortalise murine BM cells in vitro by enhancing the 
self-renewal ability of myeloid progenitors. When transplanted into irradiated mice, 
Gata2-overexpression BM cells induced expansion of the myeloid lineage and 
lymphoid lineage block, although mice never progressed to full-blown AML 
(Nandakumar et al. 2015). Taken together, overexpression studies have shown that 
Gata2/GATA2 effects are dose-dependent, and that distinctive HSPC phenotypes can 
be observed at different Gata2/GATA2 thresholds levels. 
 
1.3.8. Gata2 function and transcriptional network during blood lineage 
specification  
 
Fine-tuning of Gata2 levels are required for HSCs differentiation into lineage-restricted 
progenitors and consequently mature blood cells. A single TF is not able to drive HSC 
differentiation; instead cooperation with other TFs is required to orchestrate the 
molecular and cellular differentiation of HSCs into mature blood cells. In this regard, 
Gata2 often liaises with Gata1 and Friend of Gata1 (Fog1) to induce erythroid 
differentiation, with Gata3 for DC differentiation, and with Pu.1 for monocyte and mast 
cell differentiation.  
 
Erythroid differentiation is symbolised by the “Gata switch” (Suzuki et al. 2013; Snow 
et al. 2011). Gata2 levels are high in HSCs, where it auto-activates its own 
transcription, whereas Gata1 are very low or non-existent (Suzuki et al. 2013; Snow 
et al. 2011). Under Epo stimulation or other intrinsic factors that direct erythroid 
specification, Gata2 binds and activates Gata1 expression in MEP cells (Guo et al. 
2016), and the Gata1 protein accumulates and reaches the desired threshold. At this 
threshold Gata1 interacts with Fog1 and other co-repressors to replace Gata2 from its 
own regulatory elements, repressing Gata2 expression and enabling terminal 
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differentiation (Grass et al. 2003). Genetic deletion of individual regulatory sites of the 
Gata2 gene have shown that the Gata switch governing erythroid differentiation, 
belongs to the -1.8 kb regulatory site of the Gata2 promoter (Fujiwara et al. 2009).  
	
Pu.1 (Spi1) is a member of the Ets family of TFs. Pu.1-/- mice die at a late embryo 
stage (E18) or within 48 hours after birth (McKercher et al. 1996). Normal levels of 
erythrocytes and megakaryocytes were found in Pu.1-/- mice, however a lack of 
lymphoid and myeloid cells was observed (Scott et al. 1994). Pu.1-/- FL cells 
contributed to the erythroid and megakaryocyte lineages but not to other myeloid or 
lymphoid lineages, and therefore are not able to sustain long-term haematopoiesis in 
irradiated recipients (Scott et al. 1994). Administration of antibiotics to new-born Pu.1-
/- mice allowed for a 2-week follow up with the formation of T cells in the thymus and 
granulocytes in the BM, but not B cells nor macrophages, indicating that Pu.1 is 
essential for the development of B cells and macrophages (McKercher et al. 1996). 
Pu.1 is able to antagonise the transcriptional activity of Gata1 in erythroid development 
(Nerlov et al. 2000), Gata2 in monocytic development (Walsh et al. 2002), and Gata3 
in T cell specification (T helper subtype) and DC development (Yashiro et al. 2015). 
Conversely, Gata2 and Pu.1 work together in mast cell development (Ohmori et al. 
2015). In fact, Gata2 and Pu.1 interact and activate the c-kit promoter, essential for 
mast cells (Walsh et al. 2002). It is thought that Gata2 expression in mast cells is 
driven at least, in part, mediated by the Jak/stat5 signalling pathway (Li et al. 2015).  
 
Patients with GATA2 mutations frequently present with clinical immunodeficiency 
syndromes including dendritic cell (DC) deficiency, indicating a potential role for 
GATA2 in DC development (Wlodarski et al. 2017). An in vitro culture system to induce 
DC differentiation using BM feeder cells and Flt3-L, demonstrated that murine LSK, 
CMP and CDP (common DC precursor) cells have reduced capacity to produce 
Cd11c+ cells after tamoxifen-mediated Gata2 deletion (Onodera et al. 2016). Gene 
expression analysis revealed that Gata2D/D CMP differentiated towards the DC 
lineage, had higher expression of Gata3, and validated the Gata2-mediated 
repression of Gata3 by ChIP assay, highlighting the Gata-switching phenomenon in 
different cell types (Onodera et al. 2016). The authors also found a decrease in the 
frequency and number of DCs after in vivo deletion of Gata2 using a tamoxifen-Cre 
deletion, and concluded Gata2 is important for DC differentiation (Onodera et al. 
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2016). However, the authors failed to detect decrease in DCs in Gata2;Cd11c-cre mice 
or Gata2+/- mice, suggesting that in vivo pan-deletion of Gata2 produced BM multi-
lineage failure instead of a Gata2-specific DC deficiency (Onodera et al. 2016). Future 
studies should address whether the DC deficiency observed in GATA2-deficient 
patients is human specific or if it can be recapitulated in the mouse using other DC-
specific promoters.    
 
1.3.9. Gata2 function in the haematopoietic bone marrow niche  
	
Gata2 is a critical regulator of adipocytes, a key negative cell regulator of the 
haematopoietic bone marrow niche (Brodsky and Jones 2005). Gata2 and Gata3 
expression is high in preadipocytes of white adipose tissue, and differentiation to 
adipocytes is associated with reduction of Gata2/3 levels (Tong et al. 2000). It has 
been reported that Gata2/3-mediated adipocyte suppression occurs through two or 
more different mechanism. In preadipocytes, Gata2/3 bind to regulatory elements of 
the promoter and repress the transcriptional activity of the well-known adipocyte 
marker PPARg (Tong et al. 2000), and independently, Gata2/3 physically interacts with 
the positive TF regulators of adipogenesis CEBPa and CEBPb (Xu et al. 2009a; Tong 
et al. 2005). This inhibitory interaction is mediated through the ZF2 domain of Gata2/3 
and the bZip domain of CEBPa/b (Xu et al. 2009a; Tong et al. 2005). A series of 
studies validated this mechanism for Gata2-mediated adipocyte regulation in mouse 
and human MSCs using loss of function and overexpression techniques in in vitro 
differentiation assays (Schupp et al. 2009). It has also been shown that Gata2 not only 
regulates adipocyte differentiation and preadipocyte levels, but also that of MSCs 
which produce adipocytes and positive regulators of the niche, such as osteoblasts. 
In vitro deletion of Gata2 with lentiviral Cre or in vivo deletion employing niche-specific 
Cre in MSCs, resulted in differentiation of MSC into adipocytes, but also into 
osteoblasts (X. Li et al. 2016). Gene expression analysis showed that Gata2 could 
block osteoblastogenesis by inhibiting Runx2 and β-catenin signalling, well-known 
positive regulators of osteoblast differentiation (X. Li et al. 2016). In addition, Gata2 
deletion in murine MSCs or GATA2 knockdown in human MSCs reduced MSC 
proliferation in vitro, with increased G0/G1 phase (X. Li et al. 2016). Taken together, 
this evidence points to Gata2 as a key regulator for MSC function and proliferation, 
and for adipocyte terminal differentiation.  
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The impact of Gata2 deletion in BM MSCs in haematopoiesis has recently been 
evaluated (Hasegawa et al. 2017). Gata2 deletion using the Nestin-CreER, Prx1-Cre, 
and LepR-Cre had no impact in HSPCs frequency or total counts in the BM of young 
mice. However, conditional deletion of Gata2 using the global ER-Cre mice in 
transplantation setting, lead to a decrease of BM cellularity and the frequency of CMP 
progenitors. Discrepancy between the results obtained with different mouse models 
could be due the wider spectrum of BM microenvironment or extramedullary tissues 
that ER-Cre deletes, and can influence haematopoiesis (Hasegawa et al. 2017). 
Alternatively, experiments with niche-specific Cre mice were performed under steady-
state conditions while experiments with ER-Cre mice were executed in (stress-related) 
transplantation assays. In addition, longer follow up after BM niche deletion, HSC self-
renewal, and specific EC Gata2 deletion were not explored in this study (Hasegawa 
et al. 2017). Therefore, the function that Gata2 has, in niche-dependent 
haematopoiesis regulation, is still largely unclear.  
 
1.3.10. GATA2 function in human haematopoiesis  
 
Expression of GATA2 in human haematopoietic cells has been reported. Expression 
of the GATA2 IS isoform is restricted to the CD34+ fraction, whilst the GATA2 IG 
isoform is higher in CD34+ cells, but also present in the CD34- fraction (Pan et al. 
2007). Modelling of EHT and haematopoietic differentiation using human ESCs has 
provided information about the role of GATA2 during human haematopoietic 
development. GATA2-/- ESCs formed similar levels of HECs (CD31+ CD34+ CD43-) 
compared to parental ESCs, however they generated a very low number of HPCs 
(CD34+ CD43+), indicating that GATA2 is dispensable for specification of HECs but 
essential for EHT and HPC formation in vitro (Huang et al. 2015). The few GATA2-/- 
HPCs left were able to form CFU-E and CFU-M colonies, but lacked CFU-G, 
suggesting that GATA2 is required for granulocyte specification in human HPCs 
(Huang et al. 2015). Using a GATA-2 GFP reporter ESC line, GATA2 was observed 
to be present in HECs, and only GATA2-HECs were able to produce HPCs (CD34+ 
CD43+) (Huang et al. 2016). In addition, GATA2 marks HPCs, since the ability to form 
CFCs was exclusive to GATA2 expressing HPCs (Huang et al. 2016). In agreement 
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with previous work, GATA2 expression was observed in mature CFU-G, while 
differentiated CFU-E and CFU-M were GFP- (Huang et al. 2016).  
Enforced GATA2 expression induces quiescence of CB CD34+CD38- HSCs in vitro 
and in vivo by reducing the expression of the cell-cycle regulators CDK4, CDK6 and 
CCND3 (Tipping et al. 2009). Knock-down of GATA2 by two-fold in CB CD34+ HSPCs 
reduced the gene expression of HSC regulators such KIT, GFI1B and HOXB4 
(Fujiwara et al. 2012). In addition, luciferase and ChIP assays confirmed the activation 
and direct HOXB4 promoter-binding by GATA2 (Fujiwara et al. 2012). Interestingly, 
enforced expression of HOXB4 has been shown to expand HSC both in vitro and in 
vivo (Antonchuk et al. 2002; Schiedlmeier et al. 2003). In agreement with the role of 
GATA2 in murine HSCs, it appears that both down and upregulation of GATA2 
reduces proliferation of human HSCs. However, to date, the requirement of GATA2 in 
human HSPC is largely unexplored.   
 
1.3.11. GATA2 in bone marrow failure syndromes and malignant 
haematopoiesis  
 
Consistent with its role in adipocyte differentiation, GATA2 is downregulated in the BM 
of aplastic anaemia (AA) (Fujimaki et al. 2001), where patients present with a reduction 
of HSPCs and followed by a replacement of adipocytes (Brodsky and Jones 2005). 
AA patients also showed decreased GATA2 and increased PPARg levels in MSCs, a 
mechanism found to be responsible for terminal differentiation of adipocytes (Xu et al. 
2009a).  
 
Haploinsufficiency of GATA2 has been associated with EVI1 AML in the poor 
prognosis t(3;3)(q21;q26) chromosomal translocation and inv(3)(q21;q26) inversion. 
Patients with this chromosomal translocation/inversion display high EVI1 levels. In this 
context, two studies found that a previously described GATA2 distal haematopoietic 
enhancer (G2DHE) located at -77 Kb of the GATA2 transcriptional start site, is 
relocated in close proximity to the EVI1 gene in 3q21 AML (Gröschel et al. 2014; 
Yamazaki et al. 2014). In the first study, chromosome conformation capture technique 
was employed to isolate a 9 kb element from inv(3)/t(3;3) AML samples and cell lines. 
Analysis of p300 binding in the 9 kb region helped to characterise the G2DHE and 
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deletion of the enhancer decreased EVI1 expression and impaired AML growth, 
similar to that of EVI1 KD (Gröschel et al. 2014). GATA2 expression was lower in a 
mixture of AML samples and cell lines with inv(3)/t(3;3) compared to unselected non-
inv(3)/t(3;3) AML samples (Gröschel et al. 2014). Nevertheless, two previous reports 
showed that GATA2 is overexpressed (77-83%) in patients with inv(3)/t(3;3) compared 
to healthy BM cells (Lahortiga et al. 2004; Vicente et al. 2012), suggesting that despite 
single-allele contribution to GATA2 expression, EVI1-mediated activation of GATA2 
appears to compensate and even increase GATA2 levels.   
 
In the second study, a bacterial artificial chromosome (BAC) containing the 
inv(3)(q21;q26) inversion was used to generate a transgenic mouse with the inversion, 
with and without the G2DHE (Yamazaki et al. 2014). Only inv(3)(q21;q26) mice with 
the G2DHE developed leukaemia with a median latency of 200 days, indicating that 
G2DHE is required for EVI1 upregulation in inv(3)/t(3;3)-leukaemias (Yamazaki et al. 
2014). Curiously, inv(3)(q21;q26) mice developed three types of leukaemia, a B 
lymphoid leukaemia (type 1), a mixed leukaemia (type 2), and a Gr1+Mac1+ (GM) 
myeloid leukaemia (type 3). Of interest, EVI1 has recently been reported to be 
expressed and contribute to the leukaemogenic potential in ALL, and especially in B-
ALL (Hinai and Valk 2016). Immunophenotypic analysis revealed an expansion of LT-
HSCs (CD34-/lowFlt3-) in 12-week-old preleukaemic inv(3)(q21;q26) mice, which is 
considerably decreased in inv(3)(q21;q26) mice lacking the G2DHE (Yamazaki et al. 
2014). Appearance of an abnormal CD34highFlt3- population was seen in 
inv(3)(q21;q26) mice of GM myeloid or mixed type, while B lymphoid type was 
characterised by an expansion of LT-HSCs, supported by higher levels of c-kit+ and 
CD34+ in the PB blood of B lymphoid leukaemia inv(3)(q21;q26) mice (Yamazaki et 
al. 2014). Gene expression analysis showed that EVI1 was higher in inv(3)(q21;q26) 
mice compared to inv(3)(q21;q26) mice lacking the G2DHE, supporting that the 
G2DHE is essential Evi1-driven leukaemia. EVI1 was highly expressed in LT-HSC, 
while expression was minimal in the CD34highFlt3- population, suggesting that the LSC 
capacity resides in LT-HSC in Evi1-driven leukaemia (Yamazaki et al. 2014). Of 
interest, Gata2 was upregulated by 2.5-fold in LT-HSC of inv(3)(q21;q26) mice 
(Yamazaki et al. 2014). In this study, the two Gata2 alleles were present, however it 
is not clear whether Gata2 haploinsufficiency contributes to Evi1-leukaemia. However, 
it remains a possibility that Evi1 activates the expression of the remaining Gata2 allele 
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thus leading to normal or increased levels in inv(3)/t(3;3)-leukaemias. To answer this 
question, another study crossed a type II, harbouring both B and GM leukaemias, 
inv(3)(q21;q26) mice with a germ line Gata2+/- mouse (Katayama et al. 2017). 
Haploinsufficiency of Gata2 accelerated the onset of leukaemia in the starting cohort, 
and showed prevalence for the type I (B lymphoid) leukaemia. However transplant of 
total BM or B220+Gr1-c-kit+ fraction, which contains the LSC activity, from type I mice 
showed similar survival between recipients receiving cells from Gata2+/+ and Gata2+/- 
inv(3)(q21;q26) mice, indicating that Gata2 haploinsufficiency accelerates LSC 
formation but is not absolutely required for leukaemia propagation in this model 
(Katayama et al. 2017). Gata2 levels were found higher in the B220+Gr1-c-kit+ fraction 
from type III (myeloid leukaemia) mice compared to type I mice, and this negatively 
correlated with Evi1 expression, concluding that pre-leukaemic cells with high Gata2 
levels induce a GMP-like phenotype that give rise to myeloid leukaemia with longer 
latency and Gr1+ differentiation, while Gata2 haploinsufficiency leads to a B lymphoid 
blast-like phenotype with aggressive leukaemia development (Katayama et al. 2017). 
Several caveats arise from this study, since and most importantly, the authors showed 
that Gata2 expression in the LSC fraction (B220+Gr1-c-kit+) of the type I leukaemia 
from inv(3)(q21;q26) mice w identical to Gata2 levels found in Gata2+/- inv(3)(q21;q26) 
mice (Katayama et al. 2017). In addition, no proof of Gata2 downregulation in the 
Gata2+/- inv(3)(q21;q26) mice was shown in the study (Katayama et al. 2017). 
Secondly, inv(3)/t(3;3)-leukaemias have only been described in AML; that high Gata2 
levels induced a myeloid phenotype with longer latency and Gr1+ differentiation is at 
odds to the poor prognosis inv(3)/t(3;3)-leukaemias found in AML. Evi1 expression 
was also lower in the myeloid type II leukaemias, and only high Evi1 and low Gata2 
levels were correlated with B lymphoid leukaemia described in this study. Therefore, 
inv(3)(q21;q26) mice are not an ideal model to study the pathogenesis of Evi1 and 
Gata2 in relation of inv(3)/t(3;3)-AML leukaemia.  
 
Epigenetic regulation of the GATA2 locus has also been observed in AML. Mutations 
in TET2, an enzyme that converts 5-methylcytosine (5-mC) into 5-
hydroxymethylcytosine (5-hmC) to modulate gene expression, are linked to adverse 
outcome when they are found in the context of FLT3ITD (Shih et al. 2015). To 
investigate the genetic interaction between TET2 and FLT3ITD, a study generated 
Tet2D/D;Vav-Cre+;Flt3ITD transgenic mice (Shih et al. 2015). Tet2D/D;Vav-Cre+ 
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developed MPN as previously described (Li et al. 2011), while Tet2D/D;Vav-Cre+;Flt3ITD 
mice developed frank AML with a median latency of 80 weeks. LSK and GMP from 
Tet2D/D;Vav-Cre+;Flt3ITD mice were expanded, however only LSK were capable to 
propagate AML into secondary recipients, thus LSK cells contained the LSC in this 
model (Shih et al. 2015). RNA-seq and methylation profiling of LSK cells revealed a 
hypermethylated signature in genes that control self-renewal and differentiation of 
HSCs, including Gata2 (Shih et al. 2015). Enforced expression of Gata2 induced 
erythroid differentiation in colony assays and in transplantation assays, whereas no 
Gata2 expressing Tet2D/D;Vav-Cre+;Flt3ITD BM cells induced AML in vivo (Shih et al. 
2015). Therefore, methylation is an important regulator of Gata2 activity in AML. 
Epigenetic repression of Gata2 in Mll-af9 AML is mediated by Prc2, a chromatin 
regulator that methylates H3K27 sites; methylation of H3K27 is linked with inactive 
gene promoter activity. Genetic ablation of Eed, one of the Prc2 complex components, 
delays Mll-af9-mediated AML by depressing Gata2, among other genes (Danis et al. 
2015). In addition, Gata2 overexpression impaired colony formation of Mll-af9 LSK 
cells (Danis et al. 2015), in agreement with previous reports where enforced 
expression of Gata2 halts leukaemic proliferation of Mll-enl cells in vitro (Bonadies et 
al. 2011).  
 
1.3.12. GATA2 mutations in MDS/AML 
 
In 2011, a series of studies described for the first time that GATA2 heterozygous 
mutations form an autosomal dominant disorder eventually leading to MDS and AML 
(Hyde and Liu 2011; Hahn et al. 2011; Hsu et al. 2011; Ostergaard et al. 2011). In 
addition, GATA2 germline mutations linked together a group of genetic haematological 
disorders without a previous known cause. Thus, GATA2 joined an exclusive family of 
germline mutations, together with RUNX1 and CEBPA, that predispose patients to 
malignant haematopoiesis. GATA2 mutations were found in families with DCML 
deficiency, that present with loss of DCs, monocytes, and B and NK cells; families with 
monocytopenia with Mycobacterium avium complex infection (MonoMAC) syndrome; 
families with lymphoedema and MDS (Emberger syndrome); and familial MDS/AML 
(Hyde and Liu 2011; Hahn et al. 2011; Hsu et al. 2011; Ostergaard et al. 2011). 
Patients with DCML, MonoMAC and Emberger syndromes have higher likelihood to 
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develop AML, although in some GATA2 deficient families MDS and AML have been 
diagnosed without previous haematological abnormalities (Dickinson et al. 2014).  
 
Since this discovery, approximately 100 different mutations have been described in 
the GATA2 gene, in association with GATA2 syndromes (Dickinson et al. 2014) 
(Figure 1.8). Frameshift and nonsense mutations, which completely abolish GATA2 
activity in the mutated allele, often present with an earlier onset of AML (Hyde and Liu 
2011). Deletions, missense mutations, and point mutations in regulatory elements 
have also been described in GATA2 syndromes (Hyde and Liu 2011). A missense 
mutation linked with rapid onset of MDS/AML is the T354M in the ZF2 domain (Hahn 
et al. 2011), and it is believed that T354M acts as a dominant negative, thus further 
reducing GATA2 activity within HSPCs. Nevertheless, no other mutations have been 
found to act as dominant negative nor have acquired secondary mutations in the 
second GATA2 allele been observed during disease progression (Dickinson et al. 
2014). Acquired mutations of the wild-type allele leading to loss of heterozygosity 
(LOH) is a common feature of tumour suppressor genes in hereditary cancer (Hügel 
and Wernert 1999). Bearing in mind that in contrast to hereditary AML predisposing 
genes (i.e. CEBPA, RUNX1), GATA2 mutations do not present with LOH, meaning 
that low levels of GATA2 are still required for pre-leukaemic HSCs, and possibly for 
disease progression in GATA2 hereditary syndromes.  
 
 
Figure 1.8. GATA2 mutations in familial MDS/AML. GATA2 mutations found in hereditary
GATA2 syndromes. The number indicates the AA altered, and the colour and type of sign the
type of disease and mutations involved. This is only a representation, since over 100
mutations in the GATA2 gene have been identified to date.
Adapted and modified from R. Katherine Hyde et al., 2011
Zinc finger 1 Zinc finger 2NH2- -COOH
GATA2 gene
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Other secondary mutations have, however, been reported to be relevant for evolution 
to MDS and AML in GATA2 syndromes. Monosomy of chromosome 7 was linked with 
GATA2 MDS patients and adverse outcome. Indeed, a study of GATA2 syndromes in 
children and young adults showed that 72% of GATA2 MDS patients also present with 
monosomy 7 (Wlodarski et al. 2015).  In addition, mutations in ASXL1 were found in 
GATA2 patients with myeloid transformation, rapid onset and poor outcome MDS/AML 
(West et al. 2014). Curiously, ASXL1 secondary hits were almost exclusively found in 
females with GATA2 mutations, however the reason for the gender bias observed 
remains unknown (Lübking et al. 2015).  Thus, in terms of understanding leukaemic 
development, GATA2 syndromes provide a suitable model to study disease evolution 
from the pre-leukaemia stage to frank AML.   
 
In addition, it has been reported that chronic mild neutropenia or B cell deficiency 
precedes the development of GATA2-related MonoMAC syndrome, MDS and AML 
(Pasquet et al. 2013). This suggests that earlier detection and treatment of GATA2 
syndromes should be considered prior the development of MDS and AML or late 
stages of immunodeficiency, since both infections and malignancy are responsible for 
GATA2-related deaths. 
	
1.3.13. GATA2 mutations as secondary hits in CEBPA AML.  
 
GATA2 loss-of-function mutations are observed in sporadic AML. In this setting, 
GATA2 somatic mutations are found almost entirely with familial and somatic CEBPA 
mutations. CEBPA double mutants define a favourable AML subtype, cytogenetically 
normal (CN) and M1-M2 FAB subtype (Greif et al. 2012). GATA2 mutations were 
detected in a large proportion of CEBPA double mutants AML (18-41%), 6-16% in 
CEBPA single mutant, and less than 1% in CEBPA wild-type patients (Greif et al. 
2012; Fasan et al. 2012; Green et al. 2013). Mutant levels analysis revealed the 
coexistence of both mutations in the same cell, suggesting that CEBPA sporadic or 
familial AML cases have a higher tendency to acquire secondary GATA2 mutations 
(Greif et al. 2012). In addition, some CEBPA double mutant patients loose or gain a 
GATA2 mutation after CR or relapse, indicating that GATA2 is a secondary hit in this 
AML subset (Green et al. 2013). While some studies reported that GATA2 improved 
the OS of the already favourable CEBPA double mutant patients, other reports showed 
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that GATA2 mutations have no impact in the OS of these patients. Thus, the biological 
and clinical impact of GATA2 mutations in this setting is unclear.   
 
1.3.14. GATA2 overexpression in AML  
 
Evidence supporting an oncogenic role for GATA2 was discovered in CML. The L359V 
missense mutation in the ZF2 domain of GATA2 confers a gain of function with 
increased DNA binding activity (Zhang et al. 2008). L359V GATA2 mutation was found 
exclusively in CML patients during acute myeloid blast crisis (which is similar to acute 
myeloid leukaemia), which was linked with a more aggressive disease progression 
(Zhang et al. 2008). Downstream analysis showed that L359V GATA2 was able to 
bind and inhibit PU.1, a key regulator for myeloid differentiation (Zhang et al. 2008). 
Indeed, in vitro differentiation assays with HL60 and in vivo BCR/ABL-mediated CML 
revealed that L359V GATA2 impaired myelomonocytic differentiation, implying that 
increased GATA2 transcriptional activity is a key event for the differentiation blockade 
in BCR/ABL CML cells, a requirement for the transformation from chronic phase to 
acute myeloid blast crisis phase (Zhang et al. 2008).  
 
To date, the L359V GATA2 gain of function mutation has never been described in 
AML or any other malignancy (Zhang et al. 2009). However, overexpression of GATA2 
has been linked with poor prognosis in a high proportion of MDS and AML patients. 
GATA2 overexpression has been linked with the Lin-CD34+CD38-CD123+ population 
in high-grade MDS; this is a CSC population also observed in AML (Li et al. 2014). In 
addition, another study showed GATA2 overexpression correlated with GATA1 
downregulation in 84.8% (28 of 33) in the BM of patients with high-grade MDS (Fadilah 
et al. 2002). In AML, overexpression of GATA2 was found in 65% (155 of 237) of 
paediatric patients, compared to healthy BM (Maaike Luesink et al. 2012). GATA2 
levels decreased in patients who achieved CR, while remaining high in patients who 
relapsed. GATA2 is an independent poor prognostic factor in paediatric AML, with 
shorter OS, EFS and DFS, especially in association with WT1 overexpression, FAB-
M5, inv(16), MLL translocation, and FLT3ITD (Maaike Luesink et al. 2012). In adult 
AML, a study showed that GATA2 is overexpressed in 37.4% of AML patients, and 
that the overexpression group correlated with the adverse outcome cytogenetics and 
molecular AML subgroups, including complex karyotype, −5/5q- and/or −7 
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monosomies, inv(3)/t(3;3), WT1 and EVI1 overexpression, elder patients, and 
secondary AML (Vicente et al. 2012). In agreement with this, adult AML patients with 
GATA2 overexpression had worst OS, EFS and DFS (Vicente et al. 2012). How 
overexpression of GATA2 impacts leukaemic cell fate in AML, however, remains 
unclear. 
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1.4 Specific aims of thesis 
 
Our laboratory has previously demonstrated that Gata2 haploinsufficiency negatively 
impacts HSC and GMP numbers and functionality (Rodrigues et al. 2005; Rodrigues 
et al. 2008). However, the requirement for Gata2 in HSCs remains poorly defined. 
Increasing evidence for a novel putative oncogenic role for GATA2 in AML, has 
become apparent from expression analysis that link GATA2 overexpression with 
adverse outcome. However, the biological role of GATA2 in leukaemia initiation and 
progression has not been tested. This thesis will therefore evaluate the impact of 
Gata2 in normal and leukaemia cells, including LSCs, with the following aims: 
 
1. Evaluate the impact of conditional acute deletion of Gata2 in murine HSCs 
using the Mx1-Cre mouse model. 
  
2. Assess the expression and biological impact of acute deletion and 
pharmacological blockade of Gata2 in established pre-LSCs and LSCs, driven 
by the introduction of the AML causing Mll-af9 translocation or Meis1a/Hoxa9 
oncogenes.   
 
3. Investigate the effect of GATA2 reduction with RNAi or a small molecule 
inhibitor in established human AML cell lines.  
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Chapter 2 
 
Material and Methods 
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Suppliers name and addresses are listed in Table 2.1  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name	of	company Address
Applied Biosystems, Warrington, UK Lingley House, 120 Birchwood Boulevard, Warrington, WA3 7QH, UK 
BD Biosciences, Oxford, UK Edmund Halley Road - Oxford Science Park, OX4 4DQ Oxford, UK
BioLegend UK Ltd. 4B Highgate Business Centre, 33 Greenwood Place,London, NW5 1LB, UK
Bioquote limited Bioquote Limited,The Raylor Centre, James Street York, YO10 3DW, UK
BioLine Reagents Ltd. Edge Business Centre, Humber Rd, London NW2 6EW, UK
Cell Biolabs InC. 7758 Arjons Dr, San Diego, CA 92126, USA
ClonTech Avenue du President Kennedy 78100 Saint-Germain-en-Laye, France 
Eppendorf UK Ltd. Endurance House, Vision Park, Histon, Cambridge, CB24 9ZR 
Fisher Scientific UK Bishop Meadow Road, Loughborough, Leicestershire, LE 1 5RG, UK 
GE Healthcare Nightingales Lane ,Chalfont St Giles , Buckinghamshire ,HP8 4SP
Genecopoeia 39 rue de Houdan – BP 15, 78612 Le Perray-en-Yvelines Cedex,France
GraphPad Software, Inc. 7825 Fay Avenue, Suite 230, La Jolla, CA 92037 USA
Invitrogen, Paisley, UK Ltd. Part of Life Technologies Invitrogen, Paisley, UK Ltd, 3 Fountain Drive, Paisley, UK 
The Jackson laboratories 600 Main Street, Bar Harbor, ME USA 04609
Leica Microsystems Davy Avenue Knowlhill, Milton Keynes, MK5 8LB, UK 
Miltenyi Biotech Almac House, Church Lane, Bisley, Surrey, GU24 9DR, UK 
New England Biolabs 75-77 Knowl Piece, Wilbury Way, Hitchin, Herts SG4 0TY, UK 
PeproTech EC Ltd PeproTech House, 29 Margravine Road, London, W6 8LL, UK 
Qiagen Fleming Way, Crawley, West Sussex, RH10 9NQ, UK 
Sigma-Aldrich The Old Brickyard, New Rd, Gillingham, Dorset, SP8 4XT, UK 
STEMCELL Technologies Building 7100, Cambridge Research Park, Beach Drive, Waterbeach, Cambridge, UK, CB25 9TL
Tree Star, Inc. 340 A Street #101 Ashland, OR 97520, USA 
Table 2.1 Supplier addresses 
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2.1.  Plasmids and DNA preparation.  
 
psPAX2, VSVG, MSCV-neo, MSCV-puro, MSCV-Meis1a-puro, MSCV-Hoxa9-neo, 
pRRL-Cre-iVenus, and pRRL-iVenus were a kind gift from Prof. Kamil Kranc 
(University of Edinburgh). MSCV-MLLAF9-GFP and MSCV-GFP were a kind gift from 
Dr. Daniela Krause (Goethe University Frankfurt). psi-LVRU6GP containing shGATA2 
were purchased from Genecopoeia. shGATA2 plasmids details and sequences for 
knockdown can be found in Figure 2.1 and Table 2.2.  
 
All plasmids were transformed in Stbl3 bacteria (Sigma) and cultured in LB Broth 
media (Sigma) with 100 μg/mL of ampicillin (Gibco). Bacteria from glycerol stock were 
cultured overnight in 250 mL of media in a shaker. The next day, culture was harvested 
and DNA plasmid extracted following manufacturer’s instructions from the EndoFree 
Plasmid Maxi Kit (Qiagen). DNA was eluted in DNAase free water (Molecular probes) 
and aliquoted at >1 μg/mL concentration, with 260/280 ratio between 1.8-2 and 
260/230 ratio between 1.8-2.2. Purified DNA was stored at minus 20°C.  
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Figure 2.1. Vector information for psi-LVRU6GP plasmid. shGATA2 target sequences are listed
in Table 2.2. U6 is the human U6 small nuclear 1 promoter (polimerase III promoter); Simian virus
40 (SV40) alloqs the transcription termination and polyadenylation of mRNA transcribed by RNA
polymerase II; enhanced green fluorescent protein (eGFP) allows for the detection and isolation of
cells transduced with shRNA; Encephalomyocarditis virus internal ribosome entry site (IRES)
recruits ribosome to initiate translation internally on a transcript independent of its 5’ end. Multiple
proteins can be made from a polycistronic transcript containing multiple ORFs separated by IRES;
puromycin resistance gene (puro) allows cells to be resistant to puromycin; woodchuck hepatitis
virus posttranscriptional regulatory element (WPE) enhances viral RNA stability in packaging cells
leading to higher titer of packaged virus; truncated HIV-1 3’ long terminal repeat (3’-LTR) allows
packaging of viral RNA into virus and self-inactivate the 5’LTR by a copying mechanism during viral
genome integration, contains polyadenylation signal for transcription termination; pUC origin of
replication (pUC ori) facilitates plasmid replication in E. coli leading to high-copy plasmid number;
Ampicillin resistance gene (Amp’) allows E. coli to be resistant to ampicillin; truncated HIV-1 5’ long
terminal repeat (5’ LTR) allows transcription of viral RNA and its packaging into virus; HIV
packaging signal (Ψ) allows packaging of viral RNA into virus; HIV-1 Rev response element (RRE)
allows rev-dependent nuclear export of viral RNA during viral packaging; central polypurine tract
(cPPT) facilitates the nuclear import of HIV-1 cDNA through a central DNA flap;
Adapted from Genecopoeia
Clone Target	sequence Location
scramble 5’-gcttcgcgccgtagtctta-3’ -
31 5’-gcaaattgtcagacgacaacc-3’ 1382
32 5’-ggacaactttatgtagagaaa-3’ 2027
33 5’-cctctctgaaatagccgaact-3’ 2269
34 5’-cctttaaagtgagtactgtta-3’ 3324
Table 2.2 GATA2 knockdown sequences. Knockdown based on accession number NM_032638.3
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2.2.  Mouse models and mouse husbandry. 
 
All mice were of C57BL/6 genetic background. Sex-matched 8 to12 week-old mice 
were used. Animal experiments were authorized by the UK Home Office (project 
license 30/3380).  
 
2.2.1. C57BL/6 and C57BL/6 SJL.  
 
C57BL/6 and their counterparts C57BL/6 SJL were purchased from The Jackson 
Laboratory (Bar Harbor, ME USA). C57BL/6 mice express the CD45.2 isoform in white 
blood cells, while C57BL/6 SJL mice express the CD45.1 isoform.  
 
2.2.2. Gata2tm1Sac.  
 
Gata2 transgenic mouse was kindly donated by Professor Julian Downward (The 
Francis Crick Institute, London). The mice were originally engineered in laboratory of 
Sally Camper (Charles et al. 2006). A targeting vector containing a neomycin resistant 
cassette and loxP sites flanking the fifth exon were inserted into the Gata2 locus 
(Figure 2.2). The fifth exon contains the C-terminal zinc finger domain, thus abolishing 
the DNA binding of Gata2 and generating a Gata2 KO mouse after crossing with a 
Cre transgenic mouse. The deletion of the exon 5 gives rise to a non-functional 
truncated Gata2 protein, according to Charles et al. 2006. Western blot showed the 
appearance of protein band different of the size of wild-type Gata2 protein. In addition, 
they crossed the Gata2fl/fl mice with a generic Cre mouse (Cmv-Cre) to delete Gata2 
in all organs. As observed in the original papers from Stuart Orkin lab using 
conventional Gata2 KO mice (Tsai et al. 1992), no Gata2 null mice were born, and 
they observed that the mice died between E10.5 and E11.5 due to severe anaemia, 
in agreement with the conventional Gata2 KO mice (Charles et al. 2006).  
 
2.2.3. Mx1-Cre, breeding with Gata2tm1Sac and induction of Gata2 deletion 
in vivo.  
 
Mx1-Cre transgenic mouse was kindly donated by Professor Kamil Kranc (Scottish 
Centre for Regenerative Medicine, Edinburgh). Mx1-Cre transgenic mouse has been 
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described previously (Kühn et al. 1995). In this strain, Cre recombinase is expressed 
in the entire haematopoietic system, and in the bone marrow microenvironment. Mx1-
Cre+/;Gata2fl/fl were bred with Mx1-Cre-/-;Gata2fl/fl to obtain Mx1-Cre+/-;Gata2fl/fl and 
control Mx1-Cre-/-;Gata2fl/fl mice.  
 
To achieve full deletion of Gata2 alleles in Mx1-Cre+/-;Gata2fl/fl and control Mx1-Cre-/-
;Gata2fl/fl, mice were administered 6 intraperitoneal doses (250 μg/dose) every other 
day of polyinosinic:polycytidylic acid (pIpC) (GE Healthcare). pIpC is a double-
stranded RNA that binds to Tlr3 receptors and activates the type I IFN pathway which 
ultimately activates the Mx1-Cre promoter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2 Gata2tm1sac transgenic mouse construct. The fifth exon contains the C-terminal zinc finger domain, thus abolishing the DNA
binding ability of Gata2. A targeting vector containing a neomycin resistant cassette flanked by FRT sites and loxP sites flanking the fifth exon were
inserted into the Gata2 locus in ES cells.Mediating Flpe recombinase, the neomycin cassettewas excisedgenerating the Gata2fl allele.
Modified from Charles et al. 2006
Recombination in EScells
Flpe recombinase
Cre recombinase
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2.2.4. ID method.  
 
Three weeks-old pups were ear notched for identification purposes according to our 
ID system (Figure 2.3). Ear punch samples were used for genotyping of mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 mouse ID system
Right	ear	:	units
Left	ear:	tens	
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30
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2.2.5. DNA extraction and genomic PCR. 
 
DNA extraction was carried out according to the manufacturer’s protocol (ISOLATE II 
Genomic DNA Kit, Bioline). Ear punch samples were incubated in lysis buffer GL and 
proteinase K for 2-3 hours at 56°C. Next, to achieve finale lysate, lysis buffer G3 was 
added and the sample further incubated for 10 minutes at 70°C. Ethanol (96%) was 
added to adjust DNA binding conditions, and the samples were then loaded in an 
ISOLATE II Genomic DNA Spin Column. Samples were then centrifuged, washed with 
wash buffer GW1 and GW2, and eluted in 70°C preheated nuclease free water 
(Molecular probes). Samples were stored at -20°C until required for PCR. Genomic 
PCR was carried out following manufacturer’s protocol (MangoMix™, Bioline). DNA 
primers (Sigma) and PCR settings are listed in Table 2.3. Electrophoresis was 
performed using 1% agarose (Molecular probes)	gel for Cre, and 2% agarose gel for 
Gata2.  
 
 
 
  
2.2.6. Dissection and PB extraction. 
 
Mice were culled by cervical dislocation, and spleen, thymus, femur, tibia, and hip 
bone were aseptically removed and placed in PBS (Gibco) with 2% FBS. To obtain 
PB, a blade was used to nick the tail vein. Blood (around 30-50 μL) was collected in a 
EDTA-coated bleeding tube (Starstedt).  
Primer	name sequence PCR	programme
Gata2 forward	 5’-GCCTGCGTCCTCCAACACCTCTAA-3’
1. 95oC 5 minutes
2. 94oC 1 minute
3. 60oC 1 minute
4. 72oC 1 minute
Repeat steps 2-4 34 times 
5. 72oC 10 minutes 
6. 4oC hold
Gata2	reverse	 5’-TCCGTGGGACCTGTTTCCTTAC-3’
Generic Cre forward 5’-TGACCGTACACCAAAATTTG-3’
1. 95oC 3 minutes
2. 94oC 30 seconds
3. 55oC 30 seconds
4. 72oC 1 minute
Repeat steps 2-4 340times 
5. 72oC 5 minutes 
6. 4oC hold
Generic	Cre reverse 5’-ATTGGCCCTGTTTCACTATC-3’
Table 2.3 Genotyping primers
 70 
2.3.  Human samples. 
 
Human BM MNCs for gene expression analysis were purchased from STEMCELL 
technologies. Human AML samples were obtained from the Bristol Royal Infirmary 
(NHS University Hospitals Bristol). Details from human AML samples are listed in 
Table 2.4.     
 
 
 
 
 
ID	name Age Sex Clinical	details
HD209 6 M 2ry AML to Ewing Sarcoma
HG352 7 M t(8;21)(q22;q22)
CP338 14 M APML t(15;17)(q22;q12)
RD279 14 F -
RD296 14 F -
OD368 2 M t(9;11)(p22;q22), t(11;21)(p23;q8)
CG336 14 F MLL rearranged
AB312 15 F MDS/AML
ZH340 3 M t(8;21)(q22;q22)
RT161 6 M AML M5
OA342 2 F AMKL
KU250 7 F 2ry AML/relapse
DS356 - - Adult AML
JC125 12 M AML
MD064 - - Relapse after BMT, M0/1
KA122 10 F -
ND026 8 F M4/M5
MS332 17 F NK AML
BD002 7 F Bi-lineage Del5q abnormal 21
JC110 - - -
SW104 18 M Post-BMT
WW061 1 M t(9;11)
FJ080 4 M -
SW238 11 F -
DD226 6 M Relapse
RG126 10 M -
OP067 7 M -
Table 2.4 AML samples
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2.4. Bioinformatics analysis.   
 
AML and control patient datasets were downloaded from GEO (Edgar et al. 2002) and 
ArrayExpress (Kolesnikov et al. 2015), to yield a case/control AML cohort hybridized 
to the same array (Affymetrix Human Genome U133 Plus 2.0 GeneChip). AML cohort 
(n=2611), control cohort: (n=77) from GEO (GSE14468, GSE22845, GSE10358, 
GSE12417, GSE13159, GSE14062, GSE15434, GSE16015, GSE38987, GSE22056, 
GSE33223, GSE17855, GSE15389) and ArrayExpress (E-MTAB-3444). Raw 
Affymetrix data were downloaded in raw CEL format and imported into an in-house 
analysis pipeline written in R (version 3.1.1) using Bioconductor (Huber et al. 2015) 
packages from limma (Ritchie et al. 2015), affy (Gautier et al. 2004) and oligo 
(Carvalho and Irizarry 2010). Data were normalised using RMA and differentially 
expressed genes/transcripts were identified using limma “best practice”, and p-values 
were corrected for multiple testing using Benjamini-Hochberg (false discovery rate). 
Samples were then run through 2 bespoke R scripts to enable visualization per gene, 
where the WGNCA package (Langfelder and Horvath 2008) was used to convert 
probe-level data to gene-level data. These datasets were then used to produce 
boxplots. 
 
2.5.  GATA2 inhibitor and chemotherapeutics. 
 
GATA2 inhibitor K-7174 (Bioquote limited) was dissolved in DMSO with a stock 
concentration of 10 mM and stored at minus 20°C protected from the light. Each 
working aliquot was used and stored at 4°C for up to one week. Etoposide (VP16; 
Sigma) was dissolved in DMSO and stored protected from the light at room 
temperature with a stock concentration of 10 mM. Ara-C (Cytosine β-D-
arabinofuranoside; Sigma) was dissolved in PBS with a stock concentration of 1 mM 
and stored protected from the light at minus 20°C. 
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2.6.  Tissue culture. 
 
All cell culture experiments were performed in a Maxisafe 2020 Class II Biological 
Safety Cabinet (Thermofisher) and incubated at 37°C, 20% O2 and 5% CO2.  
 
2.6.1. Human cell lines. 
 
All cell lines used in this study tested negative for mycoplasma.  
 
HEK293T (Cell Biolabs) cell line was derived from HEK293 by stably transfecting the 
SV40 large T antigen. Upon transfection of a viral plasmids encoding the SV40 origin, 
the plasmid will transiently replicate and produce a high copy number, increasing the 
viral production. HEK293T cells were maintained in DMEM (Gibco, UK) with 10% 
heath inactivated FBS (Gibco) and 2mM L-glutamine (Gibco). Doubling time of 
approximate 24 hours. Cells were passaged every 2-3 days when confluency reached 
70-90%. 
 
Platinum E (Cell Biolabs) cell line was derived from HEK293T by introducing the 
packaging plasmids gag, pol and env under the expression of the strong promoter 
EF1α. Internal ribosome entry site (IRES) were added in order to select the packaging 
plasmid with puromycin (env) and blasticydin (gag-pol). Platinum E cells were 
maintained in DMEM with 10% heath inactivated FBS and 2mM L-glutamine. 
Puromycin (1 μg/mL; Gibco) and blasticydin (10 μg/mL; Gibco) were added to the 
Platinum E cell line to maintain the packaging plasmids, but withdrawn prior 
transfection with calcium phosphate.  Doubling time of approximate 24 hours. Cells 
were passaged every 2-3 days when confluency reached 70-90%. 
 
THP1 cell line was a kind gift from Professor Dipak Ramji (Cardiff University). THP1 
is a human monocytic cell line derived from a 1-year-old male with AML FAB M5. THP1 
cells were maintained in RPMI 1640 (Gibco) with 10% FBS and 2mM L-glutamine. 
Doubling time of approximate 30 hours. Cells were passaged every 2-3 days at a 
density of 200,000-400,000 cells/mL. 
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K562 cell line was a kind gift from Professor Richard Darley (Cardiff University). K562 
is a human erythroleukaemia cell line derived from a 53-year-old female with CML in 
blast crisis. K562 cells were maintained in RPMI 1640 with 10% FBS and 2mM L-
glutamine.  Doubling time of approximate 20 hours. Cells were passaged every 2-3 
days at a density of 100,000-200,000 cells/mL. 
 
KG1 cell line was a kind gift from Professor Richard Darley (Cardiff University). KG1 
is a human erythroleukaemia derived from the parental KG1 cell line, derived from a 
59-year-old male with erythroleukaemia that transformed into AML at relapse. KG1a 
cells were maintained in IMDM (Gibco) with 20% FBS and 2mM L-glutamine.  Doubling 
time of approximate 20 hours. Cells were passaged every 2-3 days at a density of 
100,000-200,000 cells/mL. 
 
NOMO1 cell line was a kind gift from Professor Richard Darley (Cardiff University). 
NOMO1 is a human monocytic cell line derived from a 31-year-old female with AML 
FAB M5a. NOMO1 cells were maintained in RPMI 1640 with 10% FBS and 2mM L-
glutamine.  Doubling time of approximate 35 hours. Cells were passaged every 2-3 
days at a density of 300,000-500,000 cells/mL. 
 
2.6.2. Murine AML cell lines.  
 
Cell lines from murine Meis1a/Hoxa9 and Mll-af9 Pre-LSCs at CFC3 and LSCs from 
moribund mice were established liquid culture in IMDM 10% FBS, 100 U/ml penicillin 
(Gibco), 100 μg/ml streptomycin (Gibco), 20 ng/mL SCF (Peprotech), 10 ng/mL IL-3 
(Peprotech), and 20 ng/mL IL-6 (Peprotech).  Doubling time of approximate 24 hours. 
Cells were passaged every 2-3 days at a density of 100,000-200,000 cells/mL. 
 
2.6.3. Bone marrow extraction.  
 
Cleaned bones were crushed using a pestle and mortar. BM was collected in PBS 2% 
FBS and filtered through a 70 μm strainer (Miltenyi Biotec) to remove cell aggregates. 
This step was repeated 2 times until obtaining a 30 mL BM single cell suspension.  
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2.6.4. Red blood cell lysis.  
 
PB red blood cell lysis was carried out using ammonium chloride (NH4Cl) (STEMCELL 
technologies). When RBCs are in NH4Cl under hypotonic conditions (0.8% NH4Cl), 
H2O enters the cells. Non-nucleated RBCs have weaker membrane tonicity, in 
comparison to leukocytes or nucleated RBCs therefore, they undergo osmotic lysis. 
12 μL of blood were added into 600 μL of NH4Cl, incubated for 6’, mixed thoroughly 
by inverting the tube 3 to 4 times, and incubated for another 6’. Samples were then 
centrifuged for 10’ at 370 xG at RT and supernatant containing lysed RBCs was 
removed to obtain a pellet of WBCs. For BM, cell pellet was resuspended in 1 mL of 
NH4Cl and incubated 2’ at RT. Red blood cell lysis was stopped by adding 9 mL of 
PBS 2% FBS.  
 
2.6.5. Splenocyte and thymocyte extraction. 
 
Spleen or thymus was placed into a 70 μm strainer in PBS 2% FBS inside a 6-cm petri 
dish. Spleen or thymus was then homogenised using a 5mL syringe plunger. Cell 
suspension was resuspended to eliminate cell aggregates. This step was repeated 2 
times to obtain a 7-mL spleen or thymus single cell suspension. 
 
2.6.6. AutoMACS magnetic cell separation – c-kit+ enrichment. 
 
BM WBC pellet (after red blood cell lysis) was resuspended in 300 μL of PBS 2% FBS 
containing 20 μL of mouse CD117 (c-kit) microbeads (Miltenyi Biotec), and incubated 
for 12’ at 4°C while rotating. Cells were washed, filtered through a 30 μm strainer 
(CellTrics), and placed into the AutoMACS (Miltenyi Biotec). C-kit+ cells were 
separated using the “posselds” program, which is ideal for rare cell populations with 
low or medium antigen expression. C-kit+ cells were then used for downstream 
applications: cell sorting (to isolate HSCs/HPCs), HSPCs culture, or normal/leukaemic 
transduction experiments.    
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2.6.7. Colony forming cell (CFC) assay. 
 
CFC assays were performed according to the manufacturer’s protocol. Cells and 
media up to 250 μL were added into the methylcellulose (STEMCELL technologies), 
vortexed twice for 3’’, incubated for 5 minutes, and plated using a 2 mL syringe and 
19G blunt-end needle. MethoCult™ M3434 was used for wild-type murine 
haematopoiesis studies; MethoCult™ H4434 was used for human leukaemia 
experiments; and MethoCult™ M3231 supplemented with 20 mL of IMDM, 1 mL of 
Pen/Strep, 20 ng/mL of murine SCF, 10 ng/mL of murine IL-3, 10 ng/mL of murine IL-
6, 10 ng/mL of murine GM-CSF (peprotech) was employed for murine leukaemogenic 
assays. Colonies were counted and scored using an inverted microscope (Leica) at 
day 12 for assays using M3434 and H4434, and at day 6 for M3231.  
 
2.6.8. Culture of murine HSPCs for normal haematopoiesis experiments.  
 
Murine HSPCs (after c-kit enrichment) were cultured in STEMSpan (STEMCELL 
technologies) supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 
100 μg/ml streptomycin, 50 ng/mL of murine SCF, 50 ng/mL of murine TPO 
(peprotech), 50 ng/mL of murine FLT3L (peprotech), and 5 ng/mL of IL-3.   
 
2.6.9. Cryopreservation media.  
 
Human cell lines were frozen down in 70% of media, 20% FBS and 10% DMSO 
(Sigma). Murine BM cells and leukaemia cell lines were frozen down in 90% FBS and 
10% DMSO. All cells were frozen down by centrifuging at 4°C. Pellet was resuspended 
in ice-cold freezing media, transferred to a 1 mL cryovial (Camlab limited), and stored 
into an alcohol-free cell freezing container (Biocision) that allows for a -1ºC/minute 
freeze rate. Cryovials were stored at minus 80°C for short term storage (less than one 
month) or in liquid nitrogen (minus 175°C) for long term storage (longer than one 
month). 
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2.6.10.  Generation of retroviruses and lentiviruses.  
 
Calcium phosphate method was used to generate retroviruses (Kingston et al. 2003). 
10 μg of retroviral vectors containing oncogenes (or empty vectors) were diluted in 
437.5 μL of H2O, and then mixed with 62.5 μL of calcium chloride (Sigma). This mix 
was added drop-wise to 500 μL of 2x hepes buffered saline (HBS; Sigma) and after 
15’ incubation, added to the media of Platinum E cells at 70% confluency in a 10-cm 
dish. 25 μM Chloroquine (Sigma) was added to Platinum E cells media before 
transfection. Supernatant-containing retroviruses was collected at 24 and 48 hours 
after transfection, passed through a 0.45 μm filter (Sigma), snap freeze in dry ice, and 
stored at minus 80°C.  
 
To generate lentiviruses, 3 μg  of VSV-G and  6.9 μg of psPAX2 plasmids were co-
transfected with 10 μg of shGATA2 or Cre lentiviral plasmids using the calcium 
phosphate method in HEK293T cells.  
 
For virus titre calculation, on day one, serial dilutions of viruses produced were added 
to 50,000 HEK293T cells while seeding into a 24-well plate. On day two, the media 
containing viral particles was replaced for fresh media. On day 4, cells were analysed 
by flow cytometry to measure efficiency of transduction. The titre was calculated from 
wells showing between 10-30% of positive cells since multiple integrations occurs at 
higher transduction rates (Fehse et al. 2004). Therefore, to obtain the titre (viral 
particles/mL), the number of plated cells (50,000) are multiplied by the proportion of 
transduced cells and divided by the volume of viruses added to the supernatant (in 
mL).  
 
2.6.11. Lentiviral GATA2 knockdown in THP1.   
 
Non-treated cell culture plates (Starlab) were coated with 100 μg/ml of retronectin 
(Clontech) overnight at 4°C. Retronectin was re-used (up to 10 times) and stored at 
minus 20°C. Lentiviruses encoding shGATA2 (31-34) and a GFP marker or scramble 
GFP control were bound to the retronectin-coated well by centrifugation for 2:30 hours 
at 2,100 xG at RT. Supernatant was discarded and 500,000 THP1 cells were bound 
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to the virus-retronectin-coated plate by centrifugation for 5’ at 500 xG at RT. 8 hours 
later, THP1 cells were transferred to another plate and expanded for 5 days before 
sorting transduced THP1 live cells based on GFP fluorescence. To avoid 
contamination, sorted THP1 cells were maintained in media or plated in 
methylcellulose supplemented with amphotericin B (Sigma).  
 
2.6.12. Lentiviral Cre deletion of Gata2 in murine HSPCs.  
 
According to the method described in 2.6.11, wild type murine c-kit+ cells were 
transduced with lentiviruses carrying Cre-iVenus or empty vector. 72 hours after 
transduction, live cells were sorted based on GFP fluorescence and plated in their 
respective media or methylcellulose supplemented with amphotericin B (Sigma). 
 
2.6.13. Retroviral mouse models of AML. 
 
The day before transduction, 1 million c-Kit+ cells were pre-stimulated with 40 ng/mL 
SCF, 20 ng/mL IL-3, and 20 ng/mL IL-6. Cell were transduced with retroviruses 
encoding Meis1a/Hoxa9, Mll-af9, or their respective control vectors according to the 
method described in 2.6.11 with minor changes. 6 hours after the first transduction, 
cells were transduced for a second time in a new retronectin-coated plate containing 
retroviruses. Next day, medium containing antibiotics geneticin 418 (G418) (1 mg/ml) 
(Gibco) and/or puromicyn (1.5 μg/ml) was added to the medium to select transduced 
Meis1a/Hoxa9 cells. 72 hours later live cells were plated in CFC1 in M3231 containing 
G418 and puromicyn to maintain selection. Mll-af9 transduced cells were left for 72 
hours before sorting live cells based on GFP fluorescence into CFC1. Colonies were 
harvested and replated every 6 days up to 3 rounds of CFC. Cells at CFC3 were 
harvested and enriched for c-kit prior to transplant into lethally-irradiated primary 
recipients or generation of pre-LSCs cell lines. LSCs from moribund mice showing 
symptoms of AML were sorted and transplanted into lethally-irradiated secondary 
recipients.   
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2.7.  Flow cytometry. 
 
All FACS analysis were performed in a 4 laser BD LSRFortessa™ (BD Biosciences), 
except the proliferation assay, which was analysed on the 2 laser BD Accuri. All FACS 
sorting experiments were performed in a 4 laser BD FACSAria™ Fusion (BD 
Biosciences). Full list of antibody clones, fluorochromes, and companies can be found 
in Table 2.5. All FACS data were analysed using FlowJo 10.0.8 (Tree Star, Inc) using 
the gating strategies for each assay that are described in Figure 2.5 to Figure 2.8. 
Manual compensation in FACS Diva software was performed using single stains for 
each antibody-associated fluorochrome within each experiment. Compensation was 
adjusted by equalising the median fluorescence intensity (MFI) of the negative and 
positive population of each fluorochrome against all individuals fluorochrome within 
the experiment (Figure 2.4). For SLAM and progenitor staining, fluorescence minus 
one (FMO) controls were used to set the background fluorescence of each antibody 
as a guidance for gating of each population.  
 
Antigen Clone Reactive	specie Fluorochome Concentration Company
CD3 17A2 Mouse Biotin, APC, FITC 1/1000 BioLegend
CD4 GK1.5 Mouse Biotin, PE, PE-Cy7 1/1000 BioLegend
CD8a 53-6.7 Mouse Biotin, PE, APC-Cy7 1/1000 BioLegend
CD9 MZ3 Mouse PE 1/1000 BioLegend
CD11b M1/70 Mouse/Human Biotin, PE, APC 1/1000 BioLegend
CD14 M5E2 Human Pacific blue 1/500 BioLegend
CD16/32 93 Mouse PE-Cy7 1/25 BioLegend
CD19 6D5 Mouse APC-Cy7 1/100 BioLegend
CD33 WM53 Human APC 1/500 BD Biosciences
CD34 RAM34 Mouse FITC, APC 1/25 eBiosciences
CD41 MWreg30 Mouse FITC 1/1000 BioLegend
CD45.1 A20 Mouse BV510,APC 1/500 BioLegend
CD45.2 104 Mouse Pacific blue, BV510, PE 1/500 BioLegend
CD45R/B220 RA3-6B2 Mouse/Human Biotin, FITC, APC 1/1000 BioLegend
CD48 HM48-1 Mouse FITC 1/50 BioLegend
CD51 RMV-7 Mouse PE 1/1000 BioLegend
CD71 RI7217 Mouse PE 1/1000 BioLegend
CD117 2B8 Mouse PE, APC 1/100 BioLegend
CD150 TC15-12F12.2 Mouse PE-Cy7 1/100 BioLegend
Gr1 RB6-8C5 Mouse Biotin, FITC, PE-Cy7 1/1000 BioLegend
Ter119 Ter119 Mouse Biotin, APC-Cy7 1/1000 BioLegend
Sca-1 D7 Mouse PE, APC-Cy7 1/25 BioLegend
Streptavidin Mouse/Human Pacific blue, PerCP 1/100 BioLegend, eBiosciences
γ-H2AX 2F3 Mouse/Human APC 1/200 BioLegend
Mouse IgG1, κ
Isotype Ctrl MOPC-21 APC 1/200 BioLegend
Fc block 93 Mouse 1/100 BioLegend
GATA2 IC2046P Human PE 1/20 R&D systems
Table 2.5 Antibodies for FACS
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2.7.1. Detection of apoptosis by annexin V. 
 
Cells were incubated in annexin binding buffer (BD biosciences) containing annexin V 
(BioLegend) for 25’ in the dark at RT. Annexin binding buffer was added to stop the 
reaction, and 2 μL of diamidino-2-phenylindole (DAPI, 20 μg/ml)(Molecular probes) 
was added to the samples before acquisition of 20,000 events in single cells gate.  
 
Figure 2.4. Compensation strategy in BD FACS DIVA. (a) Non-compensated FACS plot
showing APC-Cy7 leaking into the PE-Cy7 channel. MFI APC-Cy7 negative (21); MFI APC-Cy7
positive (1,449); Spectral overlap 0. (b) FACS plot showing compensation of APC-Cy7 into the
PE-Cy7 channel.MFI APC-Cy7 negative (8); MFI APC-Cy7 positive (9); Spectral overlap 6.25
(A)
(B)
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In healthy cells, PS resides within the inner side of the plasma membrane, and it is 
translocated to the outer side of the membrane early during apoptosis. Loss of 
membrane integrity during late apoptosis allows DNA dyes such as DAPI to enter and 
stain the nuclei. Annexin V is a 35–36 kDa Ca2+-dependent phospholipid-binding 
protein that recognises and binds phosphatidylserine (PS) residues. Annexin V 
binding buffer provides the Ca2+ required for its binding (Figure 2.5). 
 
 
2.7.2. Proliferation assay.  
 
Cells were stained with 2 μL of propidium iodide (PI, 20 μg/mL)(Sigma), vortexed, and 
10 μL acquired with a BD Accuri™ C6 Plus (BD Biosciences). BD Accuri has the ability 
to quantify the exact number of cells within a specific volume of cells. PI negative cells 
within 10 μL were used to calculate the total number of cells in each well. 
 
2.7.3. Assessment of cell cycle status. 
 
Cells were stained with 100 μL of PBS containing DAPI (5 μg/mL) 0.1% NP40 (Sigma) 
and 50 μg/mL of RNAaseA (ThermoFisher). After 5’ incubation in the dark, 20,000 
FS
C
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FSC-A
Figure 2.5 Detection of apoptosis using annexin V. (Left) Schematics of the apoptosis and necrotic death cell pathways in relation with annexin V and DAPI
binding to PS and DNA. (Right) Representative FACS plots showing the Annexin V – DAPI staining: live cells (DAPI- Annexin V-), early apoptosis (DAPI-
Annexin V+), late apoptosis (DAPI+ Annexin V+), necrosis (DAPI+ Annexin V-).
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events were acquired at low speed (< 400 events/sec). NP40 is a mild detergent that 
permeabilises the plasma and nuclear membrane allowing DAPI to bind the DNA. 
DAPI fluorescence in linear scale was used to measure the DNA content and 
distinguish the cell cycle phases (Figure 2.6). 
 
 
2.7.4. Intracellular staining. 
 
Cells were washed twice with ice-cold PBS prior to fixation with 1% methanol-free PFA 
(ThermoFisher) for 15’ on ice. Cells were then permeabilised in PBS 0.1% X-Triton 
(Sigma) 2% BSA (ThermoFisher) for 15’ on ice, and stained for 30’ on ice and in the 
dark with a fluorescence-labelled antibody diluted in the permeabilisation buffer. Cells 
Figure 2.6 Cell cycle analysis using DAPI. DNAcontent shown as DAPI fluorescence in a FACS histogram.
SubG0 corresponds to apoptotic cells (N < 2). G0 corresponds to quiescent cells. G1 corresponds to cells
preparing for DNA replication (N = 2 copies of DNA), S corresponds to the DNA replication phase (N > 2), G2
corresponds to cells preparing forMitosis (N = 4). M corresponds cells in mitosis (N = 4).
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were washed twice and resuspended in PBS 2% BSA prior to acquisition. For cell 
cycle profile, DAPI was added at a final concentration of 5 μg/mL.  
 
2.7.5. Extracellular staining.  
 
Extracellular staining was carried out in PBS 2% FBS and with an incubation time of 
25’ in the dark at 4°C, except for streptavidin staining. Cells were washed and filtered 
through a 30 μm strainer. To exclude dead cells from the analysis, 2 μL of DAPI (20 
μg/mL) was added prior to acquisition.  
 
2.7.5.1. Lineage staining.  
 
200,000 cells from BM, SP or thymus (or 12 μL of blood) were stained with antibodies 
to distinguish myeloid cells (Gr1, Mac1), T lymphocytes (CD3e, CD4, CD8a), B 
lymphocytes (CD19, B220), erythroid cells (Ter119, CD71), and megakaryocytes 
(CD41) (Figure 2.7). For transplantation experiments, CD45.1 and CD45.2 were 
included to separate donor cells from recipients and support cells. At least 20,000 
events were recorded from live cells.  
 Figure 2.7. Gating strategy for myeloid and lymphoid lineage staining.
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To assess the differentiation status of human THP1 cells, cells collected at the 
indicated time points were stained with anti-human CD14, CD11B and CD71.  
 
2.7.5.2. HSC and progenitor staining.  
 
10 million cells from BM or SP were stained with a cocktail of biotinylated antibodies 
against lineage-specific markers (Ter119, Mac1, Gr1, B220, CD4, CD8a, CD3e) plus 
antibodies to detect haematopoietic stem cells and multipotent progenitors (c-kit, Sca-
1, CD48, CD150) or lineage-restricted progenitors (c-kit, Sca-1, CD34, CD16/32, 
CD127) (Figure 2.8). Cells were then washed and incubated with fluorescence-
conjugated streptavidin for 15’ in the dark at RT. For transplantation experiments, 20 
million cells were stained with the above combinations together with CD45.1 and 
CD45.2 antibodies to separate donor cells from recipients and support cells. At least 
10,000 LSK cells were recorded for SLAM staining, and 10,000 LK for progenitor 
staining.  
 Figure 2.8. Gating strategy used for SLAM and progenitor staining.
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2.7.5.3. LSC staining.  
 
BM cells from moribund mice with AML were stained with antibodies to detect LSCs 
in the Meis1a/Hoxa9 and Mll-af9 models. According to previous publications, LSCs 
were immunophenotypically characterised as DAPI-, CD45.2+ (or GFP+ for Mll-af9 
model), c-kit+, CD16/32+, CD34low.  
 
2.7.6. Cell sorting.  
 
Cells after c-kit enrichment were stained with antibodies as described in 2.7.5. and 
sorted using a BD FACSAria™ Fusion. All sorting experiments were carried out with 
an 85-micron nozzle.   
 
2.8. Transplantation assays.  
 
C57BL/6 SJL (CD45.1) or C57BL/6 (CD45.2) adult recipient mice were irradiated 24 
hours before transplantation. Mice received a split dose of 1,000 cGy (137Cs source) 
four hours apart between doses. After second irradiation, mice were housed in 
individual ventilated cages (IVCs) and administered baytril water for four weeks. All 
transplants were carried out under Class 2 safety cabinet. Mice tail vein were dilated 
by heating the mice at 37°C for 15-30’. Cells were injected in PBS in a volume of up 
to 200 μL per mouse.  
 
2.8.1. Leukaemia transplants. 
 
For primary transplants of pre-leukaemic cells from Meis1a/Hoxa9 (or Mll-af9), 
500,000 c-kit+ CD45.2+ (or GFP+) cells were injected in the tail vein of lethally-
irradiated CD45.1+ mice, unless otherwise stated. For secondary transplants of LSCs, 
10,000 c-kit+ CD45.2+ (or GFP+) BM cells were injected in the tail vein of lethally-
irradiated CD45.1+ mice.  
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2.8.2. Normal haematopoiesis transplants. 
 
For cell-autonomous transplant, 500,000 unfractionated BM cells from Gata2 mice 
were injected in the tail vein of lethally-irradiated CD45.1+ mice. For secondary 
transplant, 500,000 CD45.2+ BM cells were transplanted. For niche studies, 500,000 
unfractionated BM cells from CD45.1+ mice were transplanted into the tail vein of 
lethally-irradiated Gata2 mice.  
 
2.9. RNA extraction and gene expression analysis.   
 
All samples were collected in RLT plus buffer (Qiagen) and stored at minus 80 until 
extraction. RNA extraction was carried out with the RNAeasy Plus Micro/Mini Kit 
(Qiagen) according to the manufacturer’s instructions. cDNA was made using the 
Cloned AMV First-Strand cDNA Synthesis Kit (Invitrogen) for Gata2 expression 
experiments in murine haematopoiesis, and QuantiTec RT Kit (Qiagen) for the rest of 
experiments. Real time quantitative PCR (RT-qPCR) was performed in a 
QuantStudio® 7 Flex Real-Time PCR System (Applied biosystems) using Taqman 
(Applied Biosystems) or Sybr green method (PCR Biosystems). Full list of primers is 
listed in Table 2.6. Differences in input cDNA were normalised against the 
housekeeping gene (Hprt for mouse and GAPDH for human) and the mRNA 
expression levels were determined by the 2-ΔΔCT method of relative quantification 
(Schmittgen and Livak 2008).  
 
 
 
Primer name ID	name Manufacturer
Gata2 Mm00492301_m1 Applied Biosystems
Hprt Mm03024075_m1 Applied Biosystems
GATA2 Hs00231119_m1 Applied Biosystems
P21 Hs00355782_m1 Applied Biosystems
P27 Hs00153277_m1 Applied Biosystems
P53 Hs01034249_m1 Applied Biosystems
P57 Hs00175938_m1 Applied Biosystems
LIG4 Hs00172455_m1 Applied Biosystems
GAPDH Hs02786624_g1 Applied Biosystems
Table 2.6 qRT-PCR primers
 86 
2.10. Data and statistical analysis  
 
FACS data were analysed using FlowJo 10.0.8 (Tree Star, Inc) software and all results 
graphed using GraphPad Prism 7 (GraphPad Software Inc, CA). Data are presented 
as mean ± standard error of mean (SEM). Significant differences were calculated 
using Mann–Whitney U test or TWO-WAY ANOVA (*p<0.05, **p<0.01, ***p<0.001, 
**** p<0.0001). 
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Chapter 3 
 
Assessing the role of Gata2 in adult murine haematopoiesis 
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3.1.  Introduction  
 
Haematopoietic stem cells (HSCs) are multipotent stem cells that give rise to 
progenitor cells, which differentiate into multiple blood lineages. External signals 
delivered from the BM niche are crucial for HSC homeostasis, alongside a cell intrinsic 
transcriptional program driven by transcription factors (TFs). To date, few TFs have 
been identified as essential for HSC survival in the mouse adult haematopoietic 
system; conditional deletion of Mcl-1, Tel1/Etv6 and Cited2 leads to a complete loss 
of immunphenotypically defined HSCs in adult mice (Kranc et al. 2009; Opferman 
2005; Hock et al. 2004).  
 
Gata2, a zinc finger TF expressed in the haematopoietic system (Tsai et al. 1994), is 
essential for the generation and survival of HSCs in development (de Pater et al. 
2013). Constitutive deficiency of Gata2 in Gata2-/- mice causes embryonic lethality 
(E10.5) due to severe anaemia, and profound effects on both primitive and definitive 
haematopoiesis (Tsai et al. 1994). Conditional deletion of Gata2 before (Vec-Cre) and 
after (Vav-iCre) HSC generation identified that loss of Gata2 leads to a detrimental 
impact on HSC function in the aorta-gonad-mesonephros (AGM) and foetal liver (FL) 
(de Pater et al. 2013).  
 
The requirement for Gata2 in adult HSC is less clear. Analysis of constitutive 
haploinsufficient Gata2 (Gata2+/-) mice showed quantitative and qualitative defects in 
transplantation assays of HSCs in adult BM (Rodrigues et al. 2005; Ling et al. 2004). 
Furthermore, Gata2+/- mice display defects in the number and functionality of 
granulocyte-macrophage progenitor (GMP) (Rodrigues et al. 2008). In humans, 
GATA2 haploinsufficiency mutations have been linked with hereditary 
immunodeficient, MonoMac and Emberger syndromes that precede transformation to 
myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) (Hyde and Liu 
2011), yet no features of GATA2 clinical syndromes were observed in Gata2+/- mice. 
However, haematopoietic analysis of Gata2+/- mice have only been conducted in 
young adult mice, and it remains unclear whether aged Gata2+/- mice would provide a 
tractable model of Gata2-related syndromes. Therefore, a better understanding of the 
genetic interactions and downstream effectors of Gata2 in normal adult 
haematopoiesis and malignant transformation is necessary. 
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3.2.  Aims and Objectives 
 
The specific aims for this chapter are: 
 
1. To assess the expression of Gata2 in the murine haematopoietic system.  
 
2. To study the impact of acute, conditional Gata2 deletion in HSCs using the 
Mx1-Cre system.  
 
3. To establish a suitable model to investigate the molecular mechanism 
downstream Gata2 in HSCs.  
 
4. To characterise the long-term effects of Gata2 haploinsufficiency employing the 
Mx1-Cre mouse model.  
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3.3.  Results  
3.3.1. Gata2 is highly expressed in HSCs.  
 
To date, expression of Gata2 has been reported to be highest in HSCs and decreases 
throughout differentiation (Lim et al. 2012) yet this has not been formally demonstrated 
in highly purified HSCs and progenitor cell subsets (Oguro et al. 2013). We therefore 
purified HSCs and multipotent progenitors (MPP, HPC1, HPC2), lineage-restricted 
progenitors (CMP, GMP, MEP) and differentiated blood cells (T and B lymphocytes, 
myeloid cells and erythroid cells) by FACS (Figure 3.1A) and performed q-PCR to 
determine mRNA levels of Gata2. Our results indeed showed that Gata2 is highly 
expressed in HSC and multipotent progenitors, and expression dramatically reduces 
during differentiation by 5-fold in CMP and 10-fold in GMP and MEP (Figure 3.1B). 
Finally, Gata2 expression was reduced in T cells (80 fold), B cells (100 fold), myeloid 
cells (20 fold) and erythroid cells (25 fold) (Figure 3.1B).   
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Figure 3.1.Gata2 is highly expressed in HSCs. HSPCs populations (HSC, MPP, HPC-1,
HPC-2, CMP,GMP, MEP) and mature blood cells (T, B, myel oid, erythroid) from adult BM
mice were sorted to assess Gata2 expressi on by Q-PCR. (A) Repr esentative FACS plots
showing sorting strategy for HSPCs. (B) Relative Gata2 mRNA levels in haematopoi etic
cells in relation with expressi on i n HSCs (HSC = 1) (n = 3-5). Two independent experiments
were performed for the analysis. Data are mean ± SEM.
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3.3.2. Acute deletion of Gata2 leads to myeloid suppression  
 
To directly assess the requirement for Gata2 in adult haematopoiesis and to overcome 
the embryonic lethality in Gata2-/- mice (Tsai et al. 1994), we employed the Mx1-Cre 
system (Kühn et al. 1995) in which acute deletion of Gata2 was achieved by the 
activation of the IFN pathway through pIpC injections. We bred Gata2 floxed (fl/fl) mice 
with Mx1-Cre to obtain a cohort of Gata2fl/fl;Mx1-Cre+ or control mice (Gata2fl/fl;Mx1-
Cre- or Gata2+/+;Mx1-Cre+ respectively). Upon pIpC induction of 8-10-week-old mice, 
we harvested mice 24 days after the first dose of pIpC (Figure 3.2A) and confirmed 
complete Gata2 deletion in Gata2D/D;Mx1-Cre+ BM cells (Figure 3.2B). We observed 
a reddish hue in the BM suspension of Gata2D/D;Mx1-Cre+ compared to control BM 
cells, indicating a reduction of white blood cells (Figure 3.2E). In addition, BM 
cellularity was significantly decreased in Gata2D/D;Mx1-Cre+ mice (Figure 3.2C). 
Immunophenotypic analysis of the BM revealed a complete reduction in the number 
of myeloid cells in the BM of Gata2D/D;Mx1-Cre+ mice (Figure 3.2F). Depletion of 
myeloid cells was also observed in the peripheral blood (PB) and spleen (SP) of 
Gata2D/D;Mx1-Cre+ mice (Figure 3.2F). The frequency and absolute number of 
erythroid cells were additionally decreased in the BM but not in the PB and SP of 
Gata2D/D;Mx1-Cre+ mice (Figure 3.2G). Red blood cell formation occurs in the BM and 
these cells lose their nuclei during their last differentiation step from reticulocyte to 
erythrocyte, and these erythrocytes are the only circulating red blood cells under 
homeostasis. Morphological and blood counts would have helped to confirm whether 
we actually detected nucleated red blood cells (Ter119+) in the PB. In addition, the 
high percentage of CD41+ cells observed in the PB of control and KO mice could be 
due the lack of EDTA in the FACS buffer used for these experiments. Interestingly, 
the BM, but not the SP or PB, of Gata2D/D;Mx1-Cre+ mice showed a significant 
expansion in the frequency and absolute number (not statistically significant) of B cells 
(Figure 3.2H and Figure 3.2J-M). Therefore, these data indicate that Gata2 is a 
critical regulator of myeloid lineages in haematopoiesis and of erythroid and B cell 
maintenance in the bone marrow. 
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3.3.3. Gata2 is essential for the maintenance of adult HSCs. 
 
Next, we addressed the impact of Gata2 deletion in HSCs and haematopoietic 
progenitor cells. We analysed the BM of Gata2D/D;Mx1-Cre+ mice at day 24 as 
described in Figure 3.2A, and found a near complete loss of the LSK compartment, 
that comprises the HSC, MPP, HPC-1 and HPC-2 populations, and LK cells, which 
capture CMP, GMP and MEP progenitor populations (Figure 3.3A and Figure 3.3B). 
From these data, we infer that Gata2 could regulate the survival of HSCs. However, 
since we have not performed a survival curve after Gata2 deletion, we cannot confirm 
the survival phenotype, and it could be argued that Gata2 regulates C-kit expression 
and therefore HSCs are still present but we were not able to detect them by the 
standard LSK definition.   
 
  
 
 
Figure 3.3. Gata2 is essential for the maintenance of adult HSCs. Analysis of HSPCs at day 14
according to 3.2A schematics. (A) Representative FACS plots of showing loss of LSK and LK populati on in
Gata2 deleted mice (blue dots). (B) Frequency of LSK cells at day 14 (n = 4). (C) Frequency of LK cells at
day 14 (n = 4). Two independent experiments were performed for all analysis. Data are mean ± SEM.
Statistical analysis: Mann-Whitney test.
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In order to study the molecular mechanism behind acute Gata2 deletion in HSCs, we 
sought to analyse Gata2D/D;Mx1-Cre+ at day 15 after the first dose of pIpC (Figure 
3.4A). After confirming complete Gata2 deletion (Figure 3.4B) we were able to 
phenocopy our data at day 24 following the first dose of pIpC, including LSK and LK 
complete loss, myeloid depletion, and B cell expansion (Figure 3.4C-G). We also 
found a complete abolition in the CFC formation of Gata2D/D;Mx1-Cre+ BM cells in this 
experimental setting (Figure 3.4E). Therefore, acute deletion of Gata2 leads to a rapid 
onset loss of HSCs, or at least, HSC immunophenotype.  
 
 
  
Figure 3.4. HSC loss at day 15 after Gata2 deletion. (A) Following the same procedure than in fi gure 3.2A, we
analysed the haematopoietic sys tem at day 15 after pIpC induc tion. (B) Genomic PCR showing Gata2 deletion. (C)
BM cell suspensi on from Gata2 KO (left) and control (right) mice. (D-to-G) FACS plots from Gata2 KO and control
mice BM showing a depl etion of HSPCs i n vivo (D) and i n CFC assays in vitro (E), depletion of myeloid cells (F),
and an increase in the frequency of B cells (G) at day 15 (n = 1). One experiment was performed for all analysis.
Data are mean ± SEM.
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3.3.4. Gata2 acts in a cell-autonomous manner and independently of the 
niche to regulate HSCs.  
 
The Mx1-Cre promoter is present both in haematopoietic cells and in the BM 
microenvironment (Kühn et al. 1995). To determine whether Gata2 functions cell-
autonomously in HSC maintenance, we transplanted untreated CD45.2+ BM cells from 
Gata2fl/fl;Mx1-Cre+ or control mice together with unfractionated CD45.1+ BM cells in a 
competitive transplant (Figure 3.5A). Similar engraftment was observed in the PB of 
recipients transplanted with Gata2fl/fl;Mx1-Cre+ and control cells (Figure 3.5B). Six-
weeks after transplant Gata2 deletion was induced and efficient Gata2 deletion in 
CD45.2+ BM cells of recipients transplanted with Gata2fl/fl;Mx1-Cre+ BM cells (Figure 
3.5C) was confirmed. We found a decrease in the frequency of CD45.2+ cells in the 
BM, and to a lesser extent in the PB and SP of recipients transplanted with 
Gata2D/D;Mx1-Cre+ BM cells (Figure 3.5D). Indeed, further immunophenotypic 
analysis revealed a complete loss of myeloid cells and significant reduction of erythroid 
cells in the BM, PB and SP (Figure 3.5E-G). Strikingly, CD45.2+ Gata2D/D cells within 
the LSK and LK compartments were undetectable (Figure 3.5H and Figure 3.5I). 
Finally, to test whether there was any residual haematopoietic activity in CD45.2+ 
Gata2D/D cells, we isolated CD45.2+ BM cells from primary transplantation and 
transplanted them together with unfractionated CD45.1+ competitor cells into 
secondary recipients. Four weeks after transplant we found no engraftment in the BM, 
PB, SP or thymus of recipients injected with CD45.2+ Gata2D/D cells (Figure 3.5J). 
Collectively these data demonstrate that Gata2 regulates HSC maintenance in a cell-
autonomous manner.  
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To independently confirm the cell-autonomous role of Gata2 in the regulation of 
HSPCs, we transduced c-kit+ cells from Gata2fl/f or control mice with lentivirus 
containing a bicistronic Cre and GFP reporter (Figure 3.6A). After confirming 
complete Gata2 deletion (Figure 3.6B), we plated GFP+ cells into a CFC assay. We 
found that GFP+ Gata2D/D cells were unable to generate colonies in methylcellulose 
(Figure 3.6C). These data indicate a dependency for Gata2 in HSPCs survival ex vivo, 
however we would need to validate this result by using Gata2+/+ infected with Cre 
compared to empty vector control to gauge the potential Cre toxicity in colony 
formation of HSPCs.  
 
 
To gauge the contribution of any Gata2-dependent impact of the niche on HSC 
maintenance, wild-type CD45.1+ BM cells were transplanted into Gata2fl/fl;Mx1-Cre+ 
and control mice. After confirming stable reconstitution, we induced Gata2 deletion in 
the BM microenvironment containing wild-type HSCs (Figure 3.7A). No engraftment 
or lineage distribution defects were observed in the PB of the Gata2 deleted niche 
recipients at weeks 3, 6 and 9 after pIpC-mediated Gata2-niche deletion (Figure 3.7B-
F). We found a slight increase in the chimerism of BM cells transplanted into Gata2-
deficient niche mice, which can be explained by the depletion of residual 
haematopoietic Gata2D/D cells in Gata2-deficient niche mice after pIpC induction, while 
the remaining haematopoiesis from control-niche mice remained, at low levels, after 
pIpC deletion (Figure 3.7D). Thus, the Gata2 deficient niche does not impact HSC 
engraftment ability and multi-lineage distribution. Despite that Mx1-Cre is known to 
delete niche in the BM microenvironment from previous publications (Kuhn et al. 
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Figure 3.6. Ex-vivo deletion of Gata2 in HSPCs using lentiviral Cre. (A) C-kit+ cells from Gata2fl /fl mice were
transduced with iCre-IRES-Venus or control vector, and 72-hours later 2,000 Venus+ cells sorted into CFC. (B)
Genomic PCR showing Gata2 deleti on (C) Number of CFU-C at day 14 (n = 2). One experiment was performed for all
analysis. Data are mean ± SEM. Statistical analysis: Mann-Whitney test. All statistical analysis were non-significant
(NS).
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1996), we did not formally test the protein levels of Gata2 in niche cells in comparison 
to normal levels from WT BM cells in this transplantation setting.  
 
 
 
3.3.5. Gata2 heterozygous mice display reduced HSCs in young and aged 
haematopoietic systems.  
 
As we were unable to detect any HSCs after acute Gata2 deletion, we sought to 
determine whether Gata2 haploinsufficient mice would be a tractable model system to 
study the HSC survival mechanism seen in Gata2D/D;Mx1-Cre+ mice. To validate 
previous studies showing a reduced number of LSK cells in constitutive Gata2 
haploinsufficient (Gata2+/-) mice (Rodrigues et al. 2005; Ling et al. 2004), we induced 
Gata2 deletion in Gata2fl/+;Mx1-Cre+ or control mice and confirmed deletion of one 
Gata2 allele in BM and LSK cells 24 days after the first dose of pIpC (Figure 3.8A and 
Figure 3.7. PB monitoring of Gata2 mice transplanted with WT BM cells. (A) wild-type CD45.1+ BM cells were
transpl anted into lethally-irradiated Gata2fl/ fl;Mx1-Cre+ or control mice. Six weeks later Gata2 niche del etion was
induced with pIpC as indicated i n Figure 3.2A. Engraftment w as measur ed every three weeks in the PB. At week 12
(ongoing experiment) CD45.1+ HSCs that have been surrounded by Gata2 deficient or control BM microenvironment
will be transplanted into lethally-irradiated CD45.2+ mice. (B) Engraftment at w eek 6 prior to pIpC (n = 2-5). (C)
Engr aftment in the PB at the indicated time points after pIpC induc tion (n = 2-5). (D) Remaining haematopoiesis before
and after pIpC induction (n = 2-5). (E-G) Engraftment i n the PB of the indicated populati ons at (E) 3, (F) 6, and (G) 9
weeks after pIpC i nduction (n = 2-5). One experiments was performed for all analysis. Data are mean ± SEM.
Statistical analysis: Mann-Whitney test. All statistical analysis were non-significant (NS).
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Figure 3.8B). We found a decrease in the frequency of LSK cells in Gata2fl/D;Mx1-
Cre+ (Figure 3.8C and Figure 3.8D). Therefore, Gata2 haploinsufficient mice will allow 
further investigation of the molecular mechanisms downstream of Gata2 in HSCs.  
 
 
 
Next, we asked whether ageing Gata2 haploinsufficient mice would serve to model 
GATA2 hereditary mutations found in humans that develop immunodeficiency, 
MonoMAC or Emberger syndrome and which progresses to MDS and AML (Hyde and 
Liu 2011). We induced Gata2fl/+;Mx1-Cre+ or control mice and monitored them for 6 
months (Figure 3.9A). Efficient deletion of one Gata2 allele in the BM of Gata2fl/D;Mx1-
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Cre+ mice was confirmed (Figure 3.9B). A non-significant decrease was observed in 
BM, but not SP, cellularity from Gata2fl/D;Mx1-Cre+ mice (Figure 3.9C-E). We detected 
a decrease in the numbers of myeloid cells in BM and erythroid cells in the SP of 
Gata2fl/D;Mx1-Cre+ mice (Figure 3.9F-I). In addition, we found a non-significant 
decrease in the abundance of MPP and HSCs from the BM Gata2fl/D;Mx1-Cre+ mice 
(Figure 3.9J). Interestingly, we detected an enhancement in the frequency and 
numbers of HPC-2 cells in the BM of Gata2fl/D;Mx1-Cre+ mice (Figure 3.9J). Finally, 
we plated BM cells into a CFC assay and unexpectedly found that Gata2fl/D BM cells 
gave rise to more colonies than control BM cells (Figure 3.9K and Figure 3.9L). 
Collectively, these data indicate that aged Gata2 haploinsufficient mice have 
perturbed haematopoiesis. Further investigation will be required to determine if these 
mice develop MDS/AML akin to clinical GATA2 haploinsufficiency syndromes. 
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Figure 3.9. Long term analysis of Gata2 heterozygousmice. (A) Following the same approach is in Figure 3.8A,
we monitor the mice for long term (6 months) prior to analysis. (B) PCR gel showing com plete deletion ofGata2 (C)
Spleen pictur es. (D) BM cellularity (n = 3). (E) SP cellularity (n = 3). (F) Frequency of each popul ation in the PB (n =
3). (G-H) Total number of each the indicated populations in the (G) BM and (H) SP ( n = 3). (I) Frequency and (J)
total numbers of the indicated populations within the LSK compartment (n = 3). (K) Number of CFU-C at day 14 (n
= 3). (L) R epresentative CFU-C pictur es at day 14. One experiment was performed for all analysis. Data are mean
± SEM. Statistical analysis: Mann-Whitney test. All statistical analysis were non-significant (NS).
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3.4.  Discussion 
 
In this study, we explored the function of Gata2 in the maintenance of adult HSCs and 
haematopoiesis. In addition, we have investigated the long-term effects of Gata2 loss 
of function of one allele in relation to the development of previously reported GATA2-
haploinsufficiency related syndromes.  
 
Our data identifies the crucial role of Gata2 in HSCs. Gata2 was one of the first TFs 
to be studied in the haematopoietic system. In addition to the anaemic phenotype 
observed in Gata2-/- mice, they also displayed a lack of multipotential reconstitution in 
chimera experiments, suggesting a HSPC defect (Tsai et al. 1994). By means of the 
conditional Cre-lox system it was later found that Gata2 KO mice were unable to 
generate or maintain HSCs in the embryo (de Pater et al. 2013). Indeed, this rapid 
loss of Gata2 deficient HSCs in this setting was due to the induction of apoptosis (de 
Pater et al. 2013). Adult Gata2 (Gata2+/-) haploinsufficient mice have reduced HSCs 
coupled with a reduction of the anti-apoptotic protein Bcl-xL, highlighting Gata2 as 
major regulator of HSC survival (Rodrigues et al. 2005).  
 
In another study, loss of c-kit in haematopoietic progenitors and BM failure was 
observed upon conditional deletion of the Gata2 C-terminal zinc finger domain in adult 
mice, using a tamoxifen-inducible Cre system to delete the Gata2 C-terminal zinc 
finger domain in all tissue-types (H. S. Li et al. 2016). To circumvent the nonspecific 
tissue effects of the tamoxifen-Cre system, the authors performed a cell-autonomous 
experiment to delete Gata2 in haematopoietic cells after tamoxifen induction and 
detected a reduction of c-kit expression in the BM of recipients with Gata2 KO cells 
(H. S. Li et al. 2016). These findings are consistent with our results using the Mx1-Cre 
system, although some differences can be seen between these two Cre-lox models. 
The authors described a multi-lineage defect at 10-days after Gata2 deletion in both 
non-cell autonomous and cell-autonomous experiments, including B cell and T cell 
lineages, while deletion in the Mx1-Cre system used here showed myeloid and 
erythroid abolition but not lymphoid 24 days after deletion. Long-term cell-autonomous 
follow-up of Gata2 KO cells will be used to further assess multi-lineage failure (which 
is an ongoing experiment). However, lethality of Gata2 KO mice treated with tamoxifen 
can also be explained by non-haematopoietic Gata2 effects, since Gata2 has been 
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reported to regulate prostate, lung, neurons, thyroid gland, and pituitary gland (He et 
al. 2014; Kumar et al. 2012; El Wakil et al. 2006; Charles et al. 2006). 
The differences observed in the frequency of mature haematopoietic lineages upon 
Gata2 deletion with the Mx1-Cre promoter can also be explained by the survival 
kinetics of each haematopoietic lineage, rather than a specific dependency of Gata2 
for myeloid and erythroid lineage maturation. In support of this, specific Gata2 deletion 
using LysM-Cre in myeloid cells did not impact haematopoiesis (H. S. Li et al. 2016). 
Also, lymphoid cells are long-lived while myeloid and erythroid are short-lived (Ho et 
al. 2015), potentially explaining the existence of residual lymphoid cells in the BM of 
Gata2 KO mice. Importantly, we found an increase in the frequency and number of B 
cells in the BM of Mx1-Cre Gata2 KO mice at day 24, and this increase was even 
stronger at day 15 after deletion.  Since this increase was not seen in the cell-
autonomous setting, it is postulated that Gata2 deletion mediates niche-dependent 
expansion of B cells. For instance, reduction of Gata3 levels upon Gata2 acute 
deletion could induce a B cell response, since Gata3 is a known negative regulator of 
B cells (Rothenberg 2013). In support of this, Gata3 is able to regulate haematopoiesis 
through sympathetic innervation present in the niche (Fitch et al. 2012), and at the 
same time Gata2 has been shown to be responsible to Gata3 activation in the nervous 
system (Tsarovina 2004).  
 
Gata2 joins a select list of TFs that are required for HSC maintenance. Conditional 
acute deletion of Cited2 and Tel/Etv6 using the Mx1-Cre system led to HSC loss and 
multilineage failure, although they were indispensable for mature haematopoietic cells 
(Kranc et al. 2009; Hock et al. 2004). In contrast, Mcl-1 affects lymphoid lineages in 
addition to its role in HSC survival (Opferman et al. 2003). Further experiments with 
lineage-specific Cre should determine whether Gata2 is required for erythroid and 
lymphoid lineages since it has been already reported that is dispensable for myeloid 
mature cells (H. S. Li et al. 2016). Exploring the Gata2-mediated HSC survival 
molecular mechanisms and genetic interactions will be of interest to understand the 
pathways governing adult HSCs, which will provide a better insight of the deregulation 
of HSCs and malignant transformation into pre-LSC/LSCs.  
 
Finally, we attempted to model GATA2-related syndromes by studying the long-term 
effects of Gata2 heterozygous deletion using the Mx1-Cre system. Our preliminary 
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data indicates a decrease in the total number of myeloid and B cells, characteristics 
found in GATA2-related syndromes (Collin et al. 2015). However, we did not analyse 
the levels of DCs or NK cells, which are other key immune cell types deficient in 
GATA2-deficient syndromes (Collin et al. 2015). Surprisingly, Gata2 heterozygous 
mice had increased CFC capacity in vitro. In addition, we found a decrease in the 
number of HSCs and MPPs together with an increase in HPC-2, and possibly HPC-1 
cells, perhaps presaging the development of MPN/MDS; this result mirrors what was 
observed in Atg7 KO mouse that develop myeloproliferative neoplasms (MPN)/MDS 
(Mortensen et al. 2011). Taken together, these findings indicate a potential for Gata2 
haploinsufficient mice to model GATA2-deficiency clinical syndromes. Longer 
monitoring and detailed immunophenotypic and histological examination will be 
required to confirm these results. Since GATA2 mutations in these hereditary 
syndromes occur at an early developmental stage, use of alternative mouse models 
to induce the deletion during HSC development would perhaps provide a more faithful 
model to investigate GATA2-related syndromes and provide a drug platform that 
would help to treat diagnosed GATA2-deficient family members at early stages. 
Moreover, since GATA2 deregulation has been reported in non-hereditary MDS/AML 
(Vicente et al. 2012; Maaike Luesink et al. 2012) cases, and in other cancer types 
(Kumar et al. 2012; Rodriguez-Bravo et al. 2016; Wang et al. 2015; Xu et al. 2016), 
elucidating the role of Gata2 in the context of Gata2-heterozygous mice will shed light 
in the molecular mechanisms involved in malignant transformation.  
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Chapter 4 
 
Exploring the function of Gata2 in murine models of Meis1a/Hoxa9 and Mll-af9 
driven AML  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 106 
4.1.  Introduction  
 
AML is driven by a subset of leukaemia cells termed leukaemia stem cells (LSCs) 
(Bonnet and Dick 1997). It is generally acknowledged that some subsets of LSCs are 
resistant to eradication, they ultimately cause relapse and, importantly, need to be 
therapeutically targeted to effect cure (Dick 2005; Tabe and Konopleva 2015; Jung et 
al. 2015). Inducing cell death and/or differentiation of LSCs are attractive targets for 
therapy, as they would eliminate the source of leukaemia cell growth/accumulation. 
 
Gata2 has been established as a critical, dose dependent regulator of haematopoiesis 
(see chapter 3) (Rodrigues et al. 2005; Ling et al. 2004), yet its role in the initiation, 
maintenance and progression of acute myeloid leukaemia (AML) remains highly 
controversial. Both down-regulation and overexpression of Gata2 are considered to 
be involved in AML pathogenesis. For instance, sporadic and hereditary GATA2 
mutations give rise to myelodysplastic syndrome (MDS) and AML (Hyde and Liu 
2011). Conversely, low-level overexpression of Gata2 is able to immortalise murine 
BM cells in vitro, with myeloid skewing without progressing to full-blown leukaemia 
(Nandakumar et al. 2015). In addition, overexpression of GATA2 has been linked with 
poor prognosis in AML patients (Vicente et al. 2012; Luesink et al. 2012). Recently, 
GATA2 has also been linked with poor prognosis and aggressiveness in other cancer 
types, including prostate, lung and breast cancer (Kumar et al. 2012; Rodriguez-Bravo 
et al. 2016; Wang et al. 2012). Though several studies have shown that 
overexpression of Gata2 reduces the clonogenic potential of Mll-af9 pre-LSCs in vitro 
(Danis et al. 2015; Bonadies et al. 2011), how such deregulation of GATA2 expression 
impacts the functionality of LSCs is not understood. 
 
Evi1 is an essential TF for HSCs and has been shown to bind and activate Gata2 
directly in HSCs and leukaemia cells (Yuasa et al. 2005; Goyama et al. 2008; Sato et 
al. 2008). Evi1 overexpression in mice generates a MDS/AML phenotype (Buonamici 
et al. 2004), and its overexpression is associated with poor outcome in both diseases 
(Barjesteh van Waalwijk van Doorn-Khosrovani et al. 2003; Lugthart et al. 2008). In 
agreement with this, Evi1 is a transcriptional target of mixed lineage leukaemia (Mll) 
translocations (Arai et al. 2010). Mll oncoproteins comprises a subset of leukaemia 
(10% overall leukaemia-subtypes (Krivtsov and Armstrong 2007)) with aggressive 
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clinical features. The Mll gene encodes a methyltransferase that when aberrantly 
fused to another protein triggers epigenetic reprogramming through activation of 
Meis1a/Hoxa9 and Evi1 in HSC or progenitor cells giving rise to LSCs, which generate 
lymphoid, myeloid, or mixed leukaemia (Krivtsov and Armstrong 2007; Bindels et al. 
2012; Faber et al. 2009). Pre-LSCs and LSCs derived from Mll oncogene expression 
have been well characterised in retroviral and transgenic mouse models (Krivtsov et 
al. 2006; Somervaille and Cleary 2006). Therefore, these models provide an amenable 
system to study the dysregulated expression of Gata2 in Pre-LSC and LSC biology. 
This knowledge can then be translated in order to appropriately target pre-LSCs and 
LSCs in MDS and AML, and perhaps cancer stem cells (CSCs) in other cancer types 
where Gata2 function is also affected. 
 
 
4.2. Aims and Objectives 
 
The specific aims and objectives for this chapter are:  
 
1. To assess the impact of genetic deletion of Gata2 in LSC development and 
maintenance in the Mll-af9 and Meis1a/Hoxa9 retroviral mouse models in vivo.  
 
2. To assess the in vitro efficacy of a small molecule inhibitor of Gata2, K-7174, 
to target pre-LSCs and LSCs from Mll-af9 and Meis1a/Hoxa9 retroviral mouse 
models.  
 
3. To investigate the co-operation between K-7174 and standard 
chemotherapeutic drugs in targeting Mll-af9 and Meis1a/Hoxa9 derived pre-
LSCs and LSCs in vitro.  
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4.3. Results 
 
4.3.1. Gata2 is downregulated in pre-LSCs and LSCs from Meis1a/Hoxa9 
and Mll-af9 retroviral AML mouse models. 
 
Preliminary data obtained in collaboration with investigators at Edinburgh University 
showed that Gata2 was increased in pre-leukaemia LSK cells from a 10-week-old 
transgenic Mll-af9 knock-in (Mll-af9KI) mouse (Figure 4.1A-C). In this model, the Mll-
af9 translocation is under the control of the endogenous Mll promoter thus generating 
a translational model to study the pathogenesis of Mll-af9 AML (W. Chen et al. 2008; 
Vukovic et al. 2015). This data demonstrates overexpression of Gata2 in pre-LSCs 
and supports the idea of a role for Gata2 in leukaemia initiation in Mll-af9-mediated 
AML.  
 
 
 
 
 
 
Figure 4.1 Gata2 is overexpressed in pre-leukaemic cells from aMll-af9+ /KI transgenic mouse. (A) LK and
LSK cells from 10 week-ol d Mll-af9+/KI or littermate contr ol (Mll-af9+/+) mice were sorted and Gata2 levels
measured by qRT-PCR. (B) Representative FACS pl ot showing LK and LSK populations. (C) Gata2 gene
expression in LK and LSK cells. Data are mean ± SEM (n = 4-5). Statistical analysis: Mann-Whitney test.
Experiment performed by Dr. Milica Vukovic (SCRM, Edinburgh).
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Next, we sought to establish well-characterised retroviral mouse models of Mll-af9 
driven AML (Krivtsov et al. 2006; Somervaille and Cleary 2006). Here, HSPCs (c-kit+ 
cells) were transduced with retroviruses encoding the Mll-af9 translocation or co-
transduced with its direct downstream targets Meis1a9 and Hoxa9, that are 
overexpressed in 40% of AML patients (Lawrence et al. 1993). Next, transduced cells 
were serially-replated in methylcellulose CFC assays, and pre-LSCs obtained after 
three rounds of CFC were injected into lethally-irradiated primary recipients. Within 
the BM environment pre-LSCs acquire secondary mutations and become LSCs that 
initiate the onset of AML in mice. LSCs from moribund mice with AML were then able 
to propagate the disease upon transplantation into lethally-irradiated secondary 
recipients (Figure 4.2).  
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Figure 4.2. Estab lishment of the Meis1a/Hoxa9 and Mll-af9 AML mouse models. (A) C-kit+ cells wer e retrovirally transduced with
Mll-af9 or Meis1a/Hoxa9 oncogenes and plated into m ethylcellulose under colony forming cell (CFC) assay. After CFC3, pre-LSCs (c-
kit+) were tr ansplanted into lethally-irradiated reci pients. LSCs from primary recipients were transpl anted into secondary recipi ents . (B)
Colonies at CFC1 from non-transformed empty vec tor (top) and tr ansformed with Meis1a/Hoxa9 oncogenes (bottom).(C) FACS plots
showing immunophenotypic leukaemic cells (CD45.2+ (GFP+) Gr1low Mac1+) and LSCs (CD45.2+ (GFP+), c-kit+, CD16/32+, CD34low).
(D) Spleenomegaly observed in leukaemic mice compared to WT control mice.
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We analysed the expression of Gata2 in Mll-af9 or Meis1a/Hoxa9 pre-LSCs (c-kit+) 
compared to empty vector transduced c-kit+ cells at CFC3 and to freshly-isolated c-
kit+ cells. Surprisingly, we found that Gata2 expression from pre-LSCs was 
downregulated compared to the empty vector control (Figure 4.3A and 4.3C). When 
compared to freshly-isolated c-kit+ cells, Mll-af9 pre-LSCs maintained similar Gata2 
levels (Figure 4.3C) while Gata2 levels were greatly reduced in Meis1a/Hoxa9 pre-
LSCs (Figure 4.3A). Thus, downregulation of Gata2 is an early event for 
Meis1a/Hoxa9 mediated leukaemia transformation, and possibly in the Mll-af9 model. 
To investigate whether downregulation of Gata2 was also seen after LSC 
development and maintenance, we analysed freshly-isolated LSC from moribund mice 
with AML according to Figure 4.2C. In agreement with the results found in pre-LSCs, 
we observed a profound decrease in Gata2 expression in Mll-af9 and Meis1a/Hoxa9 
LSCs compared to freshly isolated c-kit+ cells (Figure 4.3B and 4.3D). Therefore, 
downregulation of Gata2 is maintained during the in vivo development of LSCs.  
 
 
 
Figure 4.3. Gata2 is downregulated in pre-LSCs and LSCs from Meis1a/Hoxa9 and Mll-af9 retroviral AML
mousemodels. RNAwas extr acted andGata2 expressi on assessed by qRT-PCR at the Pre-LSC and LSC stage
of the leukaemogenic model. (A) Meis1a/Hoxa9 Pre-LSCs (n = 3-5). (B) Meis1a/Hoxa9 LSCs ( n = 3 for control and
n = 11 for LSCs). (C) Mll-af9 Pre-LSCs (n = 4-5). (D) Mll-af9 LSCs (n=3-5). Data are mean ± SEM. Statistical
analysis: Mann-Whitney test.
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4.3.2. In vitro deletion of Gata2 reduces the clonogenic capacity of Pre-
LSCs in the Meis1a/Hoxa9 and Mll-af9 models. 
 
While observing a downregulation of Gata2 expression in pre-LSC and LSC from Mll-
af9 and Meis1a/Hoxa9 models (Figure 4.2A and 4.2C), previous research has shown 
that despite a low threshold of Gata2 expression (see section 2.3.1) and activity in 
GMP (which is 10-fold reduced compared to HSCs), Gata2 is still essential for GMP 
function when expression if reduced by half (Rodrigues et al. 2008).  Thus, we elected 
to test the requirement for Gata2 in the clonogenic growth of pre-LSCs in vitro. We 
transduced Gata2fl/fl HPSCs with Meis1a/Hoxa9 or Mll-af9 retroviruses, serially 
replated for three rounds of CFC, and transduced pre-LSC with lentiviruses expressing 
Cre (Figure 4.4A). Full deletion of the Gata2 allele was confirmed (Figure 4.4B) and 
Meis1a/Hoxa9 pre-LSCs expressing Cre formed less colonies (2-to-3 fold) compared 
to empty vector transduced Meis1a/Hoxa9 pre-LSCs (Figure 4.4D). In addition, it was 
found that Mll-af9 pre-LSCs expressing Cre formed less colonies (Figure 4.4D). 
Therefore, Gata2 appears to be required for the clonogenic capacity of pre-LSCs in 
both AML models, however we would need to validate this result by using Gata2+/+ 
Meis1a/Hoxa9 transformed cells infected with Cre compared to empty vector control 
to gauge the potential Cre toxicity in colony formation of pre-LSCs. 
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4.3.3. Acute deletion of Gata2 in vivo does not impact LSC development 
and maintenance in the Mll-af9 retroviral AML mouse model. 
 
Given the requirement for Gata2 in pre-LSC growth in vitro, we sought to assess the 
requirement for Gata2 in LSC development and maintenance in Mll-af9 driven AML in 
vivo. We demonstrated that deletion of Gata2 using the Mx1-Cre promoter leads to 
the rapid loss of HSPCs (see Chapter 3); this therefore precludes use of the system 
to study the role of Gata2 in leukaemia initiation and establishment of pre-LSCs. As a 
method to circumvent this issue, we transduced HSPCs from Gata2fl/fl;Mx1-Cre or 
control mice with Mll-af9 retroviruses. After three rounds of CFC we harvested Mll-af9 
pre-LSC and transplanted them into primary recipients (Figure 4.5A). We monitored 
leukaemia development by periodical bleedings and induced Gata2 deletion with pIpC 
before the percentage of leukaemic cells in the PB reached 20-25%, a threshold for 
the diagnosis of AML (Figure 4.5B). After pIpC induction we found that the levels of 
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leukaemic cells in the PB remained similar between Gata2 excised (Gata2Δ/Δ) or 
control pre-LSC transplanted mice (Figure 4.5C). In agreement with this, recipients of 
Gata2Δ/Δ pre-LSC succumbed to AML with similar latency to transplant recipients 
receiving control pre-LSCs (Figure 4.5F). Next, to study the requirement of Gata2 in 
LSC propagation in the Mll-af9 model, we isolated LSCs from Gata2Δ/Δ or control mice 
and transplanted them into secondary recipients (Figure 4.5A). We observed no 
differences in the survival of recipients transplanted with Gata2Δ/Δ LSC compared to 
recipients transplanted with control LSC (Figure 4.5G). Analysis of BM from moribund 
mice with AML revealed that not all recipients transplanted with Gata2fl/fl;Mx1-Cre pre-
LSC/LSCs and induced with pIpC achieved full deletion of the Gata2 allele (40% for 
primary transplant, and 33% for secondary transplant)	(Figure 4.5D and 4.5E). Despite 
the caveats arising from incomplete deletion of the Gata2 allele, it appears that Gata2 
is dispensable for LSC generation and maintenance in the Mll-af9-driven AML mouse 
model. 
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4.3.4. Acute deletion of Gata2 delays LSC development and maintenance 
in the Meis1a/Hoxa9 retroviral AML mouse model.  
 
Next, we sought to investigate the in vivo role of Gata2 in a retroviral AML model driven 
by co-expression of Meis1a and Hoxa9 (Kroon et al. 1998). Following the same 
methodology as the Mll-af9 model (Figure 4.5A) we initiated and transplanted into 
primary recipients pre-LSCs from Gata2fl/fl;Mx1-Cre or control mice (Figure 4.6A). 
Surprisingly, we found that upon Gata2 deletion leukaemia cells in the PB of recipients 
of Gata2 Δ/Δ pre-LSCs were dramatically reduced at week 4 and 6 after pIpC treatment 
(Figure 4.6C and Figure 4.7). Consistent with this, recipients of Gata2Δ/Δ pre-LSCs 
succumbed to AML with a significant delay (Figure 4.6F). Immunophenotypic analysis 
of primary recipients transplanted with Gata2Δ/Δ pre-LSCs that succumbed to AML 
showed no differences in the frequency of bulk leukaemia cells or the frequency of 
LSCs in the BM when compared to primary recipients transplanted with control pre-
LSC (Figure 4.6G and Figure 4.6H).  
 
To test whether Gata2 deletion compromises LSC propagation in the Meis1a/Hoxa9 
model, we transplanted LSCs from Gata2Δ/Δ or control mice and transplanted them 
into secondary recipients (Figure 4.6A). Interestingly, recipients of Gata2Δ/Δ LSCs 
developed AML slower than recipients of control LSCs (Figure 4.6I). 
Immunophenotypic analysis of secondary recipients with AML revealed no differences 
in either the frequency of the bulk of leukaemia cells or LSCs (Figure 4.6J and Figure 
4.6K). As observed in the Mll-af9 model, full Gata2 deletion was not achieved in all 
primary and secondary recipients transplanted with Gata2fl/fl;Mx1-Cre pre-LSC (22% 
primary recipients; 40% secondary recipients) (Figure 4.6D and Figure 4.6E). To 
corroborate the requirement for Gata2 in Meis1a/Hoxa9 LSCs by an independent 
method, we transplanted Gata2fl/fl Meis1a/Hoxa9 pre-LSCs into primary recipients. 
Gata2fl/fl LSCs from primary recipients were transduced with lentiviruses expressing 
Cre and plated into CFC (Figure 4.4A). Full deletion of the Gata2 allele was confirmed 
(Figure 4.4B) and a reduction in the colony forming capacity of Meis1a/Hoxa9 LSCs 
expressing Cre was observed (Figure 4.4E). Collectively, these data demonstrate the 
requirement for Gata2 in LSC development and maintenance in the Meis1a/Hoxa9-
driven AML mouse model.  
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Figure 4.7. Leukaemia monitoring of Meis1a/Hoxa9 primary recipients. FACS plots showing
frequency of leukaemia cells in the PB of Meis1a/Hoxa9 primary recipi ents injec ted with control (black)
or Gata2 deleted pre-LSCs (n = 3).
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4.3.5. Pharmacological inhibition of Gata2 in vitro impacts the survival of 
the c-kit+ population in Meis1a/Hoxa9 and Mll-af9 Pre-LSCs.  
 
Our results suggest that pharmacological targeting of Gata2 may be effective in 
curtailing pre-LSC growth. Thus, we tested the efficacy of a validated small molecule 
inhibitor of Gata2, K-7174, to target Meis1a/Hoxa9 pre-LSCs (Majik et al. 2012). K-
7174 was first screened in a compound library by Kowa Co. Ltd for the search of 
adhesion inhibitory compounds (Umetani et al. 2000). It was found that K-7174 
reduced specifically VCAM1 mRNA and protein expression in HUVEC and U937 cells 
(Umetani et al. 2000). An electrophoretic mobility shift assay (EMSA) for all the known 
and potential binding sites to the VCAM1 promoter discarded any effects of K-7174 to 
the binding of Octamer binding site, AP1, SP1, ets1, IRF1, or NFkB sites in the VCAM1 
promoter. However, the GATA binding to the VCAM1 decrease in a dose-dependent 
manner after addition of K-7174. To corroborate the specificity of K-7174 to block 
GATA DNA binding, it was also found that K-7174 reduced GATA binding in the 
promoter of the Preproendothelin1, a well-known target of GATA2 in endothelial cells 
(Umetani et al. 2000). In addition, western blot analysis of human prostate cancer cell 
lines treated with K-7174 showed decreased protein levels, suggesting that K-7174 
binding to GATA2 can induce protein degradation (He et al. 2014), however the exact 
mechanism by which K-7174 binds GATA2 has not been described. Nevertheless, K-
7174 has been also reported to bind to subunits of the proteasome in a similar way 
than Bortezomib (Kikuchi et al. 2013), and to induce cell death in multiple myeloma 
cell lines (Kikuchi et al. 2013). Bearing in mind that proteasome inhibitors are also able 
to target AML cells, it cannot be discarded that the impact of K-7174 on our AML cell 
lines is exclusively and/or solely mediated by GATA2 inhibition.  
 
First, we plated Meis1a/Hoxa9 pre-LSCs in methylcellulose containing different 
concentrations of K-7174 or DMSO control (Figure 4.8A). We observed a reduction 
in the number of compact colonies (Figure 4.8B), which are considered to contain the 
more immature blast-like cells while the number of diffuse colonies, which contain the 
more differentiated cells (So and Cleary 2002), remained unchanged (Figure 4.8B). 
Consequently, we observed a decrease in the frequency of the c-kit+ population from 
CFCs treated with K-7174 (Figure 4.8C).  
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To confirm the effect of K-7174 in the c-kit+ population independently, we generated 
Meis1a/Hoxa9 pre-LSCs cell lines in liquid culture as previously reported (Vukovic et 
al. 2015). We then treated 100,000 pre-LSCs with K-7174 or DMSO control for 48 
hours (Figure 4.8A) and found a dose-dependent decrease in the number of live cells 
at 24 and 48-hour time points (Figure 4.8D). The proliferation defect observed in K-
7174 treated Meis1a/Hoxa9 was associated with a slight decrease in the frequency of 
cells in S and G2/M phases of the cell cycle, although not statistically significant 
(Figure 4.8E). However, we noticed an increased frequency of treated Meis1a/Hoxa9 
pre-LSC in the subG0 phase, which corresponded to apoptotic or dead cells (Figure 
4.8E) (Pucci et al. 2000). In agreement with this, we detected a dose-dependent 
increase in the number of late apoptotic cells from K-7174 treated Meis1a/Hoxa9 pre-
LSCs (Figure 4.8F and Figure 4.8G). When the frequency of apoptotic cells within 
the c-kit+ and c-kit- population was examined, it was found that K-7174 specifically 
targeted the c-kit+ rather than the c-kit- population in Meis1a/Hoxa9 pre-LSCs (Figure 
4.8H and Figure 4.8I). In fact, we observed that K-7174 treated Meis1a/Hoxa9 pre-
LSCs had an increased MFI and frequency of c-kit+ within the late apoptotic phase 
(Figure 4.8J and Figure 4.8K). To discard any off-target effect due to antibody bound 
to dead cells, we also observed that the MFI and frequency of c-kit+ was decreased in 
the live cell population of K-7174 treated Meis1a/Hoxa9 pre-LSC (Figure 4.8L and 
Figure 4.8M). Taken together, we infer that pharmacological inhibition of Gata2 
specifically targets c-kit+ cells that hold leukaemia initiating potential in Meis1a/Hoxa9 
pre-LSCs.  
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Similarly, Mll-af9 pre-LSCs cell lines were generated to test the efficacy of K-7174 
(Figure 4.9A). 48-hour time point assays were performed as described for 
Meis1a/Hoxa9 pre-LSCs and very similar results were observed. K-7174 treatment 
decreased the S and G2/M phases coupled with an increase of the sub G0 cell cycle 
phase (Figure 4.9B), reduced proliferation (Figure 4.9C), and increased apoptosis, 
especially within the c-kit+ population (Figure 4.9D-F). In addition, K-7174 increased 
the MFI and frequency of c-kit+ cells in apoptosis phase, coupled with a decrease 
within live cells confirming that the specific targeting for c-kit+ cells is not due non-
specific binding of antibody to dead cells (Figure 4.9G-J). Together, these findings 
suggest that Gata2 is required for protecting the leukaemia initiating population in Mll-
af9 pre-LSCs.  
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cells (n = 3 biological replicates). At least two independent experiments were performed for all analysis. Data are mean ±
SEM. Statistical analysis: Mann-Whitney test.
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4.3.6. VP16 and Ara-C synergise with K-7174 to eradicate Meis1a/Hoxa9 
and Mll-af9 pre-LSCs in vitro. 
To test the cooperation between K-7174 and standard chemotherapeutic drugs, such 
as VP16 and Ara-C (Kudo et al. 2007; Reese and Schiller 2013), we incubated 
Meis1a/Hoxa9 pre-LSCs with K-7174 alone or in combination with VP16 or Ara-C in a 
48-hour assay (Figure 4.10A). As expected, the proliferation capacity of 
Meis1a/Hoxa9 pre-LSCs (Figure 4.10B) with treatment of K-7174, VP16 or Ara-C 
alone was reduced. Interestingly, when K-7174 was combined with VP16 or Ara-C, 
proliferation of Meis1a/Hoxa9 pre-LSCs was further reduced (Figure 4.10B). When 
we examined the apoptotic status of these pre-LSCs, we observed that while K-7174 
specifically targets the c-kit+ population, VP16 and, to a lesser extent Ara-C, induced 
apoptosis in both c-kit+ and c-kit- populations (Figure 4.10C-E). Combination of K-
7174 with either VP16 or Ara-C considerably increased the frequency of apoptotic 
cells, with almost a two-fold increase compared to single treatments with K-7174, 
VP16 or Ara-C (Figure 4.10C). Of note, while K-7174 had no impact in the c-kit- 
population, addition of K-7174 to VP16 or Ara-C boosted their killing potency 
independently of c-kit expression in Meis1a/Hoxa9 pre-LSCs, suggesting a synergistic 
mode of action between chemotherapeutics and K-7174 (Figure 4.10C-E). 
Concurrently, the MFI and frequency of c-kit+ cells were increased within the late 
apoptotic phase, and consequently, diminished within the live cells after K-7174 
treatment alone or in combination with VP16 or Ara-C in comparison to either the 
DMSO control, VP16 or Ara-C single treatments (Figure 4.10F-I). Importantly, 
treatment with VP16 or Ara-C alone did not affect the MFI or frequency of c-kit+ within 
live cells, highlighting the non-specific killing effects of standard chemotherapeutics 
(Figure 4.10H and Figure 4.10I).  
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We also applied this combination of treatments to Mll-af9 pre-LSCs (Figure 4.11A). 
Overall, we observed the same trend as with Meis1a/Hoxa9 pre-LSCs, consisting of 
cooperative effects between K-7174 and chemotherapeutics VP16 or Ara-C in the 
reduction of proliferation (Figure 4.11B), induction of apoptosis in the c-kit+ (Figure 
4.11C and Figure 4.11D), and decrease of the MFI and frequency of c-kit+ within live 
cells (Figure 4.11H and Figure 4.11I). We also observed a moderate trend in the 
increase of MFI and c-kit+ expression in late apoptotic cells (Figure 4.11F and Figure 
4.11G), and most importantly, K-7174 appeared not to potentiate the killing activity of 
VP16 and Ara-C within the c-kit- population of Mll-af9 pre-LSCs (Figure 4.11E). 
Collectively, these data indicate that pharmacological inhibition of Gata2 potentiates 
the activity of standard chemotherapeutics against Meis1a/Hoxa9 and Mll-af9 pre-
LSCs.  
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4.3.7. Pharmacological inhibition of Gata2 impacts the survival of the c-
kit+ population in Meis1a/Hoxa9 LSCs in vitro.  
 
In order to investigate whether the K-7174 is able to directly target LSCs, we sorted 
Meis1a/Hoxa9 LSCs (CD45.2+ C-kit+ CD34low CD16/32+) from primary recipients into 
methylcellulose treated with K-7174 (Figure 4.12A). At day 6 of the CFC assay, we 
found a significant reduction in the number of compact colonies, while diffuse colonies 
remain unchanged (Figure 4.12B). In addition, the frequency of c-kit+ LSCs from 
colonies treated with K-7174 was reduced compared to DMSO control treated colonies 
(Figure 4.12C). Finally, we treated Meis1a/Hoxa9 LSCs with K-7174 alone, or in 
combination with VP16 or Ara-C (Figure 4.12A). As seen with Meis1a/Hoxa9 pre-
LSCs, treated LSC displayed a dose dependent reduction in proliferation (Figure 
4.12D), and a further reduction when K-7174 was combined with VP16 or Ara-C 
compared to single treatments of K-7174, VP16, or Ara-C (Figure 4.12E and Figure 
4.12F). From this single experiment, it appears that K-7174 treatment on its own or in 
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combination with standard chemotherapeutics could be a feasible therapeutic strategy 
to target Meis1a/Hoxa9 LSCs.  
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4.4.  Discussion  
 
In this chapter, we explored the requirement for Gata2 in pre-LSCs and LSCs from 
two different genetic mouse models of AML. To achieve this, we used different 
approaches to delete or knockdown Gata2, including in vivo and in vitro genetic 
deletion via the Cre-lox system, and pharmacological inhibition employing a small 
molecule inhibitor, K7174. Overall, our findings highlight that despite being expressed 
at relatively low threshold levels, Gata2 plays a major role in pre-LSCs and LSCs 
driven by Meis1a/Hoxa9.   
 
An increase of Gata2 expression in a pre-leukaemia population from a transgenic Mll-
af9KI mouse was observed, in disagreement with our retroviral Mll-af9 mouse model. 
These differences across models with the same genetic background could be 
explained by several factors, including cell culture conditions versus BM 
microenvironment, and oncogenic dose. In the Mll-af9KI mouse model, the pre-
leukaemia LSK cells are surrounded by a pre-malignant BM niche, which can secrete 
cytokines, growth factors or cell-to-cell interact with pre-LSCs and thus modulate its 
properties. In contrast, in the retroviral model, Mll-af9 transduced cells are maintained 
in semisolid medium containing the required but not exhaustive combination of Scf, 
IL-3, IL-6, and GM-CSF cytokines. Discrepancies between the impact of the oncogenic 
dose of Mll-af9 between the knock-in and the retroviral mouse models in relation to 
the cell of origin and differential expression of downstream effectors of Mll-af9 
pathogenesis, such Evi1, have been already interrogated (W. Chen et al. 2008). In the 
retroviral model, the copies of Mll-af9 integrated into the genome of the cells can be 
higher than one and are regulated by a strong MSCV promoter, while the knock-in 
mouse closely recapitulates the human scenario by expressing the Mll-af9 
translocation under control of the endogenous Mll promoter.  
 
There has been substantial controversy regarding the role of Gata2 at the different 
stages of AML. For instance, sporadic or hereditary MDS/AML patients with GATA2 
haploinsufficiency indicates that downregulation of Gata2 is required for leukaemia 
initiation (Hahn et al. 2011). In addition, Bonadies et al. reported downregulation of 
Gata2 in retroviral mouse models driven by the expression of Mll-enl or Moz-tif2 
translocations (Bonadies et al. 2011). This is in line with our result showing 
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downregulation of Gata2 in pre-LSC and LSCs, although we have not formerly 
quantified Gata2 protein levels or activity in this study. Bonadies et al. also described 
that upon overexpression of Gata2 in Mll-enl pre-LSCs, there is a lack of CFC capacity 
and a proliferation defect in culture. However, this overexpression system led to a 
supraphysiological 3,000-fold induction of Gata2 (Bonadies et al. 2011). As 
exemplified in overexpression studies of Gata2 in murine and human HSPCs (Persons 
et al. 1999; Tipping et al. 2009), tight regulation of Gata2 levels is crucial for normal 
haematopoiesis and supraphysiological activity of Gata2 could therefore be shutting 
down the homeostatic machinery in leukaemia cells. In agreement with this, more 
recently it has been published that low-level overexpression of Gata2, employing an 
inducible doxycycline-based system, is able to immortalize BM cells in culture with a 
myeloid lineage bias (Nandakumar et al. 2015). A chimeric mouse from ESCs 
microinjected with the same Gata2 construct was also generated in this study and 
myeloid lineage skewing was observed in vivo, though never achieving full-blown 
leukaemia (Nandakumar et al. 2015). Therefore, disruption of Gata2 steady-state 
levels leads to perturbed haematopoiesis in both murine and human cells.  As shown 
with other TFs (Johnson 2000; Yang et al. 2007; Turner and Watson 2008), the idea 
of Gata2 being able to act as both tumour suppressor and oncogene in HSCs is not 
mutually exclusive. 
 
Studies addressing the importance of Gata2 downregulation in leukaemia 
transformation, at least in murine retroviral mouse models of AML, merit further 
investigation. Bearing in mind that Gata2 deletion using the Mx1-Cre system leads to 
rapid HSPC loss (see chapter 3.3), the use of in vitro methods to delete Gata2 in 
HSPCs, prior or during leukaemia initiation would be required. For instance, a few 
studies using the Mx1-Cre model have reported that addition of IFNa into liquid or 
semi-solid culture achieved full deletion of the floxed allele (Kerenyi et al. 2013; Kranc 
et al. 2009). Doxycycline-induced Cre, lentiviral cre, or CRISPR-Cas9-mediated 
deletion of Gata2 before/during/after leukaemia transformation with oncogenes (i.e. 
Mll-af9 or Meis1a/Hoxa9) could also be used as experimental approaches to address 
this question. Conversely, inducible systems to overexpress Gata2 before/during/after 
leukaemia transformation would help to clarify the impact and target genes of Gata2 
dose dependent leukaemia initiation. Curiously, Hoxa9 was one of the top genes 
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upregulated following low-level overexpression of Gata2 in BM cells (Nandakumar et 
al. 2015). Together with our Gata2 gene expression results in Mll-af9 and 
Meis1a/Hoxa9 models, it appears that there is a reciprocal regulation and co-operation 
of Gata2 and Hoxa9 genes in leukaemia initiation.  
 
Surprisingly, we observed a differential requirement for Gata2 in two interrelated AML 
models driven by Mll-af9 and Meis1a/Hoxa9. So how does Gata2 deletion have an 
impact in leukaemia initiation when driven by Meis1a/Hoxa9 overexpression, but not 
Mll-af9 oncogenic translocation, which is an upstream activator of Meis1a/Hoxa9? Part 
of the explanation may be the heterogeneous starting HSPC (c-kit+) population used 
for leukaemia transformation in these retroviral transduction models. In fact, several 
publications have demonstrated that the cell of origin (LSK, CMP, GMP) in the Mll-af9 
model has an impact in the leukaemia initiating capacity, gene dependence, drug-
resistance, and gene expression profiles (Krivtsov et al. 2013). In this study, we have 
no control over the cell of origin driving leukaemogenesis in the Mll-af9 model since c-
kit+ cells can initiate the leukaemia from either LSK, CMP or GMP, while, in contrast, 
Meis1a/Hoxa9 are only capable of transforming LSK cells but not CMP or GMP (Arai 
et al. 2010; Krivtsov et al. 2013). Thus, we hypothesise that the differences arising 
between the Meis1a/Hoxa9 and the Mll-af9 models may be driven by the cell of origin. 
Meis1a/Hoxa9 leukaemia arise from LSK cells, which are highly dependent on Gata2 
levels and therefore could explain why even low levels of Gata2 observed in pre-LSCs 
and LSCs are important for their functions. Bearing in mind that the step-wise 
leukaemogeneic assay used in this study favours the establishment of a dominant 
clone during the replating assays, it is interesting to speculate that Mll-af9 pre-LSCs, 
and consequently Mll-af9 LSCs, arise from a single clonal population. While Mll-af9 
LSK cells might possess a clonal advantage over CMP or GMP cells, the numbers of 
CMP and GMP transduced cells would be much higher than transduced LSK cells 
within the c-kit+ starting population, which in turn could exclude the LSK competition in 
the CFC assays. The disparity between the impact of Gata2 deletion in the Mll-af9 and 
Meis1a/Hoxa9 models could also be explained by the additional downstream 
pathways that govern leukaemia development in the Mll-af9 model. It has been 
reported that Evi1 is a critical effector in Mll-af9 leukaemia but not Meis1a/Hoxa9 
(Bindels et al. 2012). In addition, another study found that while Mll-af9 binds and 
activates the Evi1 promoter, Meis1a/Hoxa9 has a low Evi1 expression (Arai et al. 
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2010). Evi1 is a zinc-finger TF that has been closely related to Gata2. In fact, Evi1 
knockout mice have a similar phenotype than Gata2 KO mice (Sato et al. 2008) and 
Evi1 is also able to activate the Gata2 promoter in HSCs (Goyama et al. 2008). Thus, 
Evi1 could replace and rescue the function of Gata2 in Gata2 deleted Mll-af9 pre-
LSCs/LSCs. Investigating the requirement for Gata2 in prospectively isolated subsets 
of HSPCs should shed light on the stage-specific requirements and molecular 
mechanisms operating in Gata2 driven leukaemogenesis.  
 
Coexistence of molecularly distinct clones of pre-LSCs and LSCs have been found 
before and after treatment in AML patients (Goardon et al. 2011; Dick 2005). 
Generally, the LSCs in the retroviral model employed are defined by c-kit+ expression 
(Somervaille and Cleary 2006; Vukovic et al. 2015), or the putative L-GMP including 
CD16/32+ and CD34low markers (Krivtsov et al. 2006). As seen in this and other 
studies, all or most of the leukaemia population within the c-kit+ LSC population 
express the CD16/32+ and CD34low markers, although variation in gating strategies of 
c-kit+ and CD34low is present in the field. Single-cell omics advances in the past years 
has shed light towards the identification of (epi)genetic heterogeneity within the 
established haematopoietic hierarchy, and challenged the conventional markers used 
to isolate HSPCs by flow cytometry (Ema et al. 2014; Guo et al. 2013; Corces et al. 
2016). In addition, this approach has been also applied to leukaemia studies (Jung et 
al. 2015; Thomas and Majeti 2017). Specifically, a study employing single-cell analysis 
has identified heterogeneity within the L-GMP LSC population in the Mll-af9 retroviral 
mouse model (Guo et al. 2013). For instance, the authors described that CD24- L-
GMP LSCs induced AML in vivo faster than CD24+ L-GMP LSCs. It could be 
hypothesised that in the Meis1a/Hoxa9 model, Gata2-dependent and Gata2-
independent L-GMP LSCs exist. Therefore, deletion of Gata2 reduces the proportion 
of leukaemia cells in the PB by killing the Gata2-dependent LSCs, but eventually 
relapse of AML is driven by Gata2-independent LSCs. Our gene expression analysis 
within the “bulk” pre-LSC/LSC could be hiding the true expression of Gata2 in specific 
subsets of Meis1a/Hoxa9 pre-LSCs/LSCs with greater leukaemia initiating activity. It 
would be worth investigating whether Gata2 defines a “true” pre-LSC/LSC subset 
within the Meis1a/Hoxa9 mouse model. For instance, a Gata2-Venus reporter mouse 
model was recently engineered to study the activity of Gata2 in HSC development 
(Kaimakis et al. 2016). Therefore, transformation of the Gata2-Venus reporter mice 
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with Meis1a/Hoxa9 oncogenes would facilitate the tracking and molecular 
characterisation of Gata2-Venus+ leukaemia cells, if any, within the established 
Meis1a/Hoxa9 pre-LSC/LSC populations. 
 
In both AML models, we obtained complete and incomplete deletion of Gata2 
employing the Mx1-Cre system in recipients transplanted with pre-LSCs. However, we 
found that recipients of Meis1a/Hoxa9 pre-LSCs succumbed to AML slower than 
control pre-LSCs, regardless of the efficiency of Gata2 deletion. In the Mx1-Cre 
system, incomplete deletion due to strong selective pressure has already been 
reported in Tel1 in normal HSCs or Jmjd1c in Mll-af9 cells (Zhu et al. 2015). In the 
leukaemia setting, the authors found complete Jmjd1c deletion 14 days after pIpC in 
the PB of leukaemic mice, while moribund mice presented incomplete Jmjd1c deletion 
in the BM. The authors found a delay in AML development, as per our case, however 
they did not mention complete deletion in any of the mice that succumbed of AML, nor 
did they report any mice that survived had complete Jmjd1c deletion (Zhu et al. 2015). 
In our experiments, we found complete Gata2 deletion in mice that succumb to AML, 
indicating that the selective pressure phenomenon cannot be applied in our data. 
Instead, PB analysis showed a massive drop in the frequency of leukaemia cells, 
initially in leukaemic mice upon acute deletion of Gata2 in Meis1a/Hoxa9 pre-LSCs, 
suggesting that Gata2 protects Meis1a/Hoxa9 pre-LSCs from cell death. As alluded to 
above, the fact that even recipients with complete Gata2 deletion succumb to AML 
indicates that a sub-population of Meis1a/Hoxa9 pre-LSCs are Gata2 independent. 
Alternatively, since we have not assessed the impact of in vivo acute deletion of Gata2 
in established LSCs (i.e. in secondary recipients) it could be hypothesised that LSCs 
are already present by the time of pIpC-mediated deletion, and that consequently 
Meis1a/Hoxa9 LSCs, but not pre-LSCs, are resistant to acute Gata2 deletion. In 
support of this, we detected a dramatic reduction in the clonogenic capacity of 
Meis1a/Hoxa9 pre-LSCs after Gata2-mediated deletion with lentiviruses expressing 
Cre. This would further support the idea of the presence of Gata2-resistant LSCs at 
the time of deletion. Further experiments are needed to validate the in vitro results with 
lentiviral Cre to assess the leukaemia initiating capacity of ex-vivo deleted pre-LSCs 
and LSCs in both AML models.  
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Finally, we tested the impact of pharmacological inhibition of Gata2 with a small 
molecule inhibitor, K-7174, against Meis1a/Hoxa9 and Mll-af9 pre-LSC. K-7174 
inhibition of Gata2 has been shown in several publications and in Chapter 5 (Imagawa 
et al. 2003; Majik et al. 2012). Nevertheless, we should formally test the inhibition of 
Gata2 in our mouse models. K-7174 reduced the proliferation and induced apoptosis 
in Meis1a/Hoxa9 and Mll-af9 pre-LSC cell lines, specifically in the c-kit+ population. 
Induction of apoptosis by K-7174 treatment could be related to apoptotic genes 
affecting both Gata2 and these mouse models of AML. For instance, downregulation 
of the anti-apoptotic gene Bcl-xL was seen in constitutive Gata2 haploinsuficient mice 
(Rodrigues et al. 2005). In addition, data in Chapter 5 showed that knockdown of 
GATA2 increases apoptosis and P21 expression in THP1 cells harbouring a MLL-AF9 
translocation (see Figure 5.). There is evidence in the literature linking downregulation 
of Bcl-xL and induction of p21 with apoptosis in retroviral mouse models, driven by 
Mll-af9 and Meis1a/Hoxa9 expression (Wu and O’Reilly 2011; Mizukawa et al. 2011). 
Decrease of c-kit expression upon K-7174 treatment can be explained by the fact that 
Gata2 is a well-known transcriptional activator of the c-kit promoter in haematopoietic 
cells (Maeda et al. 2010). Specific targeting of the leukaemia initiating population (c-
kit+) allowed for the synergism between K-7174 and standard chemotherapeutics such 
as Ara-C and VP16, that targeted both the c-kit+ and c-kit- pre-LSCs populations. 
Synergism between these two and other chemotherapeutics used in AML should be 
validated with different concentrations of each agent. Furthermore, in vivo studies 
should be conducted to explore the ability of K-7174, alone or in combination 
chemotherapeutics, to eradicate Meis1a/Hoxa9 and Mll-af9 pre-LSCs/LSCs. In 
addition, direct targeting of GATA2 with regards to HSPC toxicity should be evaluated. 
In section 3.3. we have shown that K-7174 induces apoptosis of murine HSPCs in 
vitro. However, to date, the effects of GATA2 KD or KO in human HSCs have not been 
reported. Future studies should address the toxicity of K-7174 (or GATA2 KD) in 
human HSCs, and in comparison, to the targeting efficiency of AML cells.    
 
To conclude, we have shown that pharmacological inhibition of Gata2 is effective 
against the leukaemia initiating population within Meis1a/Hoxa9 and Mll-af9 pre-LSCs 
in vitro. The caveats resulting from off-target effects of the small molecule inhibitor K-
7174 on other Gata family genes and the proteasome will be thoroughly discussed in 
the human AML chapter (see section 5.4). These caveats aside, our data indicate 
 131 
that K-7174 (or other means of GATA-2 targeting) hold potential as a therapeutic to 
treat Mll-af9 or Meis1a/Hoxa9 driven AML, either alone or as an adjunct to current 
standard AML chemotherapy.  
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Chapter 5 
 
Investigating the function of GATA2 overexpression in human AML  
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5.1.  Introduction  
 
GATA2 is a key transcriptional regulator of haematopoietic stem and progenitor cells 
(HSPCs). Strict regulation of GATA2 level is crucial for HSC homeostasis. Gata2+/- 
mice display lower numbers and qualitative defects of FL HSCs in transplantation 
experiments (Ling et al. 2004). Similarly, BM HSC from Gata2+/- mice are also 
diminished, perform poorly in transplantation assays (Rodrigues et al. 2005) and after 
5-FU myeloablative treatment (Ling et al. 2004) indicating a proliferation defect of 
Gata2+/- BM HSCs. In fact, dysregulation of GATA2 levels in HSCs leads to the 
development of BM failure.  A case in point is the decrease in GATA2 levels observed 
in BM CD34+ cells (Fujimaki et al. 2001) and BM MSCs (Xu et al. 2009b) from aplastic 
anaemia patients, a condition that presents with BM aplasia and fat replacement in 
the BM (Brodsky and Jones 2005). Furthermore, GATA2 loss of function mutations 
have been linked to immunodeficiency of DC, B, NK cells, MonoMac and Emberger 
syndrome, that can develop into MDS and AML (Hyde and Liu 2011). Over 100 
different types of mutations have been described in the ZF domains (ZF1 and ZF2) 
and untranslated regions of the GATA2 gene. Conversely, overexpression of Gata2 in 
murine or human HSCs inhibit differentiation and induce quiescence both in vitro and 
in vivo (Persons et al. 1999; Tipping et al. 2009). More recently, a study reported that 
low-level overexpression of Gata2 in murine BM cells leads to BM immortalisation in 
vitro, characterised with an increase of myeloid markers and block in lymphoid 
differentiation. In vivo experiments confirm myeloid lineage skewing after low-level 
overexpression of Gata2; however, these mice remain asymptomatic without 
progression to AML (Nandakumar et al. 2015). 
 
Over the last 5 years, several publications have pinpointed an oncogenic role for 
GATA2 in cancer. GATA2 overexpression has been associated with poor prognosis 
and aggressiveness in several cancer types including: prostate, lung, breast, and 
colorectal cancer. GATA2 overexpression was found in human breast carcinoma, and 
PTEN was inhibited directly by GATA2-promoter binding or indirectly by blocking 
androgen receptor (AR)-dependent PTEN activation (Wang et al. 2012). In non-small 
cell lung cancer (NSCLC), GATA2 expression was found in association with the poor 
prognosis KRAS mutation (Anon 2012), and GATA2 inhibition was able to reduce 
tumours size in Kras-driven NSCLC murine model (Kumar et al. 2012). GATA2 
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overexpression has also been reported with chemotherapy resistance and 
aggressiveness in prostate cancer, whilst RNAi of GATA2 reduced prostate tumours 
in vivo. The IGFR-1-AKT/ERK/JNK signalling pathways activate GATA2, which in turn 
activates the transcription of IGF2 that binds to IGFR-1, thereby configuring a positive 
feedback loop in prostate cancer cells (Vidal et al. 2015).  
 
Of relevance to haematological cancer, overexpression of GATA2 has been found in 
40% of adult AML patients (Vicente et al. 2012) correlating with cytogenetic grouping 
and overexpression of EVI and WT1, both of which confer poor prognosis (Vicente et 
al. 2012). Shorter overall survival (OS) and event-free survival (EFS) have been shown 
to correlate with higher GATA2 expression (Vicente et al. 2012). In addition, 
overexpression of GATA2 has also been documented in 60-to-85% of paediatric AML 
patients (M Luesink et al. 2012). Interestingly, GATA2 expression was normalised in 
patients in complete remission, while remaining elevated in those with resistant 
disease (M Luesink et al. 2012). Therefore, GATA2 expression could help stratify AML 
patients and operate as an independent poor prognosis marker for AML however, the 
biological impact of GATA2 overexpression on AML cell fate is currently poorly 
defined. 
 
5.2.  Aims and objectives  
 
The specific aims and objectives for this chapter were:  
 
1. To confirm that GATA2 is overexpressed in human AML by combining and 
analysing large gene expression datasets published previously.  
 
2. To investigate the role of GATA2 in human AML (M5) THP-1 cells harbouring 
MLL-AF9 translocation employing shRNA-mediated knockdown.   
 
3. To assess the impact of K-7174, a validated small molecule inhibitor of 
GATA2, in human AML cells.  
 
4. To study the synergism between K-7174 and standard chemotherapeutic 
drugs used in AML.  
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5.3.  Results 
 
5.3.1. GATA2 is overexpressed in human AML 
 
In order to validate previous studies showing the overexpression of GATA2 in AML 
patients, we sought to analyse a combination of 13 published AML databases. Briefly, 
AML (n = 2611) and control (n = 77) patient datasets were downloaded from the GEO 
to create a case/control cohort hybridised to the same array (Affymetrix Human 
Genome U133 Plus 2.0 GeneChip) and run through R using bioconductor packages. 
Data was normalised using RMA. We found that GATA2 levels were higher in AML 
patients compared to healthy controls (BM MNCs) (Figure 5.1A). Specifically, GATA2 
was overexpressed in 511 out of 2061 (25%) AML patients based on Log2FC cut-off 
(Figure 5.1B). Higher expression of GATA2 was observed across different mutations, 
FAB-subtypes, and Karyotypes (Figure 5.1C-E). Higher overexpression was 
observed in FAB-M2, M3 and M6 subtypes while M5 subtype had a similar GATA2 
expression than healthy controls (Figure 5.1D). Thus, these results indicate GATA2 
overexpression across multiple subtypes of AML.  
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Figure 5.1. GATA2 expression in AML. a) GATA2 expr ession between contr ol and AML samples . b) GATA2
expression in AML sampl es. Orange line marks GATA2 overexpressi ng samples (25%) based on Log2FC. c) GATA2
expression among the most common mutations i n AML d) GATA2 expressi on in FAB subtypes of AML. e) GATA2
expression among cytogenetics groups in AML. Bioinformatics analysis performed by Mr. Alex Gibbs (Cardiff
University).
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D
E
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* **
*
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A
Figure 5.2. GATA2 is (over)expressed in
AML patient. a) Western blot image of total
BM MNCs detecting GATA2 protein levels in
AML patients. (* indicates AML sampl es
(over)expressing GATA2). Western blot
performed by Dr. Rhys Morgan (Bristol
University).
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To corroborate this data, GATA2 levels in several human leukaemia cell lines were 
assessed. Compared to human BM MNCs, GATA2 RNA was increased by 30-fold in 
the K562 cells and 20-fold in KG1 cells (Figure 5.3A). In addition, we also assessed 
two monocytic cell lines harbouring a MLL-AF9 translocation; THP1 cells showed a 4-
fold increase in GATA2, while NOMO1 cells had similar GATA2 RNA levels compared 
to control BM MNCs (Figure 5.3A). Intracellular FACS was performed to measure the 
GATA2 protein levels in these cell lines which correlated with the RNA expression 
profile seen in NOMO1, THP1 and KG1 cells (Figure 5.3B and Figure 5.3C). We also 
detected GATA2 (over)expression in 11 out of 26 samples (42%) in primary AML 
patient samples (Figure 5.2).  
 
 
 
 
 
 
 
Figure 5.3. GATA2 expression in human
leukaemia cell lines. (A) RNA from
NOMO1, THP1, KG1a and K562 w as
extracted and GAT A2 levels assessed by
qPCR. Human BM MNCs were used as a
control. GAPDH was used as a
housekeeping gene. N = 2-5 from 2
independent experiments. (B) Intracellular
FACS histogram showing GATA2 protei n
expression in KG1, THP1, and NOMO1
compared to Jurkat cells (negative control)
(C) MFI of GATA2 from B (n = 2). Data are
mean ± SEM.
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5.3.2. GATA2 knockdown impairs the proliferation and clonogenic 
capacity of THP1 AML cells. 
 
To investigate the biological impact of GATA2 in human AML cell fate, we used a 
bicistronic lentiviral vector system carrying shRNA against human GATA2 and GFP 
reporter (See methods, Figure 2.1 and Table 2.2) to attenuate GATA2 expression. 
We validated the efficiency of GATA-2 knockdown of four constructs targeting GATA2 
(named 31, 32, 33 and 34). Knockdown efficiency of shRNA 31, 32 and 34 was 
between 50-60% compared to scramble control at the RNA level in K562 and THP1 
cells (Figure 5.4A and Figure 5.4B). Western blot of THP1 cells revealed no GATA2 
protein levels in shRNA 31 and 32, although decreased B-ACTIN loading was 
observed, especially in shRNA 32, compared to scramble control (Figure 5.4C). 
shRNA 34 showed a very faint GATA2 protein band, however B-ACTIN loading was 
comparable to the control (Figure 5.4C). For further experimentation, we used shRNA 
number 31 and 34. To corroborate the knockdown efficiency at protein level, we also 
validated the decrease of GATA2 protein levels in THP1 cells transduced with shRNA 
31 and 34 (Figure 5.4D).    
 
 
THP1 cells
SC				sh31			sh32			sh33			 sh34	
GATA2 
B-ACTIN
A B
C D
Figure 5.4. Knockdown validation of human short hairpin against GATA2. Hum an cell lines w ere
transduced with lentiviruses encoding a short hairpin agains t human GATA2 (or scrambl e control) and
a GFP reporter. GFP+ cells were FAC-sorted and GATA2 knockdown was measured by qPCR in (A)
K562, (B) THP1 (n = 3), western blot i n (C) THP1 cells, and intracellular FAC S (D) for 2 clones in
THP1 (n = 1). GAPDH w as used as a housekeepi ng gene i n the qPCR. Western blot performed by
Ms. Maria Konstantinou (Cardiff University).
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In order to study the role of GATA2 in the context of overexpression in MLL-AF9 driven 
AML, we transduced THP1 cells with shRNA 31, 34 or scramble control vector. 5 days 
later, transduced GFP+ cells were sorted and plated in a 72-hour assay (Figure 5.5A). 
Proliferation of GATA2 KD THP1 cells was severely compromised compared to control 
THP1 cells, showing a 3-to-4-fold reduction in the number of live cells at 48 and 72-
hour time points (Figure 5.5B). When the cell cycle status of GATA2 KD THP1 cells 
was analysed at 72-hour time point, there was a decrease in the frequency of 
proliferating cells (S+G2/M) compared to control THP1 cells (Figure 5.5C and Figure 
5.5D). Of interest, the cell cycle profile of GATA2 KD THP1 cells showed an increase 
in the subG0/G1 population, which is indicative of cell death (Figure 5.5C). We also 
plated transduced GFP+ cells into CFC assays, and found a 10-fold reduction in the 
clonogenic capacity of GATA2 KD THP1 cells compared with control cells (Figure 
5.5F). In addition, colonies at day 12 from GATA2 KD THP1 cells were smaller in size 
compared to colonies from control THP1 cells (Figure 5.5E). Collectively these data 
indicate that GATA2 is a critical growth regulator of THP1 AML cells.  
 
A
C
D
Figure 5.5. GATA2 knockdown impairs the proliferation and clonogenic capacity of THP1 cells. (A) THP1 cells
were transduced with l entiviruses encoding a short hairpin against human GATA2 and a GFP reporter. GFP+ cells
were FAC-sorted and 150,000 cells plated in a 72 hour assay. (B) Number of cells at 24,48, 72 hour time points (n =
2-7). (C) Representative FACS histogram showing the cell cycle profile. (D) frequency of proliferati ng cells (S+G2/M)
at 72 hours (n = 3-7). (E) Repr esentative CFC pictures at day 12 after plating. (F) Number of col onies at day 12 (n = 3-
7). “n” indicates the number of independent experiments . Data are mean ± SEM. Statistical analysis: Mann-Whitney
test.
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5.3.3. GATA2 knockdown in THP1 AML cells induces apoptosis and 
differentiation via CDKN1A.  
 
To further investigate the apoptotic status of GATA2 KD THP1 cells, we performed an 
annexin V assay. We found a significant increase in the number of apoptotic cells at 
72-hour time in GATA2 KD THP1 cells compared to control THP1 cells (Figure 5.6A 
and Figure 5.6B), indicating that GATA2 is crucial for the survival of THP1 cells.  
 
Since GATA2 is important to maintain the undifferentiated status of HSCs (Tipping et 
al. 2009; Persons et al. 1999), we investigated whether GATA2 overexpression was 
responsible for the differentiation block of THP1 cells: a general feature of AML. 
Indeed, upon GATA2 KD we found an increase in the expression of myeloid 
differentiation markers CD11b and CD14 (Figure 5.6C). A significant increase of 
CD14 was observed in shRNA-31 cells compared to scramble control cells, while a 
non-significant trend was observed with respect to CD11b expression (Figure 5.6D 
and Figure 5.6E). shRNA-34 cells showed an increasing trend of expression of 
differentiation markers, particularly in CD11b expression, in the two independent 
experiments performed (Figure 5.6D and Figure 5.6E).  
 
To explore the molecular mechanisms underpinning GATA-2 mediated control of 
proliferation, apoptosis and differentiation, gene expression analysis was performed 
for genes previously related to GATA2 in regard to its function in the cell-cycle and 
apoptosis. We observed a significant upregulation of P21 (CDKN1A) in shRNA-31 
THP1 cells compared to control THP1 cells (Figure 5.6F). P21 upregulation could 
explain the decrease of proliferating cells in the cell-cycle and increase of apoptosis 
upon GATA2 knockdown. In addition, it has been reported that upon DNA damage 
production, P21 upregulation induces differentiation of AML cells in the context of MLL-
AF9 leukaemia (Santos et al. 2014). Collectively, our results show that GATA2 
protects AML cells from apoptosis and possibly sustains their differentiation block, at 
least in part, via P21 expression.    
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CD14CD11b
shGATA2-34
shGATA2-31
Scramble
A
B C
Figure 5.6. GATA2 knockdown induces apoptosis and differentiation of THP1 AML cells via P21. (from
5.5A)THP1 cells were transduced with lentiviruses encoding a short hairpin against human GATA2 and a GFP
reporter. GFP+ cells were FAC-sorted and 150,000 cells pl ated for 72 hours prior to assessing their apoptotic and
differentiation status . (A) R epresentative FACS pl ots showing apoptotic status . (B) Frequency of annexin V+ cells at
72 hour time point (n = 4). (C) Representative FACS histogram showing CD11b (lef t) and CD14 (right) expressi on.
(D) Frequency of CD11b+ cells at 72 hour time poi nt (n = 6 for shGATA2-31; n = 2 for shGATA2-34). (E) Frequency
of CD14+ cells at 72 hour time point (n = 6 for shGATA2-31; n = 2 for shGATA2-34). (F) Relative mRNA expr ession
of P21, P27, P57, LIG4, P53 fr om GFP+ sorted cells. GAPDH was used as a housekeeping gene (n = 4). “n”
indicates the number of independent experiments. Data are mean ± SEM. Statistical analysis: Mann-Whitney test.
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5.3.4. Pharmacological inhibition of GATA2 induces apoptosis in AML 
cells. 
 
In order to corroborate the results obtained with lentiviral shRNA, we 
pharmacologically inhibited GATA2 by employing a GATA2-specific small molecular 
inhibitor (Majik et al. 2012), K-7174, in THP1 cells. To confirm GATA2 inhibition, we 
incubated THP1 cells with increasing concentrations of K-7174 and measured the 
GATA2 protein levels by flow cytometry (Figure 5.7B). As expected, the MFI of 
GATA2 in THP1 cells decreased upon incubation with increasing doses of K-7174, 
although we saw a plateau effect in the highest dose (Figure 5.7C). We then 
performed a 6-day assay to measure the impact of K-7174 on proliferation and 
apoptosis status in THP1 cells (Figure 5.7A). In line with our shRNA approach, we 
observed a reduction in the number of live cells and induction of apoptosis in a dose-
dependent manner in K-7174 treated THP1 cells (Figure 5.7F, Figure 5.7J, and 
Figure 5.7K). 
 
To validate that these effects were not THP1 cell-specific, we inhibited GATA2 using 
K7174 in a range of leukaemic cell lines harbouring different genetic/epigenetic 
aberrations and GATA2 levels (Figure 5.3). We further validated GATA2 inhibition in 
NOMO1 and KG1 cells (Figure 5.7D and Figure 5.7E). We were able to replicate 
these results, including the dose-dependent reduction of proliferation and induction of 
apoptosis, in NOMO1, KG1, and K562 treated cells (Figure 5.7G-I and Figure 5.7L-
N). Thus, GATA2 inhibition appears to induce apoptosis in AML cells regardless of 
their (epi) genetic background and level of GATA2 expression.  
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Figure 5.7. Pharmacological inhibition of GATA2 induces apoptosis of leukaemia cells. (A) 400,000 cells from
THP1, NOMO1, K562 or KG1, were treated with K- 7174 for 6 days. (B) FACS histogram showing intracellular GATA2
protei n levels in THP1 treated cells. (C) MFI of GATA2 in THP1 ( n = 3). (D) MFI of GATA2 i n NOMO1 (n = 2). (E) MFI of
GATA2 in KG1 (n =1). (F-to-I) Num ber of live cells at each time point in (F) THP1 cells (n = 4), (G) NOMO1 ( n = 3-4), (H)
K562 (n = 3), (I) KG1 (n =2-3). (J) Representative FACS pl ots showing apoptotic status of THP1 cells at 48 hour time
point. (K-to-N) Frequency of apoptotic cells at each time point i n (K) THP1 cells (n = 4), (L) NOMO1 (n = 3- 4), (M) K562 (n
= 3), (N) KG1 (n = 1-3). “n” i ndicates the number of independent experiments. D ata are mean ± SEM. Statistical analysis:
Mann-Whitney test.
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5.3.5. GATA2 is not required before or after DNA damage response (DDR) 
pathway activation in THP1 AML cells.  
 
DNA damage induction in AML cells has been shown to activate P21 (Viale et al. 2009; 
Santos et al. 2014). In order to investigate whether the induction of P21 and 
subsequent apoptosis and differentiation was driven by the induction of DNA damage 
after GATA2 KD in THP1 cells, we incubated GATA2 KD THP1 cells with etoposide 
(VP16) for 30 minutes to induce DSBs. At the indicated time points we collected the 
treated cells and measured the levels of g-H2AX, an early marker of the DDR pathway 
activation (Paull et al. 2000; Kuo and Yang 2008), along with the expression of P21 
and other GATA2 related genes (Figure 5.8A). GATA2 expression was unaltered in 
wild-type THP1 cells after treatment with etoposide in comparison to DMSO control 
(Figure 5.8B). There were no changes in the MFI of g-H2AX at any of the indicated 
time point (Figure 5.8C). As seen in untreated THP1 cells, P21 was upregulated in 
GATA2 KD THP1 cells at every time point (Figure 5.8D), in agreement with the 
increase in P21 levels observed in shRNA-31 THP1 cells. Interestingly, we also 
detected an increase in the expression of P57 at the 24-and-72-hour time point 
(Figure 5.8F). P57 is a cell-cycle inhibitor important for maintaining HSC quiescence 
(Matsumoto et al. 2011) and it has been shown that Gata2 binds and activates p57 
transcription in HSPCs (Billing et al. 2016). Taken together, these results indicate that 
GATA2 is not required for DDR pathways activation in THP1 cells.  
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Next, we assessed whether GATA2 would affect the DDR pathway response after 
DSBs induction. Since lentiviral transduction of VP16 treated cells would lead to 
toxicity and low transduction efficiency, we treated THP1 cells with VP16 for 30 
minutes to induce DSBs, and then added K-7174 to inhibit GATA2. At the indicated 
time points, we measured the levels of g-H2AX and RNA expression of treated THP1 
cells with or without K-7174 (Figure 5.9A). We found no changes in the MFI of g-H2AX 
of K-7174-treated THP1 cells compared to control THP1 cells (Figure 5.9B). 
Therefore, we concluded that GATA2 is not required for the DDR pathway activation 
and maintenance in THP1 cells.  
 
 
Figure 5.8. GATA2 knockdown does not alter DDR response after DSBs in THP1 cells. (A) THP1 cells w ere transduced
with lentiviruses encoding a short hairpin against hum an GATA2 and a GFP reporter. GFP+ cells were FACS-sorted and DSBs
induced by 30 minutes treatment with 20 µM VP16. (B) GATA2 RNA expression from wild-type THP1 cells at the indicated
time points (n = 2). (C) MFI of γ-H2AX (n = 4). (D) p21 RNA expression ( n = 4). (E) p27 RNA expressi on (n = 3). (F) p57 RNA
expression (n = 3). (G) p53 RNA expr ession (n = 3). GAPDH was used as a housekeeping gene. Data from 4 independent
experiments. Data are mean ± SEM. Statistical analysis: Mann-Whitney test.
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5.3.6. K-7174 synergises with Ara-C or VP16 to eradicate THP1 AML cells. 
 
To date, single treatment of specific inhibitors of cancer cells, with the exception of 
APL, are not yet a first line treatment option in AML (Stein and Tallman 2015). 
Recently, IDH1/2 inhibitors have shown great potential in phase 2 clinical trials (Levis 
2013; Shafer and Grant 2016). Moreover, inhibition of the enzyme dihydroorotate 
dehydrogenase (DHODH) showed therapeutic potential by inducing differentiation in 
mouse and human AML models (Sykes et al. 2016). Combination of innovative small 
molecule inhibitors with standard chemotherapeutics is a more approachable 
treatment option, especially if this allows a calibrated reduction of standard 
chemotherapeutics and its related toxicity. To assess whether GATA2 inhibition could 
improve the killing activity of standard chemotherapeutics such Ara-C and VP16, we 
incubated THP1 cells with K-7174 and VP16 or Ara-C in a 48-hour assay (Figure 
Figure 5.9. K-7174 treatment does not alter DDR response after DSBs in THP1 cells. (A) THP1 cells w ere treated with 20
µM VP16 or DMSO contr ol for 30 minutes . THP1 cells were then pl ated with K-7174 or DMSO control. (B) MFI of γ-H2AX (n =
4). (C) p21 RNA expr ession (n = 2). (D) p27 RNA expression (n = 2). (E) p57 RNA expression (n = 1). (F) p53 RNA expression
(n = 1). GAPDH was used as a housekeeping gene. Data are mean ± SEM. Statistical analysis: Mann-Whitney test.
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5.10A). As expected, treatment with K-7174, VP16, and Ara-C alone decreased the 
number of live THP1 cells compared to control THP1 cells (Figure 5.10C). 
Interestingly, combination of K-7174 and VP16 further reduced the number of live 
THP1 cells at 24-and-48-hour time points (Figure 5.10C). Combination of K-7174 and 
Ara-C reduced the number of live THP1 cells at the 24-hour time point, however cells 
appeared to recover at the 48-hour time point (Figure 5.10C), although variation was 
observed in K-7174 and Ara-C treated THP1 cells. Additional experiments would be 
required to confirm these results. When we assessed apoptotic status, we found an 
increase in the number of apoptotic cells in THP1 cells treated with K-7174, VP16, or 
Ara-C (Figure 5.10D and Figure 5.10E). Notably, addition of K-7174 to VP16 or Ara-
C increased their ability to induce apoptosis in THP1 cells (Figure 5.10D and Figure 
5.10E). Therefore, pharmacological inhibition of GATA2 enhanced the killing activity 
of VP16 and Ara-C in AML cells. 
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Figure 5.10. K-7174 synergises with Ara-C or
VP16 to eradicate THP1 cells. THP1 cells
were treated with 10 µM K-7174 in combination
with 0.5 µM VP16 or 1 µM Ara-C in a 48 hour
assay. (A) Frequency of apoptosis from VP16
(top) or Ara-C (bottom) treated cells at different
concentrations (n = 1). (B) Pr oliferation assay at
24 and 48 hour time poi nts (n = 2-3). (C)
Representative FACS pl ots showing apoptotic
status at 48 hour time point. (D) Frequency of
apoptotic cells at 48 hour time point (n = 2-4).
Data are mean ± SEM. Statistical analysis:
Mann-Whitney test.
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5.4.  Discussion 
 
GATA2 expression studies in AML and MDS have indicated that GATA2 is 
(over)expressed in a wide range of patients (Luesink et al. 2012; Nandakumar et al. 
2015; Vicente et al. 2012; Shimamoto et al. 1994). However, variability in the method 
used to quantify (over)expression and percentage of GATA2 (over)expression 
between studies is present. In addition, other reports have also highlighted lower 
GATA2 expression in AML as a consequence of somatic mutations or epigenetic 
silencing (Bonadies et al. 2011; Hyde and Liu 2011; Celton et al. 2014). This disparity 
has likely arisen due to the heterogeneous nature of AML and the relatively small 
sample size of patients analysed in the expression analysis studies. In this chapter, 
we addressed the issue of GATA-2 expression in human AML by performing large-
scale bioinformatics analysis of public AML databases and found overexpression of 
GATA2 in multiple subtypes of AML patients compared to healthy controls, including 
normal karyotype. Although stronger evidence supports the (over)expression of 
GATA2 driving poor prognosis in AML, further characterisation of the role of GATA2 
in AML is required. To this end, we also explored the requirement of GATA2 in human 
AML by RNAi mediated and pharmacological targeting, and found that targeting 
GATA2 induces apoptosis and potentially differentiation, in a variety of human 
leukaemia cell lines. 
 
When considering the role of GATA2 expression in AML, it is essential to distinguish 
between its involvement in leukaemia initiation versus its role in leukaemia 
progression. Both up and downregulation of GATA2 levels appear to play distinct roles 
at different stages of AML, a hypothesis reinforced by the fact that studies in normal 
HSCs have highlighted that both up and downregulation of Gata2 affect 
haematopoiesis in a very distinctive manner (de Pater et al. 2013; Persons et al. 1999). 
This idea is further reinforced by a report that used sequential analysis to show that 
the original GATA2 loss of function mutation might be lost during disease progression, 
while patients without such GATA2 mutations can acquire them after relapse (Hou et 
al. 2015). Importantly, patients that acquire GATA2 mutations during disease 
progression have better prognosis (Hou et al. 2015; Greif et al. 2012; Fasan et al. 
2012). Conversely, GATA2 expression driving aggressiveness and metastasis in 
established CSCs has already been documented in different cancer types (Kumar et 
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al. 2012; Vidal et al. 2015; Yilmaz et al. 2006; Wang et al. 2015; Xu et al. 2016). 
Therefore, we posit that lower GATA2 levels in normal HSC/HPCs leads to 
leukaemia/MDS transformation, while upregulation of GATA2 during disease 
progression confers aggressiveness to established CSCs (LSCs).  
 
Knockdown of GATA2 on established human THP1 MLL-AF9 AML cells dramatically 
reduced proliferative and clonogenic potential due to apoptosis and differentiation 
induction. GATA2 has been demonstrated to activate anti-apoptotic genes of the Bcl 
family (Rodrigues et al. 2005) and inhibit PU.1, a key myeloid differentiation TF (Walsh 
et al. 2002), which could explain the phenotype observed after GATA2 KD in THP1 
cells. We also found P21 upregulation after GATA2 KD, which has been previously 
linked with GATA2 in controlling HSC fate (Tipping et al. 2009). Interestingly, P21 is 
able to link all the effects observed in the context of MLL-AF9 leukaemia. A study led 
by Santos MA et al., described that upon induction of DNA damage in murine Mll-af9 
leukaemic cells, p21 is responsible to exit the cell cycle and induce differentiation of 
leukaemic cells (Santos et al. 2014). It is possible that GATA2 KD follows a similar 
mechanism in THP1 cells, yet we found no DNA damage induction in our experiments. 
One possible explanation is that P53-mediated activation of P21. Co-deletion of p53 
rescued the differentiation potential in liquid culture and colony assays of YS cells from 
Gata2-/- mice (Tsai and Orkin 1997). Despite that we found no changes in mRNA 
expression of P53 in our experiments, it is still possible that active P53 protein levels 
could be increased, as reported previously (Harris and Levine 2005). Alternatively, the 
TFGb pathway has been shown to activate P21 expression through SMAD3 and 
SMAD4 (Ijichi et al. 2004). GATA2 is known to interact with SMAD4 and inhibit its DNA 
binding activity (Dong et al. 2014), suggesting that GATA2 KD could lead to SMAD4 
upregulation and therefore P21 expression. Further experiments decreasing P21 
expression would shed light on the phenotype observed.  
 
In this study, attenuation of GATA2 appears to induce differentiation though some 
variability was observed. Our knockdown approach demonstrates enhanced CD14 
and CD11b expression, however more replicates are needed for shRNA-34. In 
addition, preliminary experiments inhibiting GATA2 using a small molecule inhibitor, 
demonstrated a slight trend towards an increase of CD14 in THP1 and CD71 
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expression in K562 cells, suggesting that inhibiting GATA2 could release the 
characteristic differentiation block of AML cells (data not shown). Thus, these data 
highlight a promising role for GATA2 as a novel differentiation agent. To further 
support this notion, in initial experiments we observed that some shRNA-32 THP1 
cells, but not scramble THP1 cells, changed morphology to fibroblast-like cells, 
reminiscent of macrophages (Figure 5.11B). Indeed, GATA2 KD THP1 cells 
resembled macrophages similar to those observed in previously published 
differentiation protocols using THP1 lines (Santos et al. 2014). Immunophenotypic 
analysis showed an approximate 6-fold increase of CD14 expression in shRNA-32 
compared to scramble THP1 cells (Figure 5.11C). Strikingly, when we looked at the 
CFC colonies at day 12, we observed macrophage-like clusters in the shRNA-32 
plates (Figure 5.11D). Positive GFP expression in these macrophage-like cells argues 
against cross-contamination from other cell lines (Figure 5.11D). Unfortunately, we 
were not able to recapitulate this remarkable morphological transformation with the 
protocol that was ultimately used in the knockdown experiments presented in this 
chapter. The initial experiments were performed on transduced THP1 cells, which 
were expanded and then frozen. The lack of morphological differentiation changes in 
the experiments presented in this chapter in comparison to this initial experiment could 
be due the stress suffered during the freeze/thawing procedures, and/or for the longer 
period that THP1 cells were in culture after knockdown. Long term monitoring of 
transduced THP1 cells in culture will help to elucidate this result.   
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Figure 5.11. GATA2 KD induces a macrophage-like phenotype in THP1 cells. (A) THP1 cells were
transduced with lentiviruses encodi ng a short hairpin against hum an GATA2 and a GFP reporter. GFP+ cells
were FAC-sorted, expanded for 3 days in cultur e and fr oze down. Thawed THP1 transduced cells wer e
recovered for 3 additi onal days before plating into liqui d culture or CFC assays. (B) Representative microscope
pictures of THP1 shGAT A2-32 and scramble control at 72 hour time point in liquid culture (scale bars 10 µm). (C)
Frequency of CD14+ cells at 72 hour time point in liqui d culture (n = 2). (D) Representative microscopic pictur es
of colonies at day 12 of CFC (scale bars 100 µm for left panel, and 10 µm for right panel). (E) Number of
coloni es at day 12 (n = 4). “n” indicates the number of independent experiments . Data are mean ± SEM.
Statistical analysis: Mann-Whitney test.
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A complementary GATA2 targeting approach used here employed K-7174, a small 
GATA2 inhibitor, that has proven to be very effective in multiple leukaemic cell lines. 
K-7174 was originally designed as a GATA specific inhibitor (Majik et al. 2012), 
therefore it can also target other members of the GATA family. It would therefore be 
of interest to assess the impact of GATA1 inhibition in these leukaemic cell lines. 
GATA3 and more recently GATA4 have been associated in lymphoid, but not myeloid, 
leukaemia (Han et al. 2017). In addition, K-7174 is able to target the proteasome by a 
unique mechanism to that of the well-known proteasome inhibitor bortezomib, since 
K-7174 is able to kill bortezomib-resistant myeloma cells (Kikuchi et al. 2013). Future 
studies in our lab will address the development of new and more specific GATA2 
inhibitors in the context of AML.     
 
Transient, pharmacological inhibition of GATA2 used in collaboration with standard 
chemotherapeutics may prove to be a novel therapeutic strategy in AML. A recent 
study already showed that treatment of KG1 cells with a wide range 
chemotherapeutics increased the expression of GATA2, whilst also increasing 
expression of the CD34+ population (Yang et al. 2017). They also showed that the 
expression of GATA2 was higher in AML patients 3 months after chemotherapy when 
compared to levels prior to chemotherapy (Yang et al. 2017). Finally, they showed that 
K-7174 in combination with chemotherapeutics were able to inhibit GATA2 expression 
in AML samples, yet they did not formally test the functional impact of K-7174 
treatment in AML samples or KG1 cells (Yang et al. 2017). Taken together, if GATA2 
expression is increased after chemotherapy treatment, it would provide a plausible 
explanation as to why K-7174 enhances the killing activity of VP16 and Ara-C in our 
study. Future studies using human AML patient samples should assess the efficacy of 
K-7174 alone and in combination with chemotherapeutics to target leukaemia cells, 
and in particular LSCs. Inducing cell death and/or differentiation of LSCs are attractive 
targets for therapy, as they would eliminate the source of leukaemia cell 
growth/accumulation. 
 
Given that GATA2 is essential for adult HSCs/HPCs (see Section 3.3), toxicity in the 
normal haematopoietic system needs to be taken into account when considering 
pharmacologically targeting the GATA2 axis in AML patients. K-7174 has been tested 
in vivo in the context of multiple myeloma (Kikuchi et al. 2013). The authors injected 
 154 
human multiple myeloma lines into NOD/SCID mice and treated them with K-7174. 
Some weight loss was reported at higher doses of K-7174, yet lower doses were well-
tolerated and able to reduce tumour growth without affecting the weight or white blood 
cell (WBC) count of the mice during the 28-day experiment (Kikuchi et al. 2013). 
Promisingly, K-7174 has been shown to rescue anaemia in vivo (Imagawa et al. 2003), 
which would ameliorate the anaemic status of AML patients (De Kouchkovsky and 
Abdul-Hay 2016). However, future experiments will need to directly assess the toxicity 
of K-7174 in human haematopoietic cells, specifically HSC/HPCs.  
 
Bearing in mind that GATA2 is widely expressed across different AML subtypes and 
that overexpression has been documented in up to 40% and 65% of adult and 
paediatric AML patients (Vicente et al. 2012; Luesink et al. 2012), we propose that 
GATA2 or GATA2 related pathways are a promising, generic therapeutic target in 
AML. We observed that K-7174 was able to target not only high expressing GATA2 
leukaemic cells such as K562, KG1, and THP1, but also low or normal expressing 
GATA2 leukaemic cells like NOMO1. Interestingly, the killing activity of K-7174 in the 
high expressing GATA2 cells was present at the 24-hour time point, while NOMO1 
cells showed no clear effect until the 72-hour time point, indicating oncogenic addiction 
to GATA2 in leukaemia cells. This therefore suggests that GATA2 inhibition could be 
a valid therapeutic strategy for both high expressing GATA2 AML patients, and low or 
normal GATA2 expressing AML patients.      
 
Thus, to conclude, GATA-2 is required to regulate key aspects of leukaemic cell fate 
in human AML. To date, the characteristic differentiation block observed in AML has 
been successfully targeted therapeutically in a subtype of AML, acute promyelocytic 
leukaemia (APL), where a combination of all-trans retinoic acid (ATRA) and arsenic 
trioxide (ATO) has achieved cure in up to 80% in APL patients (Long et al. 2014). 
However, attempts to reproduce this induction of differentiation across the broad, 
genetically and clinically diverse AML subtypes has met with limited success 
(Ryningen et al. 2008; Johnson and Redner 2015). Recently, David Scadden’s lab has 
developed a DHODH inhibitor that overcomes the differentiation blockade in 
preclinical models of AML (Sykes et al. 2016). Thus, a better understanding of GATA-
2 mediated mechanisms regulating the cell fate, including the differentiation block, 
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could assist with new therapeutic approaches to broadly improve AML patient 
outcome in this otherwise poor prognosis disease. 
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Chapter 6 
 
Discussion 
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In this three-year thesis, using different genetic or pharmacologic approaches to alter 
GATA2 levels, we have studied the role of GATA2 in normal and malignant 
haematopoiesis. This work has demonstrated the critical role of Gata2 in the 
maintenance of mouse HSCs, in the delay of leukaemia progression in a mouse model 
of Meis1a/Hoxa9 AML driven by pre-LSCs/LSCs, and the potential for GATA2 
pharmacological inhibition in human AML, which induces cell death in concert with 
standard AML chemotherapeutics. This sets the basis for future work aiming to identify 
downstream molecular mechanisms mediating Gata2 in normal HSCs and leukaemia 
stem cells.  
  
6.1.  Gata2 is a critical regulator of adult HSCs.  
 
In this thesis, it is shown that Gata2 is a critical regulator of adult HSC maintenance, 
consistent with previous reports that pinpointed a role for Gata2 in foetal and adult 
HSC regulation (de Pater et al. 2013). Acute deletion of Gata2 leads to a rapid loss of 
HSCs in a cell autonomous fashion, suggesting a survival defect in Gata2 deficient 
HSCs. This phenotype is reminiscent of the one observed in Cited2 (Kranc et al. 2009), 
Mcl1 (Opferman 2005), Etv6 (Hock et al. 2004), Nkap (Pajerowski et al. 2010), and 
Notchless (Le Bouteiller et al. 2013) deficient HSCs using the same genetic deletion 
approach. Thus, Gata2 joins a select group of TFs that are essential for adult HSCs. 
In studies where the mechanism was interrogated (in Cited2, Nkap, Notchless), a 
common pathway implicating the activation of the p53-p21 axis and Ink4/Arf leads to 
programmed cell death, or apoptosis, of HSCs (Figure 6.1A) (Kranc et al. 2009; 
Pajerowski et al. 2010; Le Bouteiller et al. 2013). With this in mind, future studies will 
be directed at identifying Gata2 target genes in HSCs. Several strategies can be used 
to advance these aims - in vitro deletion of Gata2 in HSCs (or LSK cells) employing 
IFNa stimulation, followed by assessment of apoptosis and expression analysis of 
candidate genes (p21, p53, Bcl2 family); in vivo deletion of Gata2 in HSCs using a 
single dose of pIpC and analysis four days later; genetic rescue experiments by 
crossing Gata2 floxed mice with potential candidate genes (i.e. p53 or Ink4/Arf floxed 
mice). 
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Our preliminary analysis of the impact of Gata2 on the haematopoietic niche suggests 
that Gata2 deletion in the BM niche has no impact on survival or multilineage 
maintenance. As the function of Gata2 in the niche remains ill-defined, efforts will be 
directed at comprehensively elucidating the role of Gata2 in the BM niche in different 
contexts (steady-state, regeneration after HSC transplant, homing, self-renewal of 
HSCs post contact with a Gata2-deficient niche) and other cell types which Gata2 
regulates in different settings, specifically endothelial (Vec-CreERT2 or Tie2-Cre), and 
adipocytes (Adipoq-Cre) (Tsai et al. 2005; Kamata et al. 2014; Kawana et al. 1995). 
Given that niche interactions with normal haematopoietic cells appear to be 
deregulated in the context of AML or that a mutant niche can induce haematopoietic 
malignancy (Dong et al. 2016; Walkley et al. 2007; Calvi et al. 2003), study of the 
Gata2-deficient niche in the initiation and progression of AML merits further 
investigation.  
 
6.2.  Modelling GATA2 deficiency syndromes using mouse models  
 
Since the discovery of GATA2 mutations in hereditary AML in 2011, over 100 different 
mutations in the GATA2 gene have been described in more than 50 publications. 
Importantly, 90% of patients harbouring GATA2 germline mutations will develop high 
risk MDS/AML moreover, 30-50% of these patients are at the MDS/AML stage of 
disease at diagnosis (Dickinson et al. 2014; Collin et al. 2015; Hyde and Liu 2011). 
Therefore, a better understanding of GATA2 syndromes biology is an area of unmet 
research and clinical need.  
 
Gata2 germline mutations occur in all somatic cells. Therefore, the initiation of GATA2 
deficiency syndromes may be determined by either the niche or cell-autonomously, or 
through a combination of both mechanisms. Germline deletion of a single Gata2 allele 
in mice results in reduced foetal and adult HSCs numbers and functionality (Ling et al. 
2004; Rodrigues et al. 2005), in agreement with our short and long term Mx1-Cre-
mediated Gata2 haploinsufficiency in adult HSC and the BM microenvironment. 
Interestingly, unpublished observations from a collaborator at Edinburgh University 
found that haematopoietic Gata2-deletion after formation of HSCs in the embryo using 
the Vav-iCre system has no impact on HSC function. Characterising mouse models 
that faithfully recapitulate GATA2 syndromes from a pre-leukaemic state (i.e. Gata2 
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haploinsufficiency alone) to MDS/AML (i.e. by addition of secondary mutation 
frequently observed in GATA2-MDS/AML such Asxl1, Flt3ITD or chromosome 7 
deletion) will offer a tractable platform to screen and test specific inhibitors or treatment 
combinations to benefit GATA2 syndrome patients, and as a preventive therapy to 
non-symptomatic family members carrying the GATA2 mutation that are in a pre-
leukaemic phase. Finally, information obtained from a well-defined stem cell AML 
progression model will expand our knowledge of leukaemia stem cell biology in this 
setting, and in particular of pre-LSCs intrinsic functions with regard to chemotherapy 
resistance (observed in these patients) and clonal evolution of the disease.  
 
6.3.  Gata2 delays LSC development in the Meis1a/Hoxa9-mediated AML 
model but is dispensable for AML driven by the Mll-af9 translocation.  
 
We employed a step-wise model of AML, driven by Mll-af9 or its downstream targets, 
Meis1a/Hoxa9, that permitted testing of the requirement for Gata2 in LSC 
development and maintenance. A delay in the onset of AML upon acute Gata2 deletion 
in recipients transplanted with Meis1a/Hoxa9 Pre-LSCs was observed, while the 
development of AML in the Mll-af9 model appears to be Gata2-independent. However, 
the results gained from these models was complex and contradictory in some 
respects; namely, Gata2 levels in pre-LSCs and LSCs were severely depleted in both 
models, not all the recipients induced for Gata2 deletion showed complete Gata2 
deletion when they succumbed to AML, and a disparity in Gata2 function was 
observed in two closely related AML models.  
 
As outlined in Chapter 4 discussion (see section 4.6), the working hypothesis is that 
deletion of Gata2 triggers apoptosis of Gata2-dependent Meis1a/Hoxa9 LSCs. Future 
work will quantify the levels of Gata2 mRNA in Meis1a/Hoxa9 (and Mll-af9) pre-
LSCs/LSCs using droplet digital PCR (ddPCR) technology that is capable of 
quantifying absolute numbers of low-abundance and rare mRNA (Hindson et al. 2013; 
Hindson et al. 2011). Our peripheral blood (PB) analysis of Meis1a/Hoxa9 leukaemia 
cells just after pIpC induction indicates a massive drop of Gata2 KO leukaemia cells 
suggestive of a survival defect, and either complete or incomplete deletion was 
observed in the BM of moribund mice, eliminating the idea of a selective pressure 
phenomenon. We postulate that a subset of Gata2-dependent Meis1a/Hoxa9 pre-
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LSCs/LSCs undergo apoptosis, delaying the onset of AML development. This would 
explain that even when there is incomplete deletion of Gata2 there is a delay in the 
onset of AML, and why complete Gata2 deletion does not prevent AML development; 
ultimately Gata2-independent Meis1a/Hoxa9 pre-LSCs/LSCs are then capable of 
driving disease progression (Figure 6.1B).  
 
 
 
Human AML studies suggest that the standard or normal HSC hierarchy cannot 
entirely capture the clonal complexity that characterise LSCs (Levine et al. 2015; 
Alexandrov et al. 2013). Consistent with this, Stuart Orkin’s (Guo et al. 2013) 
laboratory found clonal variability within the “classical” GMP-like LSC population 
described in these AML models (Krivtsov et al. 2006). Single cell clustering of Mll-af9 
GMP-like cells showed no correlation with the surface-marker hierarchy of these cells, 
and for instance, CD24+ GMP-like LSCs developed AML slower than CD24- GMP-like 
LSCs (Guo et al. 2013). Use of recently described Gata2-GFP knock-in mice 
(Kaimakis et al. 2016) to monitor Gata2 expression during the leukaemogenic 
Figure 6.1. Working hypothesis for Gata2 deletion effects in HSCs and Meis1a/Hoxa9 LSCs. (A) Adult BM HSCs express high
levels of Gata2. Acute Gata2 deletion with the Mx1-Cre system produces a rapid HSC loss, consistent with a survival defect. (B)
Introduction of Meis1a/Hoxa9 oncogenes in HSCs initiates the leukaemia transformation alongside a reduction in Gata2 levels. Upon
acute Gata2 deletion with the Mx1-Cre system, Gata2-dependent Meis1a/Hoxa9 LSCs quickly disappear suggesting a survival defect.
However,Gata2-independent Meis1a/Hoxa9 LSCs are insensitive to Gata2 deletion and are able to drive AML progression.
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transformation, to test the LSC activity in Gata2+ and Gata2- Meis1a/Hoxa9 pre-
LSC/LSCs would allow validation of this hypothesis.  
 
The dichotomy between the results observed in the Meis1a/Hoxa9 versus the Mll-af9 
model could be explained by the cell of origin used in this study. While Meis1a/Hoxa9 
is able to transform LSK cells, the Mll-af9 can transform LSK, CMP and GMP 
progenitor cells (Krivtsov et al. 2013). We used a heterogeneous HSPCs (c-kit+) 
population as starting material indicating that we do not have control over the origin of 
which clone is selected through the serial replating assays. This could be affecting the 
results observed in Mll-af9-mediated AML since it has been shown that LSK or GMP 
derived LSC behave differentially in vivo and have distinctive expression profiles. In 
addition, specific deletion of some genes (i.e. b-catenin) show differential cell of origin 
and oncogene-dependent requirement (Wang et al. 2010; Yeung et al. 2010). Future 
work will specifically initiate the leukaemic program in specific populations to 
investigate the requirement for Gata2 in specific subsets of HSPCs.  
 
Finally, we will attempt to elucidate the molecular mechanisms downstream Gata2 in 
pre-LSCs/LSCs. This can be approached using single-dose pIpC pulse experiments 
followed by flow cytometry and genome-wide gene expression analysis, which have 
been described in these AML models (Nguyen et al. 2011; Sykes et al. 2011). In 
addition, in order to circumvent the low efficiency of deletion with the Mx1-Cre model 
in this setting, we may employ alternative and more effective genetic deletion that has 
been observed using tamoxifen-dependent Cre-mediated (i.e. lentiviral vectors, or 
Rosa26-CreERT2 mouse models) deletion, allowing specific deletion of Gata2 in vitro 
or in vivo at stage-specific time-points in the leukaemogenic assay.  
 
6.4. Can we target GATA2 in AML?  
 
Targeting TF expression is an attractive option for therapy in haematopoietic 
malignancy, including AML, where overexpression is often observed. Yet, such an 
approach is also considered difficult due to the lack of specificity in targeting AML cells 
at both the cellular and molecular level. TFs regulate normal blood cell functionality, 
which could be affected directly. Moreover, specific TFs function as part of multi-
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protein complexes and efforts to interfere with particular transcription factors of 
interest, through targeting of protein-protein or protein – DNA interactions, will likely 
inadvertently impact other transcription factors in a transcriptional complex in the 
normal haematopoietic setting. During this research, the GATA2 inhibitor, K-7174 was 
able to induce apoptosis of human AML cells and murine pre-LSC cell lines. 
Furthermore, K-7174 targets the leukaemia initiating population (c-kit+) in pre-LSC cell 
lines and enhances the killing activity of standard chemotherapeutics. Notably, pre-
LSCs/LSCs are known to expand after treatment because of their inherent chemo-
resistant characteristics (Shlush et al. 2014; Shlush and Mitchell 2015).Our results are 
in agreement with a recent study showing an increase in the stem cell marker CD34 
and GATA2 expression in treated AML patients (Yang et al. 2017), suggesting that 
pre-LSCs/LSCs might become more sensitive to GATA2 treatment in combination or 
after treatment with chemotherapy. K-7174 not only targets GATA2 but can also target 
other GATA factors and components of the proteasome (Fujiwara et al. 2013; Kikuchi 
et al. 2013; Majik et al. 2012). Proteasome inhibitors are widely used in multiple 
myeloma and are currently being tested in AML clinical trials (van Dijk et al. 2011; 
Larrue et al. 2016; Orlowski et al. 2002). Whereas proteasome inhibitor (Bortezomib) 
single treatment does not seem to improve AML survival, Bortezomib (and other 
proteasome inhibitors) show positive effects when combined with AML chemotherapy 
(Csizmar et al. 2017). However, proteasome-related toxic effects, such peripheral 
neuropathy, hypoxia and liver damage, are some of the limiting factors seen in clinical 
trials (Csizmar et al. 2017). In addition, bortezomib-mediated resistance has also been 
described (Csizmar et al. 2017). In order to prospectively assess the effects of GATA2 
blockade in AML, we are currently employing drug modelling techniques to develop 
GATA2 specific small molecule inhibitors (GATA2i) that will be independent of 
targeting the proteasome. We postulate that GATA2i could be integrated using two 
different treatment strategies: combination chemotherapy with GATA2i followed by 
BMT, or inductive chemotherapy plus GATA2i consolidation treatment to target 
chemoresistant pre-LSCs or LSC.  
 
As GATA-2 is required for normal HSC maintenance in mouse, haematopoietic-related 
toxicity derived from GATA2i in AML could induce deleterious effects in residual 
human HSCs or progenitor cells like MLP or GMP. With GATA2 loss of function 
observed in pre-leukaemic GATA2 haploinsufficiency syndromes, the risk of inducing 
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a pre-leukaemia state should be also considered. However, short term, transient 
GATA2 inhibition may not be sufficient to generate a pre-leukaemic state, since 
GATA2 syndromes harbour a germline mutation and often present with MDS/AML 
after a relatively long-latency. Thus, it is crucial to assess the short and long-term 
effects of acute-transient GATA2 blockade in human HSPCs in xenograft mouse 
models.  
 
Overexpression of a non-haematopoietic GATA factor, GATA4, has been observed in 
acute lymphoblastic leukaemia (ALL) (Han et al. 2017). Considering the redundancy, 
regulation, and interactions among GATA factors, and especially the relationship 
between GATA2 and GATA3 in many stem cell systems (MSCs (Tong et al. 2000; 
Okitsu et al. 2007), neural stem cells (Haugas et al. 2016; Tsarovina 2004), prostate 
(Xiao et al. 2016; Nguyen et al. 2013; Vidal et al. 2015)), it would be worth investigating 
whether GATA2-related AML could benefit from pleiotropic targeting or synthetic 
lethality of two or more GATA factors. Perhaps targeting another GATA factor that is 
not GATA2 could overlap with some of the GATA2 related pathways important for 
LSC, but not HSCs-intrinsic functions. Hence, measuring the expression levels and 
genetic interactions of GATA factors in AML and other GATA related cancers will be 
of interest. This analysis could be extended to normal HSCs, especially the study of a 
potential interaction, synergistic or antagonist functions, of GATA2 and GATA3, both 
of which are highly expressed in HSCs.  
 
6.5. GATA2 in the initiation versus progression in AML. 
 
Gene expression data from retroviral mouse models and GATA2 syndromes patients 
suggest that GATA2 downregulation is a recurrent, necessary event for disease 
initiation. GATA2 knockdown experiments in human HSPCs are not yet reported, 
however we can infer the role of GATA2 in human HSCs from immunophenotypic 
analysis of BM progenitor and stem cells performed in GATA2 syndrome patients with 
immunodeficiency (DCML, MonoMAC or Emberger’s syndromes). The MLP and GMP 
population are absent in immunodeficient patients, whereas reduced HSCs and MPP 
population are still present, suggesting that GATA2 might be more relevant for MLP 
progenitors, which would be the closest in function to murine LMPPs (Doulatov et al. 
2012; Kondo et al. 1997), in human haematopoiesis. A role for GATA2 in MLPs is clear 
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owing to the fact MLPs give rise to DCs, NK cells, B cells, T cells, and monocytes, the 
blood cell types affected in GATA2 syndromes, while granulocytes, megakaryocytes, 
and erythrocytes are neither produced by MLPs nor affected in GATA2 
immunodeficient syndromes (Doulatov et al. 2012). In humans, LSCs have been 
described as MPP-like, LMPP-like, and GMP-like (Goardon et al. 2011; Thomas and 
Majeti 2017). No reports have characterised the LSCs in GATA2 AML patients, but 
consistent with their preleukaemic status, it could be theorised that LSCs in these 
patients arise from the MPP-like compartment, although it cannot be discarded that 
upon acquisition of secondary mutations required for disease progression, this 
preleukaemic MPP could differentiate into LMPP-like or GMP-like LSCs.  
 
Patients with AML and cell lines derived from established AML patients demonstrate 
a predominance of overexpression in GATA2, and an associated link with poorer 
outcome (Vicente et al. 2012). This association is also described in a variety of solid 
cancers (lung, breast, glioblastoma, prostate, colorectal) where GATA2 expression 
appears to be a marker of aggressiveness. Nevertheless, it remains a possibility that 
GATA2 levels are increased in leukaemic blasts but decreased in LSCs, since in these 
studies, GATA2 expression was assessed in the total bulk of AML cells. Bearing in 
mind that the well-established CSC model, at least in AML, dictates that LSCs are 
responsible for AML progression and relapse, the incorporation of GATA2 gene 
expression, as well as other prognostic factors, including LSC signatures in AML 
diagnostics, would be warranted (Ng et al. 2016; Jung et al. 2015; Richard-Carpentier 
and Sauvageau 2017). This will answer whether GATA2 is a poor prognosis biomarker 
of AML and also address the issue of up-regulation in disease-driven LSCs.   
 
Together, our data, combined with our analysis of GATA2 gene expression analysis 
in human AML (Chapter 5) and published data in GATA2 syndromes, argue for a 
cooperative step-wise model (Figure 6.2) where GATA2 downregulation, but not 
overexpression, perturbs HSCs to a clonal-preleukaemic state characterised by BM 
failure. Acquisition of secondary hits mediated through GATA2 in pre-LSCs drives 
progression to MDS and AML. Thereafter, established LSCs (or AML blasts) that gain 
GATA2 expression show a more aggressive phenotype. Therefore, it seems that there 
is a tipping point where GATA2 downregulation may not be beneficial for LSCs 
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of GATA2 relate to better prognosis in non-GATA2 related AMLs (Fasan et al. 2012; 
Hyde and Liu 2011; Green et al. 2013). Whether the proposed model involves 
fluctuation of GATA2 levels as a key event during AML initiation and progression is 
unknown. Importantly, GATA2-AMLs never present with loss of heterozygosity (LOH), 
a recurrent event in tumour suppressor genes that is employed by cancer cells as a 
disease-progression mechanism. This suggests that GATA2 expression is required 
for the maintenance for LSCs, at least, in GATA2-AMLs.  
 
 
 
 
 
 
 
 
Figure 6.2. Dual requirement for GATA2 during initiation and progression of AML. (A) GATA2 mutations induce the formation of clonal
haematopoieisis and pre-LSCs, which after acquisition of secondary mutations will become LSCs and develop AML. (B and C) Non-GATA2 initiating
mutations lower GATA2 expression required for pre-LSCs formation. (B) Secondary mutations/events that maintain low GATA2 expression in LSCs (or
AML blasts) will present with a better AML prognosis, whereas (C) secondary mutations/event (i.e. FLT3ITD, high EVI1) that overexpress GATA2 will
correlate with more aggressive and poor prognosis AML.
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